Heterocyclic derivatives as Janus kinase inhibitors

Abstract

The present invention relates to compounds of general formula (I) that inhibit the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), processes for preparing such compounds, pharmaceutical compositions containing them, and their therapeutic uses. The compounds of the present invention may be useful in treating diseases or conditions associated with dysregulation of the JAK family of non-receptor kinases, in particular in treating various inflammatory diseases, including asthma, COPD, and other respiratory diseases.

Description

[Technical Field]

[0001] The present invention relates to compounds, derivatives of which are useful as JAK, such as JAK1, inhibitors, useful in the treatment of various inflammatory diseases, including asthma, COPD and other respiratory diseases. [Background technology]

[0002] The JAK family consists of non-receptor tyrosine protein kinases and has four major members: JAK1, JAK2, JAK3, and TYK2. More than 50 cytokines and growth factors bind to type I and type II receptors, non-covalently associated with various combinations of JAK kinases. Ligand-induced signaling involves tyrosine phosphorylation of the receptor by JAK and recruitment of one or more STAT proteins. Tyrosine-phosphorylated STATs dimerize and are then transported across the nuclear membrane into the nucleus to regulate specific genes. JAKs contain seven homology domains (JAK homology domains, JH). Starting from the carboxyl terminus, JH1 is the first JH, also known as the kinase domain, and consists of approximately 250 amino acid residues. JH1 encodes a kinase protein that constitutes the kinase structural domain, which phosphorylates substrates; JH2 is a pseudokinase domain that regulates the activity of the kinase domain. JAK3 is expressed in the bone marrow and lymphoid system, as well as in endothelial and vascular smooth muscle cells; other members are expressed in almost all tissues (Hu X et al., Signal Transduct Target Ther. 2021, 26; 6(1): 402). Many cellular processes, including hematopoiesis, immune balance, tissue repair, inflammation, apoptosis, and adipogenesis, are downstream of JAK / STAT signaling. Various biological responses are regulated by specific pairings of JAK isoforms. The JAK1 / JAK3 combination mediates the signaling of IL-2, -4, -7, -9, -15, and -21, which are involved in lymphoid cell growth / maturation, T cell / NK cell differentiation / homeostasis, B cell class switching, and other inflammatory processes. The JAK1 / TYK2-JAK1 / JAK2 combination regulates signaling associated with innate immune responses, such as IL-6 and type I interferons, which are associated with naive T cell differentiation, T cell homeostasis, granulopoiesis, and other inflammatory processes (Howell MD et al., Front. Immunol. 2019, 10, 2342).JAK2 frequently binds to itself (JAK2 / JAK2) and regulates the signaling of various cytokines and growth factors, such as IL-3, IL-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO) (Hodge et al., Clin Exp Rheumatol 2016; 34(2): 318-28).

[0003] Genetically modified mouse experiments and human diseases demonstrate the importance of the JAK / STAT pathway in immune fitness. In particular, overexpression or mutations involving several JAK isoforms, as well as aberrant JAK / STAT signaling, lead to hematopoietic or lymphoid malignancies and inflammatory disorders. Currently, several Food and Drug Administration (FDA)- and / or EU-approved JAK inhibitors are in clinical use. Two small molecules (ruxolitinib and fedratinib) are used to treat hematologic disorders such as myelofibrosis and polycythemia vera; six JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, filgotinib, upadicitinib, and delgocitinib in Japan) are used for immune-mediated disorders such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis, and acute graft-versus-host disease. Furthermore, several of these drugs, as well as others, are currently in Phase II and III clinical trials for indications ranging from autoimmune diseases (lupus, vitiligo, etc.), inflammatory bowel disease to non-Hodgkin's lymphoma and COVID-19 (Hu X. et al., Sig Transduct Target Ther 2021, 6:402).

[0004] Small molecules targeting JAK / STAT are also attractive options for the treatment of fibrotic disorders. In fact, inflammatory cytokines (IL-4, IL-3, IL-6, IL-11, IL-31, etc.) and growth factors (FGF, VEGF, etc.) involved in the fibrotic process activate the JAK / STAT pathway. Ruxolitinib, tested in a bleomycin-induced fibrosis mouse model, improved pulmonary fibrosis and reduced the levels of fibrotic molecular markers (Zhang, Y et al., Ann. Rheum. Dis. 2017, 76, 1467-1475), while tofacitinib acted as a preventive agent in experimental skin and lung fibrosis (Wang, W et al., Scleroderma Relat. Disord. 2020, 5, 40-50). Several case reports have been studied in patients. A case report confirmed the efficacy and safety of tofacitinib in combination with nintedanib in the management of poor-prognosis malignant interstitial lung disease (Conca, W et al., Front. Pharmacol. 2020, 11, 5857619). Baricitinib has proven to be a safe immunomodulatory agent that reduces levels of pulmonary fibrosis and inflammatory biomarkers in patients with RA, including subgroups of interstitial lung disease (D'Alessandro M et al., Int. Immunopharmacol. 2020, 86, 106748).

[0005] Several JAK inhibitors are undergoing clinical trials for COVID-19: tofacitinib, baricitinib, and ruxolitinib. Baricitinib and ruxolitinib have been associated with a reduced risk of death. They have reduced the use of invasive mechanical ventilation, with a borderline impact on intensive care unit admission rates and the incidence of acute respiratory distress syndrome (ARDS) (Wijaya, I. et al., Clin. Epidemiol. Glob. Health 2021, 11, 100755). Ruxolitinib has also been tested in COVID-19 patients and improved clinical signs and chest computed tomography scans (Cao Y. et al., J. Allergy Clin. Immunol. 2020, 146, 137-146).

[0006] Asthma is one of numerous immune-mediated diseases whose pathogenesis is characterized by the essential role of JAK / STAT signaling. It is a chronic inflammatory disease of the airways resulting from a complex interplay between immune responses, genetic susceptibility, and nonspecific external stimuli such as colds, allergens, and exercise, which leads to hyperresponsiveness, airway remodeling, and ultimately airflow limitation. Severe asthma affects 5% to 15% of the adult asthma population (300 million people worldwide) and represents a public health problem associated with increased mortality, hospitalizations, significant symptom burden, medical costs, and loss of work and education (Steve NG et al., J Allergy Clin Immunol 2021;148:953-63). Severe asthma represents a subgroup of difficult-to-treat asthma and occurs in patients whose disease remains uncontrolled despite the use of high-dose inhaled corticosteroids (ICS) in combination with long-acting beta-agonists or other control agents. To date, four types of biologics have been approved for severe asthma: omalizumab (anti-immunoglobulin E antibody), mepolizumab and reslizumab (anti-interleukin [IL]-5 antibodies), benralizumab (anti-IL-5 receptor α antibody), and dupilumab (anti-IL-4 receptor alpha antibody). Despite their efficacy, many patients continue to experience exacerbations or uncontrolled disease, indicating the need for novel therapeutic agents (Israel E, Reddel HK. N Engl J Med 2017;377:965-76).

[0007] In recent years, improved understanding of asthma pathogenesis has led to a shift from phenotypic classification systems to the introduction of the concept of "endotypes." According to the latter, classification is based on the pathophysiological mechanisms and clinical biomarkers associated with a given patient (Wenzel SE et al., Am J Respir Crit Care Med 2021;203:809-21). There are two major endotypes of asthma: type 2 and non-type 2. The type 2 pathway is defined by the activation of cytokines derived from Th2 cells and group 2 innate lymphoid cells (ILC2s); these include IL-4, IL-5, and IL-13, which initiate airway inflammation by activating eosinophils, B cells, airway epithelial cells, and other cell types. Biomarkers of type 2 asthma include blood / sputum eosinophils and elevated levels of exhaled nitric oxide (FENO) and IgE. The Type 2-low pathway is characterized by the absence of Type 2-high cytokines and biomarkers, as manifested either by elevated airway neutrophil levels or a granulocyte-reduced profile with normal airway neutrophil and eosinophil levels. Type 2-low asthma is currently poorly understood and may encompass multiple distinct endotypes. Potential mediators and / or biomarkers for the Type 2-low endotype under investigation include IL-6, IL-17A / F, IL-23, type I interferons, CXCL10, TNF, alarmins (TSLP, IL-25, IL-33), IL-1β, IL-8, and IFN-γ (Hinks TSC et al., ERJ 2021, 57(1) 2000528).

[0008] In both T2 and T2-low endotypes, nearly all of the mediators mentioned above activate the JAK / STAT pathway, providing a rationale for the potential use of JAK inhibitors in both endotypes of severe asthma. Targeting several cytokines simultaneously with JAK inhibitors may offer advantages over biologics (in unresponsive patients) and standard therapy (in uncontrolled patients), given their administration in addition to ICS.

[0009] Despite the strong rationale for using JAK inhibitors in asthma, systemic administration of inhibitors can raise safety concerns and limit their use in certain asthmatic subjects, such as children. Given that asthma is a lung-limited disease, the inhaled route of administration of JAK inhibitors may offer therapeutic benefits while limiting systemic exposure and associated side effects. To date, several companies are developing inhaled JAK inhibitors for the treatment of asthma. AstraZeneca's pipeline includes AZD-0449 (completed Phase I clinical trials) and AZD-4604 (ongoing Phase I clinical trials); Theravance Biopharm has initiated a new preclinical program for the inhaled JAK inhibitor TD-8236, and Kinaset / Vectura is developing an inhaled compound, VR588 (ongoing Phase I clinical trials). Numerous preclinical studies sponsored by these companies have demonstrated the efficacy of JAK inhibitors in the management of asthma. In the preclinical phase of drug development, oral administration of the JAK1 / 3 inhibitor R256 (now called AZD0449) was shown to reduce airway resistance, BAL eosinophilia, and mucus production, and even TH2 cytokine responses when administered during sensitization (Ashino S et al., J Allergy Clin Immunol 2014;133:1162-74). iJak-381, available as a dry powder from Genentech, reduced BAL eosinophilia, CCL11, airway resistance, and Muc5AC in mice challenged with OVA. Furthermore, it reduced BAL eosinophilia, neutrophilia, CCL11, and CXCL1 in mice chronically exposed to AAH allergen (Dengler HS et al., Sci Transl Med 2018;10:eaao2151). Furthermore, an oral JAK inhibitor, tofacitinib, formulated to be administered as an aerosol, reduced eosinophil numbers in a house dust mite mouse model of asthma (Younis US et al., AAPS PharmSci-Tech 2019;20:167).

[0010] Another respiratory disease that could benefit from restricting JAK inhibition to the lung is chronic obstructive pulmonary disease (COPD), an inflammatory lung condition most commonly caused by cigarette smoke exposure and characterized by largely irreversible, progressive airflow limitation. Although proinflammatory cytokines are drivers of chronic airway inflammation, and several of these (e.g., IL-6, IFN-γ, and IL-2) induce JAK / STAT activation, the role of this pathway in COPD pathogenesis is poorly characterized. Phosphorylated STAT4+ cells (Di Stefano A et al., Eur Respir J. 2004 Jul;24(1):78-85) have been found to be increased in COPD compared with healthy nonsmoker controls. In another study, the number of phosphorylated STAT3+ and phosphorylated STAT1+ cells was higher in samples from COPD patients than in non-smoker controls, whereas previous data on phosphorylated STAT4 molecules could not be replicated (Yew-Booth L et al., Eur Respir J 2015;46(3):843-5). These data may also suggest the therapeutic use of JAK inhibitors in COPD disease.

[0011] In view of the many pathological responses mediated by JAK enzymes, there is a continuing need for inhibitors of JAK enzymes that may be useful in the treatment of numerous disorders, particularly respiratory diseases. Thus, there remains a significant need to find novel, potent JAK inhibitors suitable for local administration to the lung for the treatment of asthma and respiratory diseases. Summary of the Invention

[0012] Thus, compounds of formula (I): [ka] wherein W, X1, X2, X3, X4, R1, R2, and R3 are as defined in the detailed description of the invention. It is an object of the present invention to provide a compound of the formula: or a pharmaceutically acceptable salt thereof.

[0013] It is another object of the present invention to provide pharmaceutical compositions containing such compounds, methods of using such compounds in the treatment of respiratory disorders, and processes and intermediates useful in making such compounds.

[0014] In one aspect, the present invention provides a compound of formula (I) for use as a medicament. In one aspect, the present invention provides the use of a compound of the invention in the manufacture of a medicament.

[0015] In a further aspect, the present invention provides the use of a compound of the invention in the manufacture of a medicament for the treatment of any disease associated with the mechanism of action of a JAK enzyme.

[0016] In another aspect, the present invention provides a method for preventing and / or treating any disease associated with the mechanism of action of the JAK enzymes defined above, which method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention.

[0017] In certain embodiments, the compounds of the present invention, used alone or in combination with other active ingredients, may be administered for the prevention and / or treatment of pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), interstitial lung disease and idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS). DETAILED DESCRIPTION OF THE INVENTION

[0018] definition The term "pharmaceutically acceptable salts" refers to derivatives of the compounds of formula (I) where the parent compound, if any, is suitably modified by converting any of its free acidic or basic groups, if any, into the corresponding addition salts with any base or acid conventionally considered to be pharmaceutically acceptable.

[0019] Suitable examples of such salts may thus include inorganic or organic acid addition salts of basic residues such as amino groups, as well as inorganic or organic base addition salts of acidic residues such as carboxyl groups.

[0020] Cations of inorganic bases which may suitably be used to prepare the salts of the present invention include ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium. Salts formed by reacting primary compounds which function as bases with inorganic or organic acids include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, acetic acid, oxalic acid, maleic acid, fumaric acid, succinic acid and citric acid.

[0021] Many organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are known as "solvates," which are a further object of the present invention. Polymorphs and crystalline forms of the compound of formula (I), or its pharmaceutically acceptable salts, or solvates, are a further object of the present invention.

[0022] The term "halogen" or "halogen atom" includes fluorine, chlorine, bromine, and iodine atoms; it refers to fluoro, chloro, bromo, and iodo as substituents. The term "(C1-C6) alkyl" refers to a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Particular alkyl groups are, for example, methyl, ethyl, n-propyl, isopropyl, t-butyl, 3-methylbutyl, and the like.

[0023] The expression "(C-C)haloalkyl" refers to a "(C-C)alkyl" group as defined above, in which one or more hydrogen atoms are replaced with one or more halogen atoms, which may be the same or different from one another. Examples include halogenated, polyhalogenated, and fully halogenated alkyl groups in which all hydrogen atoms are replaced with halogen atoms, such as trifluoromethyl or difluoromethyl groups.

[0024] Similarly, "(C1-C x ) hydroxyalkyl" or "(C1-C x The term "(C-C)aminoalkyl" refers to the above-mentioned "(C-C x )alkyl" groups in which one or more hydrogen atoms are respectively replaced by one or more hydroxy (OH) or amino groups.

[0025] The definition of aminoalkyl includes alkyl groups substituted with one or more amino groups (-NR4R5) (i.e., "(C1-C6) alkyl" groups). An example of an aminoalkyl is R4R5N-(C1-C6) alkyl, or -(CH2) m and mono-aminoalkyl groups such as NR4R5 (wherein R4 and R5, and m are as defined in the detailed description of the present invention).

[0026] With respect to the substituents R and R defined above, it is further noted that when either R or R, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group, at least one additional ring carbon atom of the heterocyclic group may be substituted with at least one heteroatom or heterogroup (e.g., N, NH, S, or O), or may have an -oxo (=O) substituent. The heterocyclic group may be optionally further substituted at an available point of the ring, i.e., at an available carbon atom for substitution, or at a heteroatom or heterogroup. Thus, examples of the heterocyclic group include 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, piperazin-4-yl-2-one, and 4-methylpiperazin-1-yl.

[0027] "(C3-C 10The term "(C-C)cycloalkyl" as well as "(C-C)cycloalkyl" refer to a saturated cyclic hydrocarbon group containing the indicated number of ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, as well as polycyclic ring systems such as adamantanyl.

[0028] The term "aryl" refers to a mono-, bi-, or tricyclic carbocyclic ring system having 6 to 20, preferably 6 to 15, ring atoms, in which at least one ring is aromatic. The term "heteroaryl" refers to a mono-, bi-, or tricyclic ring system having 5 to 20, preferably 5 to 15, ring atoms, in which at least one ring is aromatic and at least one ring atom is a heteroatom (e.g., N, S, or O).

[0029] Examples of aryl or heteroaryl monocyclic ring systems include, for example, phenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinylnyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furanyl groups and the like.

[0030] Examples of aryl or heteroaryl bicyclic ring systems include naphthalenyl, biphenylenyl, purinyl, phteridinyl, pyrazolopyrimidinyl, benzotriazolyl, benzimidazol-yl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, indazolyl, benzothiopheneyl, benzodioxinyl, dihydrobenzodioxinyl, indenyl, dihydro-indenyl, dihydrobenzo[1,4]dioxinyl, benzothiazol-2-yl, dihydrobenzodioxepinyl, benzoxazinyl, 1,2,3,4-tetrahydroisoquinolin-6-yl, 4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl, 5,6,7,8-tetrahydro-1,7-naphthyridine groups, and the like.

[0031] Examples of aryl or heteroaryl tricyclic ring systems include fluorenyl groups, as well as benzo-fused derivatives of the heteroaryl bicyclic ring systems discussed above.

[0032] "(C3-C 10 The derived expressions "(C-C)heterocycloalkyl" as well as "(C-C)heterocycloalkyl" refer to saturated or partially unsaturated mono-, di-, or tri-cycloalkyl groups of the indicated number of carbons, where at least one ring carbon atom is replaced with at least one heteroatom (e.g., N, NH, S, or O) and / or optionally has an -oxo (=O) substituent (e.g., C(=O), S(=O)). The heterocycloalkyl (i.e., heterocyclic group) may be optionally further substituted at available points on the ring, i.e., on carbon atoms available for substitution or on heteroatoms. Examples of heterocycloalkyl are oxetanyl, tetrahydro-furanyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydro- or tetrahydro-pyridinyl, tetrahydropyranyl, pyranyl, 2H- or 4H-pyranyl, dihydro- or tetrahydro-furanyl, dihydroisoxazolyl, pyrrolidin-2-one-yl, and the like. aryl, dihydropyrrolyl, 5-oxopyrrolidin-3-yl, (1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl, 1,1-dioxidethiomorpholino, octahydrocyclopenta[c]pyrrol-5-yl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl; 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl group, or the like.

[0033] The term "aryl(C1-C6)alkyl" refers to an aryl ring linked to a straight or branched alkyl group having from 1 to 6 member carbon atoms, for example, phenylmethyl (i.e., benzyl), phenylethyl, or phenylpropyl.

[0034] Similarly, the term "heteroaryl(C1-C6)alkyl" refers to a heteroaryl ring linked to a straight or branched alkyl group having from 1 to 6 member carbon atoms, for example, furanylmethyl.

[0035] The term "alkanoyl" refers to an HC(O)- or alkylcarbonyl group (e.g., (C1-C6)alkylC(O)-), where the "alkyl" group is defined above. Examples include formyl, acetyl, propanoyl, and butanoyl.

[0036] "(C1-C 10 )alkoxy" or "(C1-C 10 The terms "(C-C)alkoxy" or "(C-C)alkoxyl" and the like, as well as "(C-C)alkoxyl," refer to a straight or branched chain hydrocarbon of the indicated number of carbons linked to the remainder of the molecule through an oxygen bridge. "(C-C)alkylthio" refers to a hydrocarbon as defined above linked through a sulfur bond. Similarly, the term "(C-C)alkylthio" refers to a haloalkyl as defined above linked through a sulfur bond. Examples of (C-C)alkylthio and (C-C)haloalkylthio are methylthio and (difluoromethyl)thio, respectively.

[0037] The derived expressions "(C-C)haloalkoxy" or "(C-C)haloalkoxyl" refer to a haloalkyl as defined above attached through an oxygen bridge. Examples of (C-C)haloalkoxy are difluoromethoxy and trifluoromethoxy.

[0038] The similarly derived expressions "(C3-C6)heterocycloalkyl-(C1-C6)alkyl" and "(C3-C6)cycloalkyl-(C1-C6)alkyl" refer to the above-described heterocycloalkyl and cycloalkyl groups linked to the remainder of the molecule via an alkyl group of the indicated number of carbons, e.g., piperidin-4-yl-methyl, cyclohexylethyl.

[0039] The derived expression "(C1-C6)alkoxy(C1-C6)alkyl" refers to an alkoxy group as defined above linked to the remainder of the molecule via an alkyl group of the indicated number of carbons, e.g., methoxymethyl.

[0040] Similarly, "(C1-C6)haloalkoxy(C1-C6)alkyl" refers to a (C1-C6)haloalkoxy as defined above linked to the remainder of the molecule via an alkyl group of the indicated number of carbons, e.g., difluoromethoxypropyl. Similarly, "(C1-C6)alkoxycarbonyl" refers to an alkoxy group as defined above linked to the remainder of the molecule via a carbonyl group.

[0041] And, "(C1-C6)alkoxycarbonyl-(C1-C6)alkyl" refers to an alkoxy group as defined above linked to the remainder of the molecule via a carbonyl group further linked by an alkyl group of the indicated number of carbons, e.g., methoxycarbonylmethyl. And, "(C1-C6)alkoxycarbonyl-(C1-C6)alkylthio" refers to a linked group, such as methoxycarbonylmethylthio, as a result.

[0042] An oxo moiety is represented by (O) as an alternative to other common representations, such as (=O). Thus, with respect to general formulas, carbonyl groups are preferably represented herein as -C(O)- as an alternative to other common representations such as -CO-, -(CO)-, or -C(=O). In general, groups shown in parentheses are side groups that are not included in the backbone, and parentheses are used where deemed useful to help disambiguate linear chemical formulas; for example, the sulfonyl group -SO- may also be represented as -S(O)- to disambiguate, for example, with respect to the sulfinic group -S(O)O-.

[0043] When presented with a numerical index, the statement "p is zero" or "p is 0" (numerical value) refers to a substituent or group (e.g., (R) p) is absent, i.e., there are no substituents other than H when required. Similarly, if the indicator is a bridging divalent group (e.g., (CH2) n ), the statement "n is 0 in each occurrence" or "n is 0" means that the bridging group is absent, i.e., a bond.

[0044] Whenever a basic amino group or a quaternary ammonium group is present in the compounds of formula (I), a physiologically acceptable anion selected from chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, pamoate, and naphthalenedisulfonate may be present. Similarly, in the presence of an acidic group, such as a COOH group, the corresponding physiological cationic salts may also be present, including, for example, alkali or alkaline earth metal ions.

[0045] Compounds of formula (I), if they contain one or more stereoisomeric centers, may exist as optical stereoisomers.

[0046] When the compound of the present invention has at least one stereoisomeric center, the compound may exist as an enantiomer, depending on the circumstances. When the compound of the present invention has two or more stereoisomeric centers, the compound may additionally exist as a diastereomer. It should be understood that all such single enantiomers, diastereomers, and mixtures thereof in any proportion are included within the scope of the present invention. The absolute configuration (R) or (S) of the carbon having a stereoisomeric center is assigned based on the Cahn-Ingold-Prelog naming rules, which are based on group preference.

[0047] "Single stereoisomer," "single diastereomer," or "single enantiomer," when reported near the chemical name of a compound, indicates that the isomer has been isolated (e.g., via chiral chromatography) as a single diastereomer or enantiomer, but the absolute configuration at the relevant stereoisomeric center has not been determined / assigned.

[0048] Atropisomers can result from hindered rotation around a single bond when the steric strain barrier to rotation is high enough to isolate the conformers (Bringmann G et al., Angew. Chemie Int. Ed. 44(34), 5384-5427, 2005. doi: 10. 1002 / anie. 200462661).

[0049] Oki defined atropisomers as conformers that interconvert with half-lives of 1000 seconds or more at a given temperature (Oki M, Topics in Stereochemistry 14, 1-82, 1983).

[0050] Atropisomers differ from other chiral compounds in that in many cases they can be thermally equilibrated, whereas in other forms of chirality isomerization is usually only possible chemically.

[0051] Separation of atropisomers is possible by chiral resolution methods such as selective crystallization. In atropo-enantioselective or atroposelective synthesis, one atropisomer is formed at the expense of another. Atroposelective synthesis may be achieved using chiral auxiliaries such as the Corey Bakshi Shibata (CBS) catalyst, an asymmetric catalyst derived from proline, or by thermodynamic equilibrium-based solutions where the isomerization reaction favors one atropisomer over the other.

[0052] The racemic forms of the compounds of formula (I) as well as the individual atropisomers (substantially free of their corresponding enantiomers) and stereoisomerically enriched atropisomer mixtures are within the scope of the present invention.

[0053] The present invention further relates to the corresponding deuterated derivatives of the compounds of formula (I). In the context of the present invention, a deuterated derivative means that at least one position occupied by a hydrogen atom is occupied by deuterium in an amount greater than or equal to its natural abundance. Preferably, the proportion of deuterium at that position is at least 90%, more preferably at least 95%, and even more preferably 99%.

[0054] All preferred aspects or embodiments mentioned above and hereinafter for compounds of formula (I) may be combined with one another and apply mutatis mutandis as well.

[0055] As mentioned above, the present invention refers to compounds of general formula (I) that act as JAK inhibitors, to their preparation, and to pharmaceutical compositions comprising them either alone or in combination with one or more active ingredients, in admixture with one or more pharmaceutically acceptable carriers.

[0056] In a first aspect, the present invention provides a compound of formula I: [ka] [In the formula, X1 and X2 are alternately N or CH; X3 and X4 are alternately N or CH, and the two dashed lines indicate that a double bond alternates between X3=N or N=X4 accordingly; W is heteroaryl selected from pyrazolo[1,5-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl, and (3-oxo-3,4-dihydropyrazin-2-yl)amino; R1 is selected from the group pyridinyl, piperidinyl, phenyl or benzyl, which is halogens, preferably Cl and F; -OH, -CN, -NO2, -(CH2) m NR4R5, preferably -NH2, (C1-C6) alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, preferably methoxy; (C1-C6) alkylthio-, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, preferably difluoromethoxy; (C1-C6) haloalkylthio- optionally substituted with one or more, preferably two or three, further independently selected groups; R1 particularly preferably has the formula K when it is phenyl: [ka] optionally substituted with at least one further group of the formula: L is absent or a divalent radical selected from O, S, S(O)2, (CO), C(O)O, O(O)C, C(O)N(R6), N(R6)C(O), NHCONH, N(R6)S(O)2, S(O)2N(R6); Z is H, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxy(C1-C6) alkyl, (C1-C6) alkoxycarbonyl, -(CH2) m selected from the group consisting of NR4R5, -C(O)NH(R6), (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl; wherein the (C3-C8)cycloalkyl, aryl, heteroaryl and (C3-C6)heterocycloalkyl are further defined as (C1-C 10 Optionally substituted by one or more substituents selected from the group consisting of alkyl, (C-C)alkoxy, alkanoyl, (C-C)alkoxycarbonyl, oxo, —C(O)NH(R), (C-C)alkoxy(C-C)alkyl; R2 and R3, when present, are selected from H, (C1-C6) alkyl, preferably methyl, and a group of formula J: [ka] (In the formula, V is absent or O, S, S(O)2, C(O), C(O)O, O(O)C, C(O)N(R6), N(R6)C(O); N(R6)-(CH2) m -N(R6), -N(R6)- is a divalent group selected from; Q is H, -CN, -OH, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxycarbonyl, hydroxycarbonyl, -(CH2) m selected from the group consisting of NR4R5, -C(O)NR4R5, -N(R6)C(O)R6, -CH(CN)NR4R5, (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl; wherein the (C3-C8)cycloalkyl, aryl, heteroaryl and (C3-C6)heterocycloalkyl are selected from the group consisting of -OH, oxo, (C1-C 10 ) alkyl, (C1-C 10 ) alkyl-S(O)2-O-, alkanoyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxy(C1-C6) alkyl, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonyl-NH-, -N(R6)(CH2) moptionally further substituted with one or more substituents selected from the group consisting of C(O)NR4R5, —NR4R5, (C3-C6)heterocycloalkyl; wherein n and m, in each occurrence, are independently 0 or an integer selected from 1, 2, 3, and 4; R4 and R5 are the same or different; -H, (C1-C6) alkyl, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, Alkanoyl, (C1-C6)alkoxycarbonyl, and (C3-C6)heterocycloalkyl selected from the group consisting of: R6, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, and alkanoyl; R7, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl, and -NR4R5. and independently selected from the group consisting of: The present invention is directed to a series of derivatives of the compound of the formula: or a pharmaceutically acceptable salt or solvate thereof.

[0057] The compounds according to the invention are preferably 1H-pyrazolo[4,3-c]pyridine, 1H-pyrazolo[4,3-b]pyridine or 1H-pyrazolo[3,4-b]pyridine derivatives.

[0058] Particularly preferred are compounds of 1H-pyrazolo[4,3-c]pyridine derivatives of formula I (wherein X1 is CR3 (meaning CH substituted with R3), X2 is N, X3 is CR2 (meaning CH substituted with R2), and X4 is N), which are represented by formula (Io): [ka] [In the formula, W is heteroaryl selected from pyrazolo[1,5-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl, and (3-oxo-3,4-dihydropyrazin-2-yl)amino; All other variables are as above.] or pharmaceutically acceptable salts and solvates thereof.

[0059] In a preferred embodiment, the present invention provides a compound of formula (Io) R1 further halogens, preferably Cl and F; -OH, (C1-C6)alkoxy, preferably methoxy; (C1-C6) alkylthio-, preferably methylthio; (C1-C6)haloalkoxy, preferably difluoromethoxy substituted by two or three more independently selected groups, All other variables are as defined above. A compound is provided.

[0060] The preferred compounds exhibited an advantageously balanced profile upon inhaled administration.

[0061] In another preferred embodiment, the present invention provides a compound of formula (Ib): [ka] [In the formula, R8 is (C1-C6)alkoxy, (C1-C6) haloalkoxy selected from the group consisting of: L is selected from the divalent radicals consisting of O, S, S(O)2, C(O)O, O(O)C, C(O)N(R6), N(R6)C(O); Z is H, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxycarbonyl, -(CH2) m NR4R5, -C(O)NH(R6), (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl (optionally (C1-C 10 ) optionally substituted with one or more substituents selected from the group consisting of alkyl, alkanoyl, (C1-C6)alkoxycarbonyl, —C(O)NH(R6), (C1-C6)alkoxy(C1-C6)alkyl; R3 is —H or (C1-C6) alkyl; V is absent or O, S, S(O)2, C(O), C(O)O, O(O)C, C(O)N(R6), N(R6)C(O), N(R6)-(CH2) m -N(R6), -N(R6)-; Q is H, -CN, -OH, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxycarbonyl, -(CH2) m NR4R5, -C(O)NR4R5, -N(R6)C(O)R6, -CH(CN)NR4R5, (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl (optionally, -OH, oxo, (C1-C 10 ) alkyl, (C1-C 10 ) alkyl-S(O)2-O-, alkanoyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxy(C1-C6) alkyl, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonyl-NH-, -N(R6)(CH2) m -C(O)NR4R5, -NR4R5, (C3-C6)heterocycloalkyl); n and m, in each occurrence, are independently 0 or an integer from 1 to 4; R4 and R5 are the same or different; -H, (C1-C6) alkyl, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, Alkanoyl, (C1-C6)alkoxycarbonyl, and (C3-C6)heterocycloalkyl selected from the group consisting of: R6, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl, and (C1-C6) hydroxyalkyl; R7, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl. or a pharmaceutically acceptable salt or solvate thereof.

[0062] In a preferred embodiment, the present invention provides a compound of formula (Ib1): [ka] [In the formula, The R8 is (C1-C6)alkoxy, (C1-C6) haloalkoxy selected from the group consisting of: L is selected from the divalent radicals consisting of O, S, S(O)2, C(O)O, O(O)C, C(O)N(R6), N(R6)C(O); Z is H, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxycarbonyl, -(CH2) m NR4R5, -C(O)NH(R6), (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl (optionally, (C1-C 10) optionally substituted by one or more substituents selected from the group consisting of alkyl, alkanoyl, (C1-C6)alkoxycarbonyl, —C(O)NH(R6), (C1-C6)alkoxy(C1-C6)alkyl; R3 is —H or (C1-C6) alkyl; V is absent or O, S, S(O)2, C(O), C(O)O, O(O)C, C(O)N(R6), N(R6)C(O);N(R6)-(CH2) m -N(R6), -N(R6)-; Q is H, -CN, -OH, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) alkoxycarbonyl, -(CH2) m NR4R5, -C(O)NR4R5, -N(R6)C(O)R6, -CH(CN)NR4R5, (C3-C8)cycloalkyl, aryl, heteroaryl, and (C3-C6)heterocycloalkyl (optionally, -OH, oxo, (C1-C 10 ) alkyl, (C1-C 10 ) alkyl-S(O)2-O-, alkanoyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxy(C1-C6) alkyl, (C1-C6) alkoxycarbonyl, (C1-C6) alkoxycarbonyl-NH-, -N(R6)(CH2) m -C(O)NR4R5, -NR4R5, (C3-C6)heterocycloalkyl); n and m, in each occurrence, are independently 0 or an integer from 1 to 4; R4 and R5 are the same or different; -H, (C1-C6) alkyl, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, Alkanoyl, (C1-C6)alkoxycarbonyl, and (C3-C6)heterocycloalkyl selected from the group consisting of: R6, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl, and (C1-C6) hydroxyalkyl; R7, at each occurrence, is independently selected from the group consisting of H, (C1-C6) alkyl. and W is (3-oxo-3,4-dihydropyrazin-2-yl)amino, as shown in the formula (Io), or a pharmaceutically acceptable salt or solvate thereof.

[0063] Thus, a particularly preferred group of compounds are [Table 1] is.

[0064] The preferred compounds exhibit a balanced profile upon inhalation administration, preferably exhibiting inhibitory concentrations of less than 50 nM against at least JAK1-2-3.

[0065] Another particularly preferred embodiment is a compound of formula I: [ka] [In the formula, X1 and X2 are alternately N or CH; and X3 and X4 are alternately N or CH, and the two dashed lines indicate that the double bond alternates between X3=N or N=X4 accordingly; W is heteroaryl selected from pyrazolo[1,5-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl; R1 is selected from piperidinyl, phenyl, or benzyl groups (optionally substituted with one or more groups selected from cyanomethylcarbonyl, difluoromethoxy, Cl, and F); R2 is methyl or selected from hydroxycarbonylmethyl, methoxycarbonylmethyl, dimethylaminocarbonylmethyl, hydroxymethyl. or a pharmaceutically acceptable salt or solvate thereof.

[0066] According to certain embodiments, the present invention provides Examples 1a-10a (according to the last preferred embodiment described herein above), and further compounds of Examples 1 to 99 listed in the table below, and pharmaceutically acceptable salts and solvates thereof.

[0067] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10]

[0068] The compounds of the present invention, including all of the compounds listed above, can be prepared from readily available starting materials using the general methods and procedures described in the experimental description below, or by slight modifications of methods readily available to those of ordinary skill in the art. While specific embodiments of the present invention are described or illustrated herein, those of ordinary skill in the art will understand that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other known methods, reagents, and starting materials. Where typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise specified. Optimum reaction conditions will vary with the particular reactants or solvents used; such conditions can be readily determined by one of ordinary skill in the art by routine optimization. General schemes and detailed procedures are described below in the "Preparation of Intermediates and Examples" section.

[0069] As described in detail herein, the compounds of the present invention are inhibitors of kinase activity, and in particular inhibit JAK kinase activity to treat JAK-dependent diseases. In one aspect, the present invention provides a compound according to the invention, i.e. a compound of formula (I) or a pharmaceutical composition thereof, for use as a medicament, preferably for use in the prevention and / or treatment of respiratory diseases, particularly pulmonary diseases.

[0070] In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disorder associated with a JAK mechanism of action, particularly for the treatment of disorders such as respiratory and pulmonary diseases. In particular, the present invention provides compounds of formula (I) for use in the prevention and / or treatment of a pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury, and acute respiratory distress syndrome (ARDS).

[0071] Moreover, the present invention provides a method for preventing and / or treating disorders associated with a JAK mechanism of action, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention. In particular, the present invention provides methods for the prevention and / or treatment of respiratory diseases wherein the disorder is selected from asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury, and acute respiratory distress syndrome (ARDS).

[0072] The compounds of the invention are preferably used to prevent the disorders mentioned above. The use of the compounds of the invention to treat the disorders mentioned above is also preferred. Generally speaking, compounds that are JAK inhibitors may be useful in treating many disorders associated with the mechanism of action of JAK enzymes.

[0073] In one embodiment, the disorder that may be treated by the compounds of the invention is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF), acute lung injury, and acute respiratory distress syndrome (ARDS). In a further embodiment, the disorder is selected from asthma and chronic obstructive pulmonary disease (COPD).

[0074] The therapeutic method of the present invention involves administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof. As used herein, an "effective amount" with respect to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or other pharmaceutically active agent, means an amount of the compound sufficient to treat the patient's symptoms, yet low enough to avoid serious side effects, which amount can still be routinely determined by one of ordinary skill in the art. The compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in a single dose or according to a dosing regimen comprising multiple doses administered at various intervals over a predetermined period of time. Typical daily doses may vary depending on the particular route of administration selected.

[0075] The present invention also provides pharmaceutical compositions of a compound of formula (I) in admixture with one or more pharmaceutically acceptable carriers or excipients, such as those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., NY, USA. The present invention is also directed to the use of the compounds of the present invention and pharmaceutical compositions thereof suitable for various routes of administration.

[0076] Administration of the compounds of the present invention and pharmaceutical compositions thereof can be achieved, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally, and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and ocularly, depending on the needs of the patient.

[0077] A variety of solid oral dosage forms can be used to administer the compounds of the present invention, including solid forms such as tablets, gelcaps, capsules, caplets, granules, lozenges, and bulk powders.The compounds of the present invention can be administered alone or in combination with known excipients, including various pharmaceutically acceptable carriers, diluents (sucrose, mannitol, lactose, starch, etc.), and suspending agents, solubilizers, buffers, binders, disintegrants, preservatives, coloring agents, flavoring agents, lubricants, etc.Time-release capsules, tablets, and gels are also advantageous.

[0078] A variety of liquid oral dosage forms can also be used to administer the compound of the present invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups and elixirs.Such dosage forms can also contain suitable known inert diluents such as water, and suitable known excipients such as preservatives, wetting agents, sweeteners, flavoring agents, and agents for emulsifying and / or suspending the compound of the present invention.The compound of the present invention can also be formulated as an injectable composition, for example, in the form of an isotonic sterile solution to be injected intravenously.Other formulations are also possible.

[0079] Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylate and polyethylene glycol. Preparations for vaginal administration may be in the form of cream, gel, paste, foam, or spray formulation containing, in addition to the active ingredient, suitable carriers, as are known in the art.

[0080] For topical administration, the pharmaceutical compositions may be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays and drops suitable for administration to the skin, eyes, ears or nose. Topical administration also includes transdermal administration via means such as transdermal patches.

[0081] For treating diseases of the respiratory tract, the compounds of the invention described above may be administered by inhalation. Inhalable formulations include inhalable powders, propellant-containing metered dose aerosols or propellant-free inhalable formulations, which may be individually administered via a suitable inhalation device selected from a dry powder inhaler, a pressurized metered dose inhaler, or a nebulizer.

[0082] When administered as a dry powder, single or multi-dose inhalers known in the art may be utilized, in which case the powder may be filled into gelatin, plastic or other capsules, cartridges or blister packs, or into a reservoir. A diluent or carrier, such as lactose or any other additive suitable for improving the inhalable fraction, may be added to the powdered compounds of the invention.

[0083] Inhalation aerosols containing propellants such as hydrofluoroalkanes may contain the compounds of the present invention either in solution or in dispersed form. Formulations using propellants may also contain other ingredients such as cosolvents, stabilizers, and optionally other excipients.

[0084] Propellant-free inhalable formulations comprising the compounds of the invention may be in the form of solutions or suspensions in aqueous, alcoholic or hydroalcoholic vehicles and may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft mist nebulizers such as Respimat (©), a registered trademark of Boehringer Ingelheim Pharmaceuticals (Wachtel, H., Kattenbeck, S., Dunne, S. et al., Pulm Ther (2017) 3: 19).

[0085] The compounds of the present invention, regardless of route of administration, can be administered as the sole active agent or in combination with other pharmaceutically active ingredients (i.e., as co-therapeutic agents administered in fixed-dose combinations or in combination therapies of separately formulated active ingredients).

[0086] The compounds of the present invention may be administered as the sole active ingredient or in combination with other pharmaceutical ingredients, including active ingredients currently used in the treatment of respiratory disorders and known to those of skill in the art, such as beta2-agonists, antimuscarinics, corticosteroids, mitogen-activated kinase (P38 MAP kinase) inhibitors, nuclear factor kappa-B kinase subunit beta inhibitors (IKK2), human neutrophil elastase (HNE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modifiers, nonsteroidal anti-inflammatory drugs (NSAIDs), and mucosal modifiers.

[0087] The present invention is also directed to kits containing pharmaceutical compositions of the compounds of the invention, alone or in combination or admixture with one or more pharmaceutically acceptable carriers and / or excipients, and to devices which may be single or multi-dose dry powder inhalers, metered dose inhalers or nebulizers.

[0088] The dosage of the compounds of the invention will depend on a variety of factors, including the particular disease being treated, the severity of the symptoms, the route of administration, the frequency of administration intervals, the particular compound utilized, the efficacy, toxicity profile, and pharmacokinetic profile of the compound.

[0089] Pharmaceutical compositions comprising compounds of the invention suitable for administration by inhalation are in a variety of respirable forms, such as inhalable powders (DPIs), propellant-containing metered dose aerosols (PMDIs) or propellant-free inhalable formulations (e.g., UDVs).

[0090] The present invention is also directed to a device comprising a pharmaceutical composition comprising a compound of the present invention, which may be a single or multiple dose dry powder inhaler, a metered dose inhaler or a nebulizer, particularly a soft mist nebulizer.

[0091] The present invention will be described in more detail below with reference to examples. Features of the present invention will become apparent in the course of the following description of exemplary embodiments, which are set forth to illustrate the invention and are not intended to limit the scope of the invention.

[0092] Preparation of Intermediates and Examples 1a-10a The following compounds, Examples 1a-10a, reported in Table 1 below, were prepared and characterized as follows: Table 1 [Table 11] [Table 12] [Table 13] [Table 14] [Table 15]

[0093] The compound of Example 1a was prepared according to the following scheme: [ka]

[0094] Process 1 Intermediate 1A: (6-Bromo-1-[5-chloro-2-(difluoromethoxy)phenyl]-3-methyl-pyrazolo[4,3-b]pyridine) A round-bottom flask was charged with 1-(5-bromo-3-fluoro-2-pyridyl)ethanone (2.00 g, 9.2 mmol), [5-chloro-2-(difluoromethoxy)phenyl]hydrazine hydrochloride (2.47 g, 10 mmol), and potassium carbonate (3.80 g, 28 mmol) in dimethylformamide (16 mL). The reaction mixture was stirred at 85° C. for 1.5 hours and then at 120° C. for 4 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (80 mL), washed with saturated aqueous NaCl (3×30 mL), and the organic layer was dried over NaSO. The solvent was partially removed under reduced pressure, and the crude product was allowed to stand at room temperature to form a solid. The solid was filtered, washed with petroleum ether, and then dried to give the title product (1.797 g). ES + m / z 388.0 / 390.0 / 392.0 [MH] +

[0095] Process 2 Intermediate 2A: (6-bromo-3-(bromomethyl)-1-[5-chloro-2-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridine) In a round-bottom flask under nitrogen, intermediate 1A (200 mg, 0.51 mmol) and 1,2-dichloroethane (4.0 mL) were added, followed by N-bromosuccinimide (110 mg, 0.62 mmol) and AIBN (2,2'-azobis(2-methylpropionitrile) (17 mg, 0.1 mmol). The reaction mixture was heated at 80 °C for 2 h, then cooled to room temperature and quenched with water (10 mL). The resulting mixture was extracted with dichloromethane (3 × 5 mL), and the organics were combined, washed with saturated aqueous NaCl (10 mL), and dried over NaSO. After evaporation under reduced pressure, the crude material was purified by SPE (solid phase extraction) on silica gel to give the title compound (134 mg). + m / z 465.9 / 467.9 / 469.9 / 491.9 [MH] +

[0096] Process 3 Intermediate 3A: ([6-bromo-1-[5-chloro-2-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-3-yl]methyl acetate) A vial charged with Intermediate 2A (140 mg, 0.30 mmol), dimethylformamide (1.5 mL), and potassium acetate (103 mg, 1.0 mmol) was heated at 60 °C for 1.5 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 5 mL). The organics were combined, washed with saturated aqueous NaCl (2 x 5 mL), dried over NaSO, and evaporated to dryness. The crude product was used in the next synthetic step without further purification. ES + m / z 446.0 / 448.0 / 450.0 [MH] +

[0097] Process 4 Intermediate 4A: ([1-[5-chloro-2-(difluoromethoxy)phenyl]-6-pyrazolo[1,5-a]pyrimidin-3-yl-pyrazolo[4,3-b]pyridin-3-yl]methyl acetate) Intermediate 3A (83 mg, 0.16 mmol) in THF (1 mL) and aqueous tribasic potassium phosphate (0.50 M, 0.65 mL, 0.33 mmol) were degassed with nitrogen for 10 minutes, followed by the addition of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (44 mg, 0.18 mmol) and XPhos-Pd-G3 ((2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate) (6.9 mg, 0.0082 mmol). The reaction mixture was heated at 55°C for 1.5 hours, cooled to room temperature, and diluted with dichloromethane (10 mL) and water (10 mL). The aqueous layer was extracted with dichloromethane (4 x 5 mL), then the organic layers were combined, washed with water (10 mL), and dried over Na2SO4. The solvent was removed under reduced pressure, and the crude residue was purified by SPE (solid phase extraction) on silica gel to give the title compound (66 mg). ES + m / z 485.1.1 / 487.1 [MH] +

[0098] Process 5 Example 1a: ([1-[5-chloro-2-(difluoromethoxy)phenyl]-6-pyrazolo[1,5-a]pyrimidin-3-yl-pyrazolo[4,3-b]pyridin-3-yl]methanol) Intermediate 4A (95%, 48 mg, 0.094 mmol) and methanol (5 mL) were charged in a round-bottom flask, followed by the addition of KCO (0.039 g, 0.28 mmol), and the mixture was stirred at room temperature overnight. The solvent was evaporated, and the crude residue was purified by SPE (solid phase extraction) on silica gel to give the title compound (30 mg). + m / z 443.1 / 445.1 [MH] +

[0099] The compounds of Examples 2a-10a were prepared in a manner similar to that of Example 1a, following the same synthetic sequence; modifications of the reaction conditions, reactants, or solvents used can be readily determined by one skilled in the art by routine optimization procedures.

[0100] Pharmacological activity of compounds (1a-10a) of the present invention Biochemical potency JAK1 (data presented as pIC50 in Table 1) The purpose of this study was to evaluate the activity of novel JAK inhibitors by measuring their ability to inhibit JAK1 kinase activity in a biochemical time-resolved fluorescence resonance energy transfer (TR-FRET) LANCE (LANCE) assay. In the LANCE Ultra kinase assay, a ULight peptide substrate (LANCE Ulight-JAK-1 (Tyr1023) peptide, Perkin Elmer, TRF0121) was phosphorylated in the presence of JAK1 kinase and ATP (equivalent to Km). It was then captured by a Eu-anti-phospho-substrate antibody (LANCE Eu-W1024 anti-phosphotyrosine (PT66), Perkin Elmer, AD0069), bringing the Eu-chelate donor and ULight acceptor dyes into close proximity. Upon excitation at 320 nm, the Eu-chelate transferred its energy to the ULight dye, resulting in fluorescence emission at 665 nm. Inhibitors were tested in duplicate at eleven 5-fold serial dilutions (30 μM to 3 pM) starting from 30 μM. IC50 data calculations, curves, and QC analysis were performed using Excel tools and GraphPadPrism software. QC criteria parameters: Z' > 0.5, Hill Slope range 0.5~5, S:B>2

[0101] In addition to enzymatic efficacy, the effect of inhibitors on JAK1 / JAK3 activity was characterized in a cellular assay against the level of IL-2-induced STAT5 phosphorylation in human peripheral blood mononuclear cells (PBMCs).

[0102] Cell-based PBMC assay (IL-2 stimulated pSTAT5) (data presented as pIC50 in the table) PBMCs were isolated from healthy human volunteers. Cells were seeded into wells and treated with compound and rhIL-2. After 30 minutes of incubation, cells were lysed and pSTAT5 was measured by PathScan Phospho-Stat 5 (Tyr694) ELISA (Cell Signaling). Inhibitors were tested in duplicate at 11 5-fold serial dilutions (30 μM to 3 pM) starting at 30 μM. IC50 data calculations, curves, and QC analysis were performed using Excel Tools and GraphPad Prism software. QC criteria parameter: Z' > 0.35, Hill Slope range 0.5~5, S:B>2

[0103] NMR spectra NMR spectra were recorded on a Bruker Avance III 600 (5 mm RT inverse sprue head), a Bruker DRX500, a Bruker Avance AV400 (5 mm RT direct probe head), and a Bruker DPX300 spectrometer using standard Bruker pulse sequences. DMSO-d6 or CDCl3 was used as the solvent, and TMS was used as the internal standard; in the latter case, the residual solvent peak was used. All experiments were recorded at 25 °C unless otherwise noted.

[0104] LC-MS spectra were recorded on an Acquity UPLC coupled to an SQD mass spectrometer. Chromatography column: Acquity UPLC BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm packing diameter) or Acquity UPLC BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm packing diameter). Column temperature: 40 °C. Mobile phase: A = 0.1% v / v formic acid solution in water, B = 0.1% v / v formic acid solution in acetonitrile, or A = 10 mM aqueous NH4HCO3 (adjusted to pH 10 with ammonia) and B = acetonitrile. Analytical samples were dissolved in a 1:1 mixture of water:acetonitrile. If necessary, approximately 10% DMSO was used to improve solubility.

[0105] Preparation of Intermediates and Examples 1-99 The preparative methods described below and reported in the following schemes should not be construed as limiting the scope of synthetic methods available for preparing the compounds of the present invention. Those skilled in the art will recognize that all embodiments or aspects of the present invention (including Examples 1a-10a) can be prepared using the methods described herein or can be readily adapted using other known methods, reagents, and starting materials.

[0106] In some cases, steps are required to mask or protect functional or reactive moieties, and commonly known protecting groups (PG) can be used in accordance with general principles of chemistry (Protective groups in organic syntheses, 3rd ed. T.W. Greene, P.G.M. Wuts).

[0107] Compounds of formula (Io), which are reported herein again for clarity, including all compounds listed herein above, may generally be prepared according to the procedures shown in the following schemes: Where specific details or steps differ from the general schemes, these are detailed in the specific examples and / or additional schemes.

[0108] [ka]

[0109] Compounds of formula (Io) can be prepared according to Scheme 1. Compound IV is an intermediate in which the general groups r1, r2, r3, and w can be converted to R1, R2, R3, and W, respectively, by procedures well known to those skilled in the art, such as deprotection of protecting groups or functional group transformations, which may involve more than one step. The procedures can be applied to one or more of these groups (r1, r2, r3, and w) to convert intermediate IV to compounds of general formula Io, as detailed in the experimental sections for specific examples. It is clear that when such a transformation is not required (when r1, r2, r3, and w correspond to R1, R2, R3, and W, respectively), any of the general solutions shown below for the preparation of intermediate IV will provide compounds of general formula Io.

[0110] Compounds of formula Io (or intermediate IV) can be obtained by reacting intermediate II with intermediate III to directly introduce W via metal / palladium-catalyzed cross-coupling reactions such as Suzuki coupling, Stille coupling, Buchwald-Hartwig coupling, etc. (Strategic Applications of Named Reactions in Organic Synthesis, L. Kurti, B. Czako, eds. 2005).

[0111] Scheme 1 [ka]

[0112] For example, a suitable palladium-catalyzed cross-coupling for introducing W, when it is a pyrazolo[1,5-a]pyrimidin-3-yl, is the Suzuki coupling. The Suzuki coupling involves the reaction of intermediate II with the corresponding boronic acid or pinacolatoboronate (intermediate III, where w is pyrazolo[1,5-a]pyrimidin-3-yl and A is dihydroxyboronyl or 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl) using tetrakistriphenylphosphinepalladium(0), PdCl(dppf), or XPhos-Pd-G3 [(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1']biphenyl]. This reaction can be carried out in the presence of a Pd catalyst, such as a ligand-palladacycle catalyst precursor, such as [( ... The PMB group can be easily removed by treating the corresponding PMB-protected intermediate IV with a strong organic or inorganic acid under acidic conditions. For example, PMB can be deprotected by treating the intermediate with trifluoroacetic acid alone or in a mixture with an organic solvent such as DCM, THF, etc., typically at room temperature for several hours (typically 1 hour).Suitable protecting groups for protecting the primary and secondary amines ultimately present in the r2 / r3 groups can be carbamate-type protecting groups such as Boc (tert-butoxycarbonyl). The Boc group can be easily removed by treating the Boc-protected intermediate IV with a strong organic or inorganic acid under acidic conditions. For example, the Boc group can be cleaved by treating the intermediate with trifluoroacetic acid alone or in a mixture with an organic solvent such as DCM, DCE, THF, etc., typically at room temperature for several hours (typically 1-3 hours).

[0113] A suitable palladium-catalyzed cross-coupling for introducing W, if it is an imidazo[1,2-b]pyridazin-3-yl, is a Stille coupling, which can be carried out by reacting intermediate II with its corresponding stannane (intermediate III, where w is imidazo[1,2-b]pyridazin-3-yl and A is tributylstannyl or trimethylstannyl) in the presence of a suitable palladium catalyst (such as Pd(PPh3)2Cl2) in a polar organic solvent (e.g., DMF or 1,4-dioxane) with or without an additive (such as a base or lithium salt). Stannanes are generally commercially available or can be easily prepared by those skilled in the art starting from commercially available reagents.

[0114] In another approach, W, when it is an imidazo[1,2-b]pyridazin-3-yl, can be introduced by direct C-H arylation by reacting intermediate II with its corresponding heterocycle (intermediate III, where w is imidazo[1,2-b]pyridazin-3-yl and A is H) in the presence of a suitable palladium catalyst (such as Pd(Oac)) and a suitable phosphine (such as PCy.HBF or CyJohnPhos) in an organic solvent (such as DMF, 1,4-dioxane, or toluene) with a base (such as CsCO or KCO) and with or without a carboxylic acid additive (such as pivalic acid) by heating at a temperature of about 110 °C.

[0115] A suitable palladium-catalyzed cross-coupling to introduce W is the Buchwald-Hartwig coupling when it is (3-oxo-3,4-dihydropyrazin-2-yl)amino. For synthetic convenience, the carbonyl group of (3-oxo-3,4-dihydropyrazin-2-yl)amino should be masked as an alkoxy group (e.g., methoxy) and removed from intermediate IV at the end of the synthesis. Intermediates II and III (where w is 3-methoxypyrazin-2-aminyl and A is H) can be reacted with RuPhos-Pd-G3 (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate) in the presence of a suitable ligand-palladacycle system, such as RuPhos-Pd-G3 (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate), or, in general, with a suitable Pd source (e.g., Pd2(dba)3 or Pd(OA)). c) Reaction of 2) with an appropriate biphenylphosphine ligand type (e.g., RuPhos, X-Phos, etc.) in the presence of a strong organic base such as sodium tert-butoxide or an inorganic base such as CsCO in an organic solvent such as 1,4-dioxane, THF, or toluene with heating at elevated temperatures (typically 80-120°C) for several hours (typically 1-5 hours) can provide intermediate IV (where w is 3-methoxypyrazine-2-aminyl). The methoxy group of intermediate IV can be demethylated by treatment with TMS-Cl (trimethylsilyl chloride) and sodium iodide in acetonitrile at 60-100°C for 1-5 hours to provide compounds of formula Io (where W is (3-oxo-3,4-dihydropyrazin-2-yl)amino).

[0116] The above method may provide at least one non-limiting synthetic route for producing Examples 1-60, Example 76, Examples 85 and 87-98, and one non-limiting synthetic route for producing intermediate IV (wherein r1, r2, r3 and / or w are independently precursors of R1, R2, R3 and / or W).

[0117] In another approach, compounds of formula Io (or intermediate IV) can be prepared by the cyclization reaction of intermediates VI and VII. The cyclization reaction can be carried out by heating (typically 60-170°C) the required reagents in a polar organic solvent such as N-methylpyrrolidone (NMP), dimethylacetamide (DMA), or 1,2-dimethoxyethane (DME) for several hours (typically 1-5 hours) or longer. Intermediate VI can be prepared from intermediates V and III via palladium-catalyzed cross-coupling using conditions similar to those described above for the reaction of intermediates II and III. This approach provides at least one non-limiting synthetic route for the preparation of intermediates 62 and 63 and formula IV.

[0118] Alternatively, compounds of formula Io (or intermediate VI) can be prepared by N-arylation (when r / R is pyridinyl or phenyl) or N-alkylation (when r / R is piperidinyl or benzyl) of intermediate VIII with intermediate IX. N-Arylation can be carried out by a copper-catalyzed Ullmann-type reaction. The Ullmann reaction between an NH heteroaryl and an aryl / heteroaryl halide (chloride, bromide, or iodide) can be carried out in the presence of a suitable copper(I) catalyst / promoter such as CuI, CuO, or CuTC (copper thiophene carboxylate), either without a ligand or with a suitable ligand such as N,N-dimethylglycine, proline, or dimethylcyclohexane-1,2-diamine (DMCHA), in the presence of an inorganic base such as KCO or CsCO, in a polar organic solvent such as DMSO, DMF, or DMA, by heating (typically 90-150°C) for several hours or longer (typically 3-12 hours). Intermediate VIII can be prepared by cyclizing intermediate V with hydrazine (or a protected derivative) using conditions similar to those described for the reaction of intermediates VI and VII. This alternative method may provide at least one non-limiting synthetic route to prepare intermediates of Example 61 and formula IV.

[0119] In another solution, compounds of formula Io can be obtained by further elaboration of specific functional groups present at r1, r2, r3 of intermediate IV (prepared according to Scheme 1) by modification of the functional groups reported in Table 1, thus providing at least one non-limiting synthetic route to prepare the examples reported in the table.

[0120] Table 1 [Table 16] [Table 17] [Table 18]

[0121] The preparation of intermediate II is detailed in Scheme 2. Scheme 2 [ka]

[0122] Intermediate II can be obtained from cyclization of intermediate V with intermediate VII using conditions similar to those described in Scheme 1 for intermediates VI and VII.

[0123] In another approach, intermediate II can be obtained from intermediates X and IX in a manner similar to that described for the N-arylation / N-alkylation of intermediates II and III. Intermediate X can be obtained from intermediate V by cyclization with hydrazine (or a protected derivative) in a manner similar to that described above for intermediates VI and VII in Scheme 1.

[0124] In another solution, intermediate II can be obtained by further modification of the r1 and / or r2 and / or r3 groups by generally accepted methods and in accordance with chemical principles. In the following schemes, the most common transformations that can be used to obtain a particular intermediate II are detailed. For clarity, they are indexed with additional letters.

[0125] Intermediates of formula IIa can be obtained by further elaboration of intermediates of formula IIa' or IIa'' as shown in Scheme 3, when r1 is phenyl and K is -S(O)2NR4R5.

[0126] Scheme 3 [ka]

[0127] Intermediate IIa' can undergo sulfonylation by treatment with chlorosulfonic acid and SO2Cl2, typically at temperatures between 0°C and 5°C, for several hours (typically 1-3 hours), to give the intermediate sulfonyl chloride, which can be converted to the corresponding amine H2N-(CH2) in the presence of a base such as triethylamine (TEA) or pyridine in an organic solvent such as DCM or THF, typically at RT for several hours (typically 1-3 hours). n Alternatively, intermediate IIa″ can be activated to give the intermediate sulfonyl chloride by treatment with SO2Cl2 in an organic solvent such as DMF, typically at temperatures between 0°C and 5°C, followed by the addition of a large excess of the corresponding amine H2N-(CH2) n Treatment with -Z (typically 10-30 equivalents) can provide intermediate IIa.

[0128] In another solution shown in Scheme 4, intermediates of formula IIb (where r2 is H and r3 is -NH(CH2) n Q or -O(CH2) nQ) can be converted into intermediate IIb' by converting it into an amine intermediate (H2N-(CH2) n -Q) or alcohol intermediate (HO-(CH2) n The intermediate IIb can be obtained by the substitution of chlorine by nucleophilic substitution with -Q). The reaction can be carried out by treating the reagents in a high boiling organic solvent such as NMP or DMA and heating at a temperature of about 150°C. Intermediate IIb can be obtained by the substitution of -Q with -NH(CH2). n Alternatively, intermediate IIb' and H2N-(CH2) can be obtained by heating in the presence of a suitable catalyst system such as Pd2(dba)3 / Xantphos, or an alternative suitable Pd source / Buchwald phosphine, and a base such as Cs2CO3, in an organic solvent such as 1,4-dioxane at a temperature of about 100 °C for up to 24 hours. n The r group of intermediate IIb can be prepared by means of Pd-catalyzed N-arylation under conditions starting from -Q. Optionally, the r group of intermediate IIb can be further elaborated by recognized methods, for example, by hydrolysis of the ester moiety in the acid followed by amide coupling to the amide.

[0129] Scheme 4 [ka]

[0130] In another solution reported in Scheme 5, intermediates of formula IIc (when r2 is -CH2CN), intermediate IId (when r2 is -CH2OH), and intermediate IIe (when r2 is -CH2NR4R5) can be prepared from intermediate IIc' in a two-step process. In the first step, the methyl group of intermediate IIc' is selectively brominated by reaction with NBS (N-bromosuccinimide) in the presence of a radical initiator such as AIBN (azobisisobutyronitrile) in a suitable inert organic solvent such as tetrachloromethane to give intermediate IIc''. In the second step, the bromine of intermediate IIc'' undergoes nucleophilic substitution with its corresponding nucleophile: sodium cyanide, potassium carbonate / water, and amine HNR6(CH2). n -Q can provide intermediates IIc, IId and IIe.

[0131] Scheme 5 [ka]

[0132] In an alternative solution reported in Scheme 6, intermediates of formula IIg (where r2 is -C(O)NR6-(CH2)) n -Q) is the corresponding amine HNR6-(CH2) n Intermediate IIf can be obtained by means of amide coupling with -Q. The amide coupling can be carried out by reacting an amine with an acid in an organic solvent such as DMF, DCM, or THF in the presence of a coupling agent such as HATU ((1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), HBTU (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate), or COMU ((1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium), in the presence of an organic base such as TEA, DIEA, or pyridine.

[0133] Scheme 6 [ka]

[0134] Intermediate IIf can be obtained from intermediate IIc''' in a two-step process. In the first step, intermediate IIc''' can be hydrolyzed to its corresponding aldehyde by heating in a mixture of water and an aqueous-organic miscible solvent such as DMSO or DMF at a temperature of about 100°C. In the second step, the aldehyde can be oxidized to its corresponding acid with an oxidizing agent such as sodium chlorite in a mixture of water and an organic solvent such as THF, using an additive such as 2-methyl-2-butene, in the presence of an inorganic phosphate such as sodium dihydrogen phosphate. Alternatively, intermediate IIf can be obtained from intermediate IId by a two-step oxidation involving oxidation of the primary alcohol to the aldehyde by treatment with DMP (Dess-Martin periodinane), followed by oxidation of the aldehyde to acid IIf as described above.

[0135] Intermediate IIc''' can be obtained simultaneously through the same reaction as in the synthesis of intermediate IIc'' shown in Scheme 5.

[0136] Scheme 7 [ka]

[0137] In an alternative solution reported in Scheme 7, intermediates of formula IIi (where r1 is phenyl and K is -S(CH2)) n -Z) and intermediate IIm (where r1 is phenyl and K is -S(O)2(CH2) n-Z) can be obtained from intermediate IIh. Intermediate IIi can be obtained from intermediate IIh by a three-step process as follows. In the first step, the bromine of intermediate IIh is replaced with S-PG by introducing a suitably protected fed-batch hydrogen source (HS-PG), for example, HS-TIPS (triisopropylsilanethiol) via CS palladium-catalyzed coupling. The CS coupling can be carried out by reacting the aryl bromide IIh with HS-PG in the presence of a suitable catalytic system, such as Pd(dba) / Xantphos or another suitable palladium / phosphine source, in an organic solvent such as toluene or DMA, in the presence of a strong base, such as sodium hydride or sodium tert-butoxide, at a temperature up to 100°C. The TIPS group can be partially deprotected during the palladium-catalyzed CS coupling and / or by treating the mixture with an acid, such as hydrochloric acid, to give the corresponding thiophenol derivative of intermediate IIh. In the third step, intermediate IIh thiophenols can be converted to Lg-(CH) by heating them in an organic solvent such as acetone or acetonitrile in the presence of a base such as KCO or CsCO and sodium iodide as an additive at reflux temperature. n In another setting, when n is 0 and Z is aryl or heteroaryl, intermediate IIi can be obtained by reacting the corresponding free thiophenol or TIPS-protected thiophenol with an aryl / heteroaryl halide via palladium-catalyzed C-S coupling as described above. In some cases, intermediate IIi can be obtained by the reaction of HS-(CH2) n -Z can also be obtained directly from intermediate IIh by palladium-catalyzed C-S coupling.

[0138] Intermediate IIm can be obtained from the corresponding intermediate IIi by oxidation of the thioether moiety to a sulfone using an oxidizing agent such as m-CPBA (metachloroperbenzoic acid) or another suitable peroxide in an organic solvent such as DCM at a temperature of about 0°C.

[0139] Scheme 8 [ka]

[0140] In another solution illustrated in Scheme 8, intermediate IIo can be obtained from intermediate IIn by amide coupling by reacting an amine with an acid under the same conditions as described for converting intermediate IIf to intermediate IIg in Scheme 6. Intermediate IIn can be obtained as reported in Scheme 2. Alternatively, intermediate IIn (when R6 is H) can be obtained by Curtius rearrangement of the corresponding carboxylic acid intermediate IIf with DPPA (diphenylphosphorylamide) and a base such as TEA or DIPEA in an organic solvent such as tert-butanol under heating (up to 100-120 °C) to give N-Boc-protected intermediate IIn (when R6 is H). N-Boc-protected intermediate IIn (when R6 is H) can be cleaved to give the free amine or used to introduce R6, which can then be cleaved to give intermediate IIn.

[0141] In another approach, intermediate X can be obtained by further elaboration of the r2 and / or r3 groups by commonly accepted methods. The following schemes (Scheme 9 and Scheme 10) detail the most common transformations that can be used to obtain intermediate Xa and Xb groups.

[0142] Scheme 9 [ka]

[0143] As reported in Scheme 9, intermediate Xa can be obtained from intermediate XIa in a three-step process. First, for synthetic convenience, the NH of the heterocycle needs to be protected with a suitable protecting group before CN arylation. THP (tetrahydropyranyl) represents a suitable protecting group, which can be introduced onto intermediate XIa by reacting with dihydropyran in the presence of a sulfonic acid such as methanesulfonic acid or p-toluenesulfonic acid in an organic solvent such as DCM or THF at reflux or below. In the second step, CN arylation of THP-protected XIa can be carried out using a copper-catalyzed Ullmann reaction or a palladium-catalyzed CN arylation. The copper-catalyzed Ullmann-type reaction can be carried out as described in Scheme 1 for the reaction of intermediate VIII with intermediate IX. The palladium-catalyzed CN arylation can be carried out in a similar manner as described for the conversion of intermediate IIb' to intermediate IIb in Scheme 4. In the final step, deprotection of the THP group can be carried out by treating the corresponding intermediate with an acid such as trifluoroacetic acid or hydrochloric acid in an organic solvent such as isopropanol, 1,4-dioxane, DCM or THF, with or without a scavenger such as triethylsilane.

[0144] Scheme 10 [ka]

[0145] Intermediate Xb can be prepared by converting the bromine of intermediate XIb' into a bromine compound of the formula: HNR(CH) nIntermediate XIb' can be obtained from intermediate XIb in a two-step process involving nucleophilic substitution with an amine of -Q, followed by deprotection of PG. Intermediate XIb' can be obtained from intermediate XIb in a two-step process involving insertion of PG and bromination in a manner similar to that described in Scheme 5. A suitable protecting group that can be used to protect the NH of intermediate XIb during the above-mentioned transformation is the trityl group. The trityl group can be inserted by reacting the substrate with trityl chloride in the presence of a hydride such as sodium hydride in an organic solvent such as THF or dioxane. Removal of the trityl group can be carried out by treating the corresponding substrate with an acid such as trifluoroacetic acid in a solvent such as DCM or THF, with or without a scavenger such as triethylsilane.

[0146] The starting intermediates reported in all schemes described above are either commercially available or can be readily prepared by one skilled in the art starting from commercially available reagents using generally accepted methods, unless their preparation is described in detail herein and / or in the experimental section.

[0147] General Experimental Details Chemical names of compounds were assigned using Structure To Name Enterprise 10.0 Cambridge Software or its latest version.

[0148] Purification by "chromatography" or "flash chromatography" refers to purification using a Biotage SP1 or Interchim puriFlash purification system, or an equivalent MPLC system using a prepacked polypropylene column containing the stationary phase (cartridge). When the product was purified using a Si cartridge, this refers to an Interchim prepacked polypropylene column (or equivalent) containing unbonded activated silica with spherical particles having an average particle size of 15 μm or an Isolute® prepacked polypropylene column (or equivalent) containing unbonded activated silica with irregular particles having an average particle size of 50 μm. When "NH-silica" and "C18-silica" are specified, they refer to aminopropyl-chain bonded silica and octadecyl carbon chain (C18) bonded silica, respectively. Fractions containing the required product (identified by TLC and / or LCMS analysis) were pooled and concentrated under vacuum. When an SCX cartridge is used, "SCX cartridge" refers to a Bond Elut® pre-packed polypropylene column (or equivalent) containing non-end-capped propylsulfonic acid functionalized silica strong cation exchange sorbent.

[0149] If preparative HPLC-MDAP was used for purification (MDAP - Mass Directed Automated Purification), fractions containing the desired product were pooled and the solvent was removed by evaporation or alternatively by lyophilization. If MDAP was used, see the methods reported in the description of the examples.

[0150] NMR method NMR spectra were obtained on a Bruker Avance III 600 (5 mm RT inverse probe head), Bruker DRX 500, Bruker Avance AV 400 (5 mm RT direct probe head), or Bruker DPX 300 spectrometer using standard Bruker pulse sequences. DMSO-d6 or CDCl3 was used as the solvent, and tetramethylsilane was used as the internal solvent. In the latter case, the residual solvent peak was used. Unless otherwise specified, all experiments were recorded at 298 K. Chemical shifts are reported in ppm as δ values ​​relative to tetramethylsilane. Coupling constants (J values) are given in hertz (Hz), and multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, and nd = not determined.

[0151] LCMS method Method 1 Coupling of Acquity UPLC with SQD mass spectrometer; Column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm), Mobile phase A: 0.1% (v / v) formic acid in water, Mobile phase B: 0.1% (v / v) formic acid in acetonitrile;

[0152] [Table 19]

[0153] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1000 AMU

[0154] Method 2 Acquity UPLC coupled to an SQD mass spectrometer; column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm); mobile phase A: 10 mM ammonium bicarbonate aqueous solution (adjusted to pH 10 with ammonia); mobile phase B: acetonitrile

[0155] [Table 20]

[0156] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1000 AMU

[0157] Method 3 Acquity UPLC coupled to an SQD mass spectrometer; Column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm); Mobile phase A: 0.1% (v / v) formic acid in water; Mobile phase B: 0.1% (v / v) formic acid in acetonitrile

[0158] [Table 21]

[0159] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1500 AMU

[0160] Method 4 Acquity UPLC coupled to an SQD mass spectrometer; column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm); mobile phase A: 10 mM ammonium bicarbonate aqueous solution (adjusted to pH 10 with ammonia); mobile phase B: acetonitrile

[0161] [Table 22]

[0162] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1500 AMU

[0163] Method 5 Acquity UPLC coupled to an SQD mass spectrometer; Column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm); Mobile phase A: 0.1% (v / v) formic acid in water; Mobile phase B: 0.1% (v / v) formic acid in acetonitrile

[0164] [Table 23]

[0165] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1500 AMU

[0166] Method 6 Acquity UPLC coupled to an SQD mass spectrometer; column: Acquity BEH C18 (50 mm x 2.1 mm i.d., 1.7 μm); mobile phase A: 10 mM ammonium bicarbonate aqueous solution (adjusted to pH 10 with ammonia); mobile phase B: acetonitrile

[0167] [Table 24]

[0168] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1500 AMU

[0169] Method 7 Agilent LC 1260 Infinity + SFC and Agilent 6540 UHD Accurate-Mass Q-TOF LC / MS; column: Acquity BEH C18 (100 mm x 2.1 mm i.d., 1.7 μm); mobile phase A: 0.1% (v / v) formic acid in water; mobile phase B: 0.1% (v / v) formic acid in acetonitrile

[0170] [Table 25]

[0171] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1500 AMU

[0172] Method 8 Agilent LC 1260 Infinity+SFC and Agilent 6540 UHD Accurate-Mass Q-TOF LC / MS; column: Acquity UPLC BEH C18 (100 mm x 2.1 mm i.d., 1.7 μm); mobile phase A: 0.05% (v / v) aqueous ammonia; mobile phase B: acetonitrile

[0173] [Table 26]

[0174] Column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternate-scan positive and negative electrospray (ES+ / ES-), scan range: 100 to 1000 AMU

[0175] Preparative method 1 Agilent 1290 Infinity II Purification System; Column: Waters XBridge® (C18, 100 mm x 19 mm i.d., 5 μm); Mobile Phase A: 0.1% (v / v) ammonia in water; Mobile Phase B: acetonitrile

[0176] [Table 27]

[0177] Preparative method 2 Agilent 1290 Infinity II Purification System; Column: Waters Xbridge® (C18, 100 mm x 19 mm i.d., 5 μm); Mobile Phase A: 0.1% (v / v) ammonia in water; Mobile Phase B: acetonitrile

[0178] [Table 28]

[0179] In the procedures that follow, some of the starting materials are identified through "Intermediate" or "Example" numbers and step names, which are provided solely to assist those skilled in the art. When reference is made to the use of "similar" or "analogous" procedures, such procedures may involve minor variations, such as reaction temperatures, amounts of reagents / solvents, reaction times, work-up or chromatographic purification conditions, etc., as would be understood by one of ordinary skill in the art.

[0180] The stereochemistry of the compounds in the examples is assigned with the assumption that, where indicated, the absolute configuration at the resolved stereocenter in the starting material is maintained throughout any subsequent reaction conditions.

[0181] Unless otherwise stated, when absolute configuration (R) or (S) is reported in the compound name, the ee% should be assumed to be 90% or greater. All solvents and commercially available reagents were used as received. Where the preparation of starting materials is not described, they are either commercially available, known in the literature, or readily accessible by one skilled in the art using standard procedures.

[0182] Abbreviation AIBN = azobisisobutyronitrile; Boc2O = di-tert-butyl dicarbonate; tBuXPhos = 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl; aq. = aqueous; DABAL-Me3 = bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct; DAST = diethylaminosulfur trifluoride; DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene; DCC = dicyclohexylcarbodiimine; DCE = 1,2-dichloroethane; DCM = dichloromethane; DIPEA = N,N-diisopropylethylamine; DMAP = 4-dimethylaminopyridine; DMCHDA = trans-N,N'-dimethylcyclohexane-1,2-diamine; DMF = N,N-dimethylformamide; DMP = Dess-Martin periodinane; DMSO = dimethyl sulfoxide; DPPA = diphenylphosphoryl azide; EEDQ = 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; EtOAc = ethyl acetate; HATU = (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium) 3-oxide hexafluorophosphate); HBTU = (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); LCMS = liquid chromatography-mass spectrometry; LiHMDS = lithium bis(trimethylsilyl)amide; mCPBA = 3-chloroperbenzoic acid; MW = microwave; NBS = N-bromosuccinimide; PE = petroleum ether; 1 H-NMR = proton nuclear magnetic resonance; RM = reaction mixture; Rt = retention time; RT = room temperature; RuPhos Pd-G3 = (2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate; sat. = saturated; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran; XPhos-Pd-G3 = (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate

[0183] Intermediate Production Intermediate 1 [ka]

[0184] 2-Bromo-4-(difluoromethyl)-1-methoxybenzene (Intermediate 1) To a solution of 3-bromo-4-methoxy-benzaldehyde (1.0 g, 4.7 mmol) in anhydrous DCM (10 mL) was added DAST (1.2 mL, 9.3 mmol) dropwise at 0 °C, and the RM was allowed to warm to RT and stirred overnight. The RM was quenched at 0 °C by slow addition of saturated aqueous NaHCO3 and extracted with DCM (3 × 15 mL). The organic layers were combined, passed through a phase separator, and the solvent was evaporated. The residue was purified by flash chromatography on a Si cartridge eluting with 0-20% EtOAc in cyclohexane to give the title product (797 mg). LCMS (method 2): Rt=1.14 min 1 H-NMR (300 MHz, DMSO-d6) δ:7.77(s,1H), 7.57(d,J=8.6Hz,1H), 7.22(d,J=8.7Hz,1H), 6.96(t,J=56.4Hz,1H), 3.89(s,3H)

[0185] Intermediate 2 [ka]

[0186] (2-Bromo-4-chlorophenyl)(difluoromethyl)sulfane (Intermediate 2) 2-Bromo-4-chloro-benzenethiol (100 mg, 0.447 mmol), sodium chlorodifluoroacetate (157 mg, 1.03 mmol), and CsCO (204 mg, 0.626 mmol) were suspended in DMF (1 mL) and stirred at 100 °C for 2 h. The RM was cooled to RT. Water (10 mL) was added, and the product was extracted with EtOAc (2 × 15 mL). The organic layers were combined and washed with saturated aqueous NaHCO (3 × 5 mL), water (5 mL), and saturated aqueous NaCl (5 mL). The organic layer was dried over NaSO and evaporated under reduced pressure to give the desired product (160 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.37 min 1 H-NMR (300MHz, CDCl3) δ:7.69(d,J=2.3Hz,1H), 7.58(d,J=8.4Hz,1H), 7.32(dd,J=8.4, 2.4Hz,1H), 6.85(t,J=56.3Hz,1H)

[0187] Intermediate 3 [ka]

[0188] 2-Bromo-4-chloro-1-cyclopropoxybenzene (Intermediate 3) N-Bromosuccinimide (52.8 mg, 0.3 mmol) was added portionwise to 1-chloro-4-(cyclopropoxy)benzene (40.0 μL, 0.3 mmol) in 1,1,1,3,3,3-hexafluoropropan-2-ol (2.0 mL), and the RM was stirred at RT overnight. The reaction was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (4 times). The organic layers were combined, passed through a phase separator, and concentrated in vacuo. The crude product was purified by flash chromatography on a Si cartridge, eluting with 0-20% EtOAc in cyclohexane, to give the title product (52 mg). LCMS (method 1): Rt=1.38 min 1H-NMR (300MHz, DMSO-d6) δ:7.67(d,J=2.4Hz,1H), 7.45(dd,J=8.7, 2.3.Hz,1H), 7.39(dd,J=8.8Hz,1H), 3.94-3.97(m,1H), 0-80-08.7(m,2H), 0.68-0.71(m,2H)

[0189] Intermediate 4 Process 1 [ka]

[0190] 4,6-Dichloro-N-methoxy-N-methylnicotinamide (Intermediate 4-1) To a suspension of 4,6-dichloropyridine-3-carboxylic acid (15.0 g, 78 mmol) in anhydrous DCM (225 mL) cooled to 5 °C, DMF (4.5 mL, 59 mmol) was added, followed by the dropwise addition of oxalyl chloride (6.6 mL, 78 mmol). The RM was stirred for 20 h at RT, then the solvent was removed under reduced pressure and the residue was azeotroped with toluene (20 mL). The residue was dissolved in DCM (40 mL) and added dropwise to a mixture of N,O-dimethylhydroxylamine hydrochloride (11 g, 117 mmol) in DCM (100 mL) and TEA (10.8 mL, 78 mmol) at 5 °C. The RM was stirred at RT overnight, quenched with saturated aqueous NaHCO3 (70 mL), the organic layer was washed with water (3 x 25 mL), dried over Na2SO4, and the solvent was removed under reduced pressure to give the title product (16.1 g), which was used in the next synthetic step without further purification. LCMS (method 1): Rt=0.82 min 1 H-NMR (300MHz, CDCl3) δ:8.34(s,1H), 7.42(s,1H), 3.47(s,3H), 3.36(s,3H)

[0191] Process 2 [ka]

[0192] 1-(4,6-Dichloropyridin-3-yl)ethan-1-one (Intermediate 4) To a mixture of intermediate 4-1 (25 g, 105 mmol) and THF (150 mL) at 0-5 °C, MeMgBr (3.0 M in diethyl ether, 79 mL, 238 mmol) was added dropwise over 1 h, and the RM was stirred for an additional 1 h. The RM was quenched with saturated aqueous NH4Cl (100 mL) and stirred for 10 min. The aqueous layer was extracted with EtOAc (100 mL), washed with water (100 mL), saturated aqueous NaCl (100 mL), dried over Na2SO4, and evaporated under reduced pressure. The residue was subjected to bulb-to-bulb distillation (91 °C / 2 x 10 -1 Purification by HPLC (millibar) gave the desired product (15.8 g). LCMS (method 2): Rt=0.89 min 1 H-NMR (600MHz, CDCl3) δ:8.59(s,1H), 7.42(s,1H), 2.66(s,3H)

[0193] Intermediate 5 [ka]

[0194] 1-(4-chloro-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyridin-3-yl)ethan-1-one (Intermediate 5) Intermediate 4 (5.00 g, 26.3 mmol) was dissolved in 1,2-dimethoxyethane (35 mL) under argon, followed by the addition of Pd(PPh) (608 mg, 0.526 mmol). After 10 min, 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (6.45 mg, 26.3 mmol) in 2-propanol (35 mL) and 2 M aqueous KCO (23.7 mL, 47.4 mmol) were added, and the RM was stirred at 95 °C for 1 h. The RM was cooled to RT, diluted with water (120 mL), and the precipitate formed was collected by filtration, washed with acetonitrile (2 × 50 mL), and dried at 45 °C for 1 h to give the title compound (5 g), which was used in the next step without further purification. LCMS (method 2): Rt=0.89 min, ES + m / z 272.9 / 274.9 [M+H] +

[0195] Intermediate 6 [ka]

[0196] 3-Methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 6) Intermediate 5 (500 mg, 1.83 mmol) in NMP (10 mL) and hydrazine monohydrochloride (126 mg, 1.83 mmol) was heated at 100 °C overnight. After cooling to RT, the RM was quenched with saturated aqueous NaHCO and extracted with EtOAc (4 × 15 mL). The organic layers were combined, washed with saturated aqueous NaCl (5 × 20 mL), dried over NaSO, and concentrated in vacuo. The crude material was triturated with DCM to give the desired product (167 mg). LCMS (method 2): Rt=0.64 min, ES + m / z 251.0 [M+H] +

[0197] Intermediate 7a Process 1 [ka]

[0198] 4-Bromo-1-(difluoromethoxy)-2-nitrobenzene (Intermediate 7a-1) 4-Bromo-2-nitro-phenol (22 g, 14 mmol), chlorodifluoroacetic acid sodium salt (35 g, 232 mmol), and CsCO (46 g, 141 mmol) were suspended in DMF / water (250 / 25 mL) and stirred at 100 °C for 1.5 h. The RM was concentrated in vacuo, diluted with water (200 mL), and extracted with EtOAc (2 × 200 mL). The organic layers were combined, washed with saturated aqueous NaHCO (3 × 150 mL), saturated aqueous NaCl (150 mL), dried over NaSO, and evaporated under reduced pressure to give the title product (25.9 g), which was used in the next step without further purification. LCMS (method 2): Rt=1.14 min 1 H-NMR (400MHz, CDCl3) δ:8.04(d,J=2.4Hz,1H), 7.71(dd,J=8.8, 2.5Hz,1H), 7.28(dt,J=8.8, 1.0Hz,1H), 6.58(t,J=73Hz,1H)

[0199] Process 2 [ka]

[0200] 5-Bromo-2-(difluoromethoxy)aniline (Intermediate 7a) Intermediate 7a-1 (25.9 g, 96.6 mmol) was dissolved in acetic acid (200 mL), then iron (8.10 g, 145 mmol) was added portionwise and the RM was stirred at 90° C. for 3 h. After cooling to RT, the RM was diluted with DCM (700 mL) and washed with saturated aqueous NaHCO (2×800 mL). The organic layer was filtered through a bed of diatomaceous earth, washed with saturated aqueous NaCl (400 mL), dried over NaSO, and evaporated under reduced pressure. The crude material was dissolved in DCM (400 mL), washed with aqueous 10% w / w NaCO (3×200 mL), dried over NaSO, and evaporated under reduced pressure. The residue was distilled (60° C. / 5.9×10 -2 Purification by HPLC at 1000 kJ / millibar gave the title product (15.5 g). LCMS (method 2): Rt=1.05 min 1 H-NMR (400MHz, CDCl3) δ:6.92-6.85(m,2H), 6.79(dd,J=8.5, 2.5Hz,1H), 6.41(t,J=73.0Hz,1H), 3.97(brs,2H)

[0201] Intermediate 7b Process 1 [ka]

[0202] (4-(difluoromethoxy)-3-nitrophenyl)(methyl)sulfane (Intermediate 7b-1) To intermediate 7a-1 (2.81 g, 11.0 mmol) in dry toluene (45 mL) was added sodium thiomethoxide (2.06 g, 29 mmol), and the RM was degassed before adding Xantphos Pd-G3 (498 mg, 0.53 mmol). The RM was stirred at 85 °C overnight. After cooling to RT, the RM was diluted with EtOAc (200 mL) and washed with saturated aqueous NaCl (2 × 100 mL) and water (3 × 100 mL). The organic layer was dried over Na2SO4, the solvent was removed under reduced pressure, and the residue was purified by flash chromatography on a Si cartridge eluting with 0-10% EtOAc in PE to give the title product (471 mg). LCMS (method 2): Rt=1.15 min 1 H-NMR (300MHz, CDCl3) δ:7.70(d,J=2.5Hz,1H), 7.42(dd,J=8.7, 2.5Hz,1H), 7.29(dt,J=8.7, 1.0Hz,1H), 6.56(t,J=73.1Hz,1H), 2.52(s,1H)

[0203] Process 2 [ka]

[0204] 2-(Difluoromethoxy)-5-(methylthio)aniline (Intermediate 7b) Intermediate 7b was prepared in a similar manner to intermediate 7a (step 2) starting from intermediate 7b-1. LCMS (method 2): Rt=1.00 min 1 H-NMR (300MHz, CDCl3) δ:6.93(d,J=8.7Hz,1H), 6.66(d,J=2.3Hz,1H), 6.58(dd,J=8.6, 2.3Hz,1H), 6.40(t,J=74.1Hz,1H), 3.84(bs,2H), 2.42(s,1H)

[0205] Intermediate 8a [ka]

[0206] (5-Chloro-2-(difluoromethoxy)phenyl)hydrazine hydrochloride (Intermediate 8a) To a solution of 5-chloro-2-(difluoromethoxy)aniline (12.8 g, 66.1 mmol) in concentrated HCl (aqueous, 37% w / w, 45 mL) at 0°C was added vigorously (maintaining the temperature at <5°C), followed by the dropwise addition of a solution of NaNO (5.93 g, 86.0 mmol) in water (45 mL). The RM was stirred at 0°C for 90 min, followed by the dropwise addition of a solution of tin(II) chloride (37.6 g, 198 mmol) in concentrated HCl (aqueous 37% w / w, 45 mL) while maintaining the temperature at <5°C. The RM was stirred overnight at 4°C. The RM was diluted with saturated aqueous NaCl (100 mL), the pH adjusted to 10 with aqueous 20% w / w NaOH, filtered through a pad of diatomaceous earth, and subsequently washed with water (2 x 100 mL) and DCM (6 x 100 mL). The organic layer was separated, washed with water (200 mL), dried over NaSO, and the solvent was removed under reduced pressure to give the first crop of crude product. Further washing of the diatomaceous earth pad with DCM gave a second crop of crude product. The combined crops were dissolved in 1,4-dioxane (100 mL) and treated with 4 N HCl in 1,4-dioxane (9.64 mL, 38.53 mmol) at RT for 30 min to form a precipitate, which was collected by filtration, washed with 1,4-dioxane, and dried to give the title compound (13 g), which was used in the next step without further purification. LCMS (method 2): Rt=0.95 min, ES- m / z 207.0 / 209.0 [MH] -

[0207] Preparation of Intermediates 8b to 8e The following intermediates were prepared in a similar manner to intermediate 8a from the starting materials indicated.

[0208] [Table 29]

[0209] Intermediate 9 Process 1 [ka]

[0210] 3-Bromo-4-methoxybenzenesulfonic acid (Intermediate 9-1) To a mixture of 3-bromo-4-methoxy-benzenesulfonyl chloride (3 g, 10.5 mmol) in 1,4-dioxane (6 mL) was added water (6 mL) and the RM was refluxed for 3 h. The RM was evaporated to dryness to give the title product (2.8 g), which was used in the next step without further purification. LCMS (method 1): Rt=0.52 min, ES- m / z 264.7 / 266.7[MH] -

[0211] Process 2 [ka]

[0212] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxybenzenesulfonic acid (Intermediate 9) Copper(I) iodide (1.13 g, 6.0 mmol), N,N-dimethylglycine (1.23 g, 12 mmol), KCO (1.65 g, 12 mmol), intermediate 9-1 (2.8 g, 10 mmol), and 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (1 g, 6 mmol) in DMSO (15 mL) were stirred overnight at 100 °C under argon. After cooling to RT, the RM was diluted with aqueous 1 M HCl (15 mL) and filtered to remove undissolved solids. The aqueous extract was washed with DCM (3 × 15 mL) and then lyophilized. The lyophilized residue was purified by flash chromatography on C18 silica gel with a gradient elution of 5–99% acetonitrile in water (+0.1% v / v HCOOH) to give the desired product (480 mg). LCMS (Method 1): Rt=0.63 min, ES + m / z 353.9 / 355.8 [M+H] +

[0213] Intermediate 10 Process 1 [ka]

[0214] 6-Chloro-1-(2-methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 10-1) Copper(I) iodide (511 mg, 2.69 mmol), N,N-dimethylglycine (554 mg, 5.37 mmol), KCO (1.48 mg, 10.7 mmol), 1-bromo-2-methoxy-benzene (2 mL, 16.1 mmol), and 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (900 mg, 5.37 mmol) in DMSO (20 mL) were stirred overnight at 100 °C under argon. After cooling to RT, the RM was diluted with EtOAc (100 mL) and washed with 15% w / w aqueous ammonia (3 × 100 mL) and saturated aqueous NaCl (5 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0–15% EtOAc in DCM to give the desired compound (950 mg). LCMS (method 2): Rt=1.09 min, ES + m / z 273.9 / 275.7[M+H] +

[0215] Process 2 [ka]

[0216] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxybenzenesulfonyl chloride (Intermediate 10) Intermediate 10-1 (500 mg, 1.8 mmol) was cooled in an ice bath, and then ClSO3H (2.8 mL, 42 mmol) was added slowly under argon. The RM was stirred at 0-5 °C for 1 h, and SOCl2 (0.56 mL, 7.6 mmol) was added and stirred for an additional 1 h. After quenching the RM in a water / ice mixture, the formed precipitate was collected by filtration, washed with ice-cold water, and dried to give the title product (620 mg), which was used in the next step without further purification. LCMS (Method 1): Rt=1.18 min, ES + m / z 371.4 / 373.6 / 375.5 [M+H] +

[0217] Intermediate 11a [ka]

[0218] 3-((3-Bromo-4-methoxyphenyl)sulfonyl)dihydrofuran-2(3H)-one (Intermediate 11a) 3-Bromo-4-methoxybenzenesulfonyl chloride (500 mg, 1.75 mmol), NaSO (441 mg, 3.50 mmol), and NaHCO (294 mg, 3.50 mmol) were stirred in water (3.75 mL) at RT for 1.5 h. Tetrabutylammonium bromide (35.0 mg, 0.109 mmol) and 3-bromotetrahydrofuran-2-one (321 μL, 3.50 mmol) were added. The RM was stirred at 70 °C for 1.5 h and then partitioned between DCM and water. The organic layer was dried over NaSO and concentrated under reduced pressure. The residue was chromatographed on silica eluting with EtOAc / hexane (1:1) to give the title product (160 mg). LCMS (method 2): Rt=0.91 min, ES- m / z=333.1 / 335.1 [MH] -

[0219] Intermediate 11b [ka]

[0220] 2-Bromo-1-methoxy-4-(propylsulfonyl)benzene (Intermediate 11b) The title compound was prepared in a similar manner to intermediate 11a, starting from 3-bromo-4-methoxy-benzenesulfonyl chloride and 1-iodopropane. LCMS (method 2): Rt=1.03 min 1 H-NMR (300MHz, CDCl3) δ:8.05(d,J=2.3Hz,1H), 7.81(dd,J=8.5,2.3Hz,1H), 6.99(d,J=8.6Hz,1H ), 3.96(s,3H), 3.00-3.05(m,2H), 1.66-1.79(m,2H), 0.98(t,J=7.1Hz,3H)

[0221] Intermediate 11c [ka]

[0222] 2-Bromo-1-methoxy-4-(methylsulfonyl)benzene (Intermediate 11c) The title compound was prepared in a similar manner to intermediate 11a starting from 3-bromo-4-methoxy-benzenesulfonyl chloride and iodomethane. LCMS (method 2): Rt=0.86 min 1 H-NMR (300MHz, DMSO-d6) δ:8.07(d,J=2.2Hz,1H), 7.90(dd,J=8.7, 2.2Hz,1H), 7.33(d,J=8.7Hz,1H), 3.99(s,3H), 3.21(s,3H)

[0223] Intermediate 12 [ka]

[0224] 4-Bromo-1-(difluoromethoxy)-2-iodobenzene (Intermediate 12) 4-Bromo-2-iodo-phenol (5.00 g, 16.7 mmol), sodium chlorodifluoroacetate (5.87 g, 38.5 mmol), and CsCO (7.63 mg, 23.4 mmol) in DMF (25 mL) were stirred at 100 °C for 2 h. After cooling to RT, the RM was poured into water (250 mL) and filtered. The filtrate was extracted with EtOAc (2 × 50 mL). The organic layers were combined, washed with saturated aqueous NaHCO (3 × 40 mL), water (40 mL), saturated aqueous NaCl (40 mL), dried over MgSO, and the solvent was evaporated under reduced pressure to give the desired product (4.50 g), which was used in the next step without further purification. LCMS (method 2): Rt=1.31 min 1 H-NMR (300MHz, CDCl3) δ:7.96(d,J=2.3Hz,1H), 7.44(dd,J=8.7, 2.4Hz,1H), 7.02(d,J=8.7Hz,1H), 6.48(t,J=73.0Hz,1H)

[0225] Intermediate 13a Process 1 [ka]

[0226] 4-Bromo-2-fluoro-5-methoxyphenol (Intermediate 13a-1) To a mixture of 2-fluoro-5-methoxy-phenol (400 mg, 2.81 mmol) in hexafluoroisopropanol (11.3 mL) was added NBS (501 mg, 2.81 mmol) and the RM was stirred at RT for 1 h. The RM was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3 (3 x 15 mL), saturated aqueous NaCl, dried over Na2SO4, and evaporated under reduced pressure to give the title product (28 mg), which was used in the next synthetic step without further purification. LCMS (Method 1): Rt=0.92 min, ES- 219.0 / 221.1 [MH] -

[0227] Process 2 [ka]

[0228] 1-Bromo-5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)benzene (Intermediate 13a) To a mixture of intermediate 13a-1 (724 mg, 3.28 mmol) in DMF (6.3 mL) at 0 °C, PMB-Cl (577 μL, 4.26 mmol) and anhydrous K2CO3 (1.36 g, 9.83 mmol) were added. The RM was stirred at 0 °C for 1 h and at RT overnight. The RM was diluted with EtOAc (25 mL) and washed with saturated aqueous NaHCO3 (3 × 15 mL) and saturated aqueous NaCl (15 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-10% EtOAc in cyclohexane to give the title product (567 mg). LCMS (method 2): Rt=1.35 min 1 H-NMR (300MHz, CDCl3) δ:7.32(m,2H), 7.25(d,J=10.2Hz,1H), 6.89(m,2H), 6.56(d,J=7.1Hz,1H), 5.06(s,2H), 3.80(s,3H), 3.78(s,3H)

[0229] Intermediate 13b-c The following intermediates were prepared in a similar manner to intermediate 13a from the starting materials indicated.

[0230] [Table 30]

[0231] Intermediate 14 [ka]

[0232] 1-Bromo-2-methoxy-4-(methoxymethoxy)benzene (Intermediate 14) (Intermediate 14) A solution of 4-bromo-3-methoxyphenol (160 mg, 0.67 mmol) in DMF (400 μL) was added to a suspension of NaH (60% dispersion in mineral oil, 48.2 mg, 1.21 mmol) in DMF (1.2 mL) at 0°C. The RM was stirred for 30 min, followed by the addition of chloro(methoxy)methane (91.0 μL, 1.14 mmol). The RM was stirred at RT for 2 h, then quenched with water (10 mL) and extracted with diethyl ether (10 mL). The organic layer was washed with saturated aqueous NaCl (2 × 10 mL), dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0–50% EtOAc in cyclohexane to give the title product (202 mg). LCMS (method 2): Rt=1.14 min 1 H-NMR (300MHz, CDCl3) δ:7.38(d,J=9.0Hz,1H), 6.60(d,J=2.7Hz,1H), 6.54(dd,J=8.7, 2.7Hz,1H), 5.14(s,2H), 3.85(s,3H), 3.46(s,1H)

[0233] Intermediate 15 [ka]

[0234] 6-Chloro-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 15) Dihydropyran (3.4 mL, 37.4 mmol) and methanesulfonic acid (0.16 mL, 2.5 mmol) were added to 6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine (3.48 g, 11.1 mmol) in DCM (33 mL) and THF (16.6 mL). The RM was stirred at 40 °C for 2 h and then at RT overnight. The solvent was evaporated and the residue was purified by flash chromatography on a Si cartridge eluting with 0-100% EtOAc in cyclohexane to give the title product (1.48 g). LCMS (method 2): Rt=1.18 min, ES + m / z 364.0 / 366.0 [M+H] +

[0235] Intermediate 16 [ka]

[0236] 6-Chloro-3-methyl-1-trityl-1H-pyrazolo[4,3-c]pyridine (Intermediate 16) Sodium hydride (60.0% dispersion in mineral oil, 1.00 g, 25.0 mmol) was added portionwise to 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (2.50 g, 14.9 mmol) in dry THF (50.0 mL). The RM was stirred at 0 °C for 1 h, then trityl chloride (5.10 g, 18.3 mmol) was added portionwise, and the RM was stirred at RT overnight. The RM was quenched with saturated aqueous NH4Cl at 0-5 °C, and the THF was removed under reduced pressure. The remaining mixture was extracted with EtOAc (3x). The combined organic layers were concentrated, and the precipitate that formed was collected by filtration, washed with EtOAc, and dried to give the title product (3.77 g). LCMS (method 2): Rt=1.51, ES + m / z 410.2 / 421.1 [M+H] +

[0237] Intermediate 17a Process 1 [ka]

[0238] N1-(6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine (Intermediate 17a-1) L-Proline (85.5 mg, 0.74 mmol) and copper(I) iodide (94.3 mg, 0.5 mmol) were added to a mixture of Intermediate 15 (900 mg, 2.48 mmol), N',N'-dimethylethane-1,2-diamine (1.23 mL, 11.3 mmol), and K2CO3 (2.05 g, 14.9 mmol) in DMF (8.0 mL), and the RM was stirred at 110 °C for 2 h under an argon atmosphere. After cooling to RT, the RM was diluted with water (80 mL) and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed with saturated aqueous NaHCO3, passed through a phase separator, and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge, eluting with 0-100% DCM / MeOH / NH4OH (90:9:0.5) in DCM to give the title compound (630 mg). LCMS (method 1): Rt=0.62 min, ES + m / z 323.9 / 325.9 [M+H] +

[0239] Process 2 [ka]

[0240] N1-(6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine (Intermediate 17a) Triethylsilane (932 μL, 5.84 mmol) was added dropwise to intermediate 17a-1 (630 mg, 1.95 mmol) in DCM (9 mL) / TFA (2.29 mL, 29.9 mmol). The RM was stirred at RT for 1 h, then diluted with DCM and extracted with saturated aqueous NaHCO (10 mL). The aqueous layer (adjusted to pH 9.6) was further extracted with EtOAc (3×) followed by DCM / iPrOH (1:1). The organic layers were combined, passed through a phase separator, and evaporated under reduced pressure to give the title product (396 mg), which was used in the next step without further purification. LCMS (method 1): Rt=0.39 min, ES + m / z 240.0 / 242.0 [M+H] +

[0241] Preparation of Intermediates 17b to 17d The following intermediates were prepared in a similar manner to intermediate 17a from the starting material indicated, used in place of N',N'-dimethylethane-1,2-diamine in step 1.

[0242] [Table 31]

[0243] Intermediate 17e Process 1 [ka]

[0244] 1-(4-(6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)piperazin-1-yl)ethan-1-one (Intermediate 17e-1) Intermediate 15 (150 mg, 0.41 mmol), 1-piperazin-1-ylethanone (63.5 mg, 0.495 mmol), Xanthphos (23.9 mg, 0.04 mmol), Pd(dba) (11.9 mg, 0.02 mmol), and CsCO (269 mg, 0.83 mmol) in 1,4-dioxane (2.7 mL) were heated at 90 °C for 16 h under a nitrogen atmosphere. After cooling to RT, the RM was diluted with water (10 mL) and extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed with saturated aqueous NaCl (10 mL), dried over anhydrous MgSO, and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0–50% DCM / MeOH (20:1) in DCM to give the title product (105.3 mg). LCMS (method 2): Rt=0.94 min, ES + m / z 364.2 / 366.2 [M+H] +

[0245] Process 2 [ka]

[0246] 1-(4-(6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)piperazin-1-yl)ethan-1-one (Intermediate 17e) HCl (4 M in 1,4-dioxane, 3.7 mL, 14.9 mmol) was added dropwise to a mixture of intermediate 17e-1 (140 mg, 0.331 mmol) in isopropanol (3.7 mL). The RM was stirred at RT for 2 h and then partitioned between water (pH adjusted to 8) and DCM (30 mL). The aqueous layer was further extracted with DCM (2 x 15 mL), and the organic layers were combined, dried over MgSO, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography on a 4-cartridge eluting with 0-50% DCM / MeOH (10:1) in DCM to give the title product (65.9 mg). LCMS (method 2): Rt=0.61 min, ES + m / z 280.1 / 282.1 [M+H]+

[0247] Intermediate 17f Process 1 [ka]

[0248] (1-(6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)methanol (Intermediate 17f-1) The title product was obtained from intermediate 15 and azetidin-3-ylmethanol hydrochloride in a similar manner to intermediate 17e-1. LCMS (method 2): Rt=0.84 min, ES + m / z 323.1 / 325.1 [M+H] +

[0249] Process 2 [ka]

[0250] (1-(6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)methanol (Intermediate 17f-2) The title product was obtained from intermediate 17f-1 in a similar manner to intermediate 17a (step 2). LCMS (method 2): Rt=0.53 min, ES + m / z 239.1 / 240.1 [M+H] +

[0251] Intermediate 18a [ka]

[0252] 6-Chloro-1-(5-fluoro-2-methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 18a) Copper(I) iodide (170 mg, 0.89 mmol), N,N-dimethylglycine (185 mg, 1.79 mmol), K2CO3 (495 mg, 3.58 mmol), 2-bromo-4-fluoro-1-methoxy-benzene (697 μL, 5.4 mmol), and 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (300 mg, 1.8 mmol) were stirred in DMSO (3 mL) at 100 °C under an argon atmosphere overnight. The RM was diluted with EtOAc (15 mL) and washed with 15% aqueous ammonia (3 × 15 mL) and saturated aqueous NaCl (10 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0–40% EtOAc in cyclohexane to give the desired product (380 mg). LCMS (method 2): Rt=1.10 min, ES + m / z 292.0 / 293.9 [M+H] +

[0253] Preparation of Intermediates 18b to 18y The following intermediates were prepared from the indicated starting materials in a similar manner to intermediate 18a. Minor modifications to base, solvent, temperature, reaction time, ligand and / or copper, where made, are detailed in parentheses.

[0254] [Table 32] [Table 33] [Table 34] [Table 35] [Table 36] [Table 37]

[0255] Intermediate 18z [ka]

[0256] 6-Chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 18z) Intermediate 4 (500 mg, 2.6 mmol), Intermediate 8a (680 mg, 2.8 mmol), and NMP (3 mL) were stirred at 60° C. for 1 h and at 120° C. for 5 h. After cooling to RT, the RM was poured into water (20 mL) and stirred for 10 min. The formed precipitate was collected by filtration, washed with water, and purified by flash chromatography on a Si cartridge eluting with 0-24% EtOAc in cyclohexane to give the title product (242 mg). LCMS (method 2): Rt=1.25 min, ES + m / z 344.1 / 346.1 / 348.1 [M+H] +

[0257] Purification by flash chromatography afforded a second pure product, which was subjected to LC-MS analysis to confirm the des-methyl structure of intermediate 18z, identifying it as intermediate 18aa. [ka]

[0258] 4-Chloro-2-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol (Intermediate 18aa) LCMS (method 2): Rt=0.65 min, ES + m / z 294.1 / 296.1 / 298.1 [M+H] +

[0259] Intermediate 18ab [ka]

[0260] 6-Chloro-1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 18ab) Intermediate 4 (180 mg, 0.95 mmol) and intermediate 8d (243 mg, 0.95 mmol) were stirred in NMP (2 mL) at RT overnight and then at 170 °C under microwave irradiation for 1 h. After cooling to RT, the RM was diluted with water (15 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were combined, washed with water (5 × 15 mL), dried over NaSO, and the solvent was removed in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-8% EtOAc in cyclohexane to give the title product (144 mg). LCMS (method 2): Rt=1.26 min, ES + m / z 356.2 / 358.1 [M+H] +

[0261] Intermediate 18ac Process 1 [ka]

[0262] 4-Chloro-2-(4,6-dichloro-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol (Intermediate 18ac-1) 2,4,6-Trichloropyridine-3-carbaldehyde (2 g, 9.5 mmol) and intermediate 8e (1.99 g, 9.0 mmol) in NMP (12 mL) were stirred at RT for 30 min, then at 150 °C under MW irradiation for 7.5 h. After cooling to RT, the RM was partitioned between EtOAc (200 mL) and water (200 mL), and the aqueous layer was further extracted with EtOAc (150 mL). The organic layers were combined, washed with water (150 mL), saturated aqueous NaCl (150 mL), dried over MgSO, and evaporated under reduced pressure to give the title compound (2.6 g), which was used in the next step without further purification. LCMS (method 2): Rt=1.26 min, ES- m / z 312.0 / 314.0 / 316.0 [MH] -

[0263] Process 2 [ka]

[0264] 4,6-Dichloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 18ac) K2CO3 (2.28 g, 17 mmol) and iodomethane (772 μL, 12 mmol) were added to a mixture of intermediate 18ac-1 (2.6 g, 8.3 mmol) in DMF (6 mL). The RM was stirred at RT for approximately 2 h, diluted with EtOAc (20 mL), and washed with saturated aqueous NaHCO3 (2 × 20 mL). The organic layer was washed with saturated aqueous NaCl and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-50% cyclohexane:DCM (3:1) in cyclohexane to give the title product (167 mg). LCMS (method 2): Rt=1.38 min 1 H-NMR (300MHz, CDCl3) δ:8.30(d,J=0.9Hz,1H), 7.46(s,1H), 7.44(dd,J=9.3, 2.3Hz,1H), 7.09(d,J=0.9Hz,1H), 7.02-7.06(m,1H), 3.81(s,3H)

[0265] Intermediate 18ad [ka]

[0266] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxy-N-methylbenzenesulfonamide (Intermediate 18ad) To a cooled (ice bath) mixture of intermediate 9 (70 mg, 0.20 mmol) in dry DMF (0.5 mL) was added SOCl (58 μL, 0.79 mmol), and the RM was stirred at 0–5° C. for 30 min, followed by the dropwise addition of methylamine (2.0 M in THF, 2.0 mL, 4.0 mmol). The RM was stirred for an additional 10 min, then diluted with EtOAc (15 mL) and washed with saturated aqueous NaHCO (3×10 mL) and saturated aqueous NaCl (10 mL). The organic layer was dried over NaSO and evaporated to dryness. The crude material was purified by flash chromatography on a Si cartridge, eluting with 0–40% EtOAc in DCM, to give the title product (40 mg). LCMS (method 1): Rt=0.91 min, ES + m / z 367.0 / 369.0 [M+H] +

[0267] Intermediate 18ae [ka]

[0268] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide (Intermediate 18ae) The title product was prepared in a similar manner to intermediate 18ad, starting from intermediate 9, ethanolamine and 1 equivalent of TEA. LCMS (Method 1): Rt=0.81 min, ES + m / z 397.0 / 398.9 [M+H] +

[0269] Intermediate 18af [ka]

[0270] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxy-N-(3-(4-methylpiperazin-1-yl)propyl)benzenesulfonamide (Intermediate 18af) Intermediate 10 (50 mg, 0.13 mmol) and TEA (56 μL, 0.4 mmol) were added to a solution of 3-(4-methylpiperazin-1-yl)propan-1-amine (22 μL, 0.13 mmol) in dry DCM (1 mL), and the RM was stirred at RT for 1 h. The RM was diluted with EtOAc (10 mL) and washed with saturated aqueous NaHCO (3 × 5 mL) and saturated aqueous NaCl (5 mL). The organic layer was dried over NaSO and evaporated to dryness. The crude material was purified by flash chromatography on a Si cartridge eluting with 0-90% DCM / MeOH / NH OH (90:9:0.5) in DCM to give the title product (45 mg). LCMS (method 2): Rt=0.86 min, ES + m / z 493.1 / 495.0 [M+H] +

[0271] Production of intermediates 18ag-18ai The following intermediates were prepared in a similar manner to intermediate 18af from the starting materials indicated. Where minor modifications to base, solvent, and / or temperature were made, these are detailed in brackets.

[0272] [Table 38]

[0273] intermediate 18aj [ka]

[0274] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-N,N-dimethyl-1H-pyrazolo[4,3-c]pyridin-3-amine (Intermediate 18aj) To a mixture of intermediate 18r (46 mg, 0.14 mmol) in MeOH (2.8 mL) / THF (2 mL) was added aqueous formaldehyde (37%, 53 μL, 0.71 mmol), acetic acid (4 μL, 0.07 mmol), and Na(CN)BH (18 mg, 0.28), and the RM was stirred at RT overnight. Another 1 equivalent of Na(CN)BH, formaldehyde, and acetic acid were added, and stirring continued at 40 °C for another 6 h. The RM was diluted with water and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge, eluting with 0-10% MeOH in EtOAc, to give the title product (42.6 mg). LCMS (method 2): Rt=1.26 min, ES + m / z 337.1 / 339.1 [M+H] +

[0275] intermediate 18ak Process 1 [ka]

[0276] N1-(1-(5-bromo-2-(difluoromethoxy)phenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)-N3,N3-dimethylpropane-1,3-diamine (Intermediate 18ak-1) The title product was prepared in a similar manner to intermediate 18a starting from intermediate 17b and intermediate 12. LCMS (method 2): Rt=1.34, ES + m / z 474.1 / 476.1 / 478.1 [M+H] +

[0277] Process 2 [ka]

[0278] N1-(6-chloro-1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N3,N3-dimethylpropane-1,3-diamine (Intermediate 18ak) Intermediate 18ak-1 (43 mg, 0.09 mmol), sodium thiomethoxide (19 mg, 0.27 mmol), Pd2(dba)3 (7.8 mg, 8.6 μmol), Xantphos (10 mg, 18 μmol), and degassed toluene (1 mL) were stirred under nitrogen at 80 °C. After 3 h, an additional equivalent of Pd2(dba)3 (7.8 mg) and Xantphos (10 mg) was added, and stirring was continued at 80 °C for another 3 h. The RM was allowed to cool to RT, and the formed precipitate was filtered. The filtrate was diluted with EtOAc (10 mL) and washed with saturated NaHCO3 (10 mL) and saturated aqueous NaCl (10 mL). The organic layer was evaporated under reduced pressure and the residue purified on a 4g Si cartridge eluting with 0-100% DCM / MeOH / NH4OH in DCM (90:5:0.5) to give the title product (27mg). LCMS (method 2): Rt=1.38, ES + m / z 442.2 / 444.2 [M+H] +

[0279] Intermediate 18al [ka]

[0280] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-3-(piperazin-1-yl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 18al) To a suspension of intermediate 18s (35 mg, 0.071 mmol) in methanol (1.7 mL), HCl (4.0 M in 1,4-dioxane, 1.7 mL, 6.8 mmol) was added dropwise and the RM was stirred at 60 °C for 2 h. The RM was partitioned between water and DCM (30 mL), and the aqueous layer (after adjusting the pH to 10.5) was further extracted with DCM (2 × 15 mL). The organic layers were combined, dried over MgSO and evaporated to dryness. The crude material was purified by flash chromatography on a Si cartridge eluting with 0-80% DCM / MeOH (10:1) in DCM to give the title product (6.6 mg). LCMS (method 2): Rt=1.09, ES + m / z 378.2 / 380.2 [M+H] +

[0281] Intermediate 18am [ka]

[0282] N-(6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)acetamide (Intermediate 18am) Intermediate 18l (35.0 mg, 0.113 mmol) was dissolved in acetic anhydride (1 mL) and stirred at RT for 4 h. The RM was poured into ice-cold water (10 mL), the pH was adjusted to 7 with saturated aqueous NaHCO3, and extracted with EtOAc. The organic layers were combined, washed with saturated aqueous NaHCO3 (2 x 3 mL), dried over Na2SO4, and concentrated. The residue was purified by flash chromatography on a Si cartridge eluting with EtOAc / MeOH (9:1) to give the desired product (29 mg). LCMS (method 2): Rt=1.01, ES + m / z 351.0 / 353.0 [M+H] +

[0283] Intermediate 19 [ka]

[0284] 4-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-3-methoxyphenol (Intermediate 19) To a solution of intermediate 18x (10.0 mg, 30 μmol) in MeOH (0.25 mL) was added 2 M aqueous HCl (127 μL, 255 μmol) at RT, and the RM was then stirred at 60 °C for 1 h. The RMs of two parallel reactions prepared on the same scale were combined, cooled to RT, diluted with saturated aqueous NH4Cl (2 mL), stirred for 30 min, and then extracted with DCM (4 × 5 mL). The organic layers were combined, passed through a phase separator, and the solvent removed under reduced pressure to give the title product (10 mg), which was used in the next synthetic step without further purification. LCMS (method 2): Rt=0.63, ES + m / z 290.1 / 292.1 [M+H] +

[0285] Intermediate 20 [ka]

[0286] 3-(Bromomethyl)-6-chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 20) NBS (2.06 g, 12 mmol) and AIBN (317 mg, 1.9 mmol) were added to a mixture of intermediate 18z (3.2 g, 9.65 mmol) in tetrachloromethane (45 mL) and refluxed under nitrogen for 3 h. An additional equivalent of NBS (2.06 g, 12 mmol) and AIBN (317 mg, 1.9 mmol) was added, and stirring was continued overnight. After cooling to RT, the formed solid was filtered and washed with tetrachloromethane. The organic layers were combined, washed with saturated aqueous NaCl (80 mL), dried over NaSO, and evaporated under reduced pressure. The crude product was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM in cyclohexane to give the title compound (550 mg). LCMS (method 2): Rt=1.35, ES + m / z 422.0 / 424.0 / 426.0 [M+H] +

[0287] Purification by flash chromatography afforded additional pure product. LC-MS analysis confirmed the structure of the dibromo derivative of intermediate 18z, identifying it as intermediate 21. [ka] 6-Chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-3-(dibromomethyl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 21) LCMS (Method 2): Rt=1.47, ES+ ion cluster major peaks m / z 501.8 and 503.8 [M+H] +

[0288] Intermediate 22 [ka]

[0289] 2-(6-chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)acetonitrile (Intermediate 22) To a mixture of intermediate 20 (2.0 g, 4.7 mmol) and ethanol (45 mL), sodium cyanide (278 mg, 5.7 mmol) in water (4 mL) was added, and the RM was stirred at 80 °C overnight. After cooling to RT, the RM was diluted with saturated aqueous NaCl (40 mL) and extracted twice with EtOAc (40 + 20 mL). The organic layers were combined, washed with saturated aqueous NaCl (20 mL), dried over MgSO4, and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge, eluting with 0-30% EtOAc in cyclohexane, to give the title compound (300 mg). LCMS (method 1): Rt=1.18, ES + m / z 369.9 / 372.0 [M+H]+

[0290] Intermediate 23a [ka]

[0291] (6-chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methanol To a mixture of Intermediate 20 (780 mg) in DMF (4 mL) was added potassium acetate (353 mg, 3.6 mmol) and the RM was stirred at 60 °C for 2 h. After cooling to RT, the RM was diluted with water (20 mL) and extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed with water (2 × 10 mL), saturated aqueous NaCl (2 × 10 mL), dried over NaSO, and the solvent was removed under reduced pressure. The residue was dissolved in a mixture of methanol (5 mL) and water (1 mL), potassium carbonate (498 mg, 3.6 mmol) was added, and the mixture was stirred at RT. The volatile solvents were removed under reduced pressure, and the residue was dissolved in EtOAc (30 mL) and washed with water (2 × 15 mL) and saturated aqueous NaCl (15 mL). The organic layer was dried over Na2SO4, the solvent removed under reduced pressure and the residue purified by flash chromatography on a Si cartridge eluting with 0-10% DCM / MeOH / NH4OH in DCM (90:5:0.5) to give the title product (184 mg). LCMS (method 2): Rt=1.04, ES + m / z 360.1 / 362.1 / 362.1 [M+H] +

[0292] Intermediate 23b [ka]

[0293] 6-Chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carbaldehyde (Intermediate 23b) Intermediate 21 (1.67 g, 3.3 mmol) in DMSO (10 mL) / water (1.0 mL) was heated at 100° C. for 5 h and at 120° C. for 3 h. After cooling to RT, the RM was diluted with water (50 mL) and extracted with EtOAc (2×20 mL). The organic layers were combined, washed with water (4×15 mL), saturated aqueous NaCl (20 mL), dried over NaSO, and the solvent was removed under reduced pressure to give the title product (1.08 g), which was used in the next step without further purification. LCMS (method 2): Rt=1.24, ES + m / z 358.1 / 360.1 [M+H] +

[0294] Intermediate 23c [ka]

[0295] 6-Chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Intermediate 23c) To a mixture of intermediate 23b (104 mg, 0.29 mmol) and THF (5 mL), NaClO (263 mg, 2.9 mmol), a solution of NaHPO (348 mg, 2.9 mmol) in water (0.8 mL), and 2-methyl-2-butene (1.38 mL, 13 mmol) were added, and the RM was stirred at 40 °C for 1.5 h. After cooling to RT, the RM was diluted with water (10 mL), acidified to pH 2.5 with aqueous 1 N HCl, and extracted with DCM (2 × 10 mL). The organic layers were combined, washed with saturated aqueous NaCl (10 mL), dried over NaSO, and the solvent was removed under reduced pressure to give the desired product (90 mg), which was used in the next step without further purification. LCMS (method 2): Rt=0.59, ES + m / z 374.1 / 376.1 [M+H] +

[0296] Intermediate 24a [ka]

[0297] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Intermediate 24a) Copper(I) thiophene-2-carboxylate (434 mg, 2.28 mmol), CsCO (2.22 g, 6.83 mmol), 2-bromo-4-chloro-1-methoxy-benzene (970 μL, 6.83 mmol), and 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (450 mg, 2.28 mmol) in DMSO (6.75 mL) were stirred overnight at 100 °C under an argon atmosphere. After cooling to RT, the RM was diluted with water and the pH was adjusted to 3 with aqueous 1 M HCl. The precipitate that formed was collected by filtration, dried, and purified by flash chromatography on a Si cartridge eluting with 0–50% DCM / MeOH / formic acid (90:10:0.3) in DCM to give the title product (570 mg). LCMS (method 1): Rt=1.01, ES + m / z 337.9 / 339.9 [M+H] +

[0298] Intermediate 24b [ka]

[0299] 6-Chloro-1-(5-fluoro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Intermediate 24b) The title compound was prepared in a similar manner to Intermediate 24, starting from 2-bromo-4-fluoro-1-methoxy-benzene and 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid. LCMS (method 1): Rt=0.96, ES + m / z 321.9 / 323.9 [M+H] +

[0300] Intermediate 24c [ka]

[0301] Methyl 6-chloro-1-(2-methoxy-5-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 24c) Copper(I) thiophene-2-carboxylate (501 mg, 2.63 mmol), CsCO (3.42 g, 10.5 mmol), Intermediate 11c (1.39 g, 5.25 mmol), and 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (519 mg, 2.63 mmol) were stirred in DMSO (9 mL) under nitrogen at 105 °C for 16 h. After cooling to RT, iodomethane (654 μL, 10.5 mmol) was added, and the RM was stirred at RT for 2 h. The RM was diluted with water (10 mL) and extracted with DCM (3 × 8 mL). The organic layers were combined, dried over NaSO, and evaporated to dryness. The residue was purified by flash chromatography on a Si cartridge eluting with 0–50% EtOAc in DCM to give the title product (682 mg). LCMS (method 2): Rt=0.94, ES + m / z 396.1 / 398.1 [M+H] +

[0302] Intermediate 24d Process 1 [ka]

[0303] Methyl 1-(5-bromo-2-(difluoromethoxy)phenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 24d-1) The title compound was prepared in a similar manner to intermediate 24c, starting from intermediate 12 and 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid. LCMS (method 2): Rt=1.26, ES +m / z 432.0 / 434.0 / 436.0 [M+H] +

[0304] Process 2 [ka]

[0305] 6-Chloro-1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Intermediate 24d) Intermediate 24d-1 (50.0 mg, 0.12 mmol), sodium thiomethoxide (24 mg, 0.35 mmol), Pd(dba) (10.0 mg, 0.01 mmol), and Xantphos (13 mg, 0.02 mmol) in degassed toluene (1.5 mL) were stirred under nitrogen at 80 °C for 3 h. The precipitate that formed was collected by filtration, washed with toluene, and dried to give the title compound (68 mg), which was used in the next step without further purification. LCMS (method 2): Rt=0.62, ES + m / z 386.1 / 388.1 [M+H] +

[0306] Intermediate 25 [ka]

[0307] Methyl 1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (Intermediate 25) Intermediate 24c (300 mg, 0.76 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (274 mg, 1.1 mmol), KPO (322 mg, 1.5 mmol), and XPhos PdG (64 mg, 0.076 mmol) in degassed water (3.75 mL) / THF (7.5 mL) was stirred at 70 °C for 2 h under nitrogen. After cooling to RT, the RM was diluted with water (10 mL) and extracted with DCM (6 × 10 mL). The organic layers were combined, passed through a phase separator, and evaporated to dryness. The residue was purified by flash chromatography on a Si cartridge eluting with 0–40% DCM / MeOH (20:1) in DCM to give the title product (262 mg). LCMS (method 2): Rt=0.84, ES + m / z 479.1 [M+H] +

[0308] Intermediate 26a [ka]

[0309] 6-Chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-N-methyl-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Intermediate 26a) To a mixture of intermediate 23c (25 mg, 0.067 mmol) in DMF (1.5 mL) was added DIPEA (23 μL, 0.13 mmol), HATU (28 mg, 0.074 mmol), and methylamine (2.0 M in THF, 334 μL, 0.67 mmol), and the RM was stirred at 50 °C overnight. After cooling to RT, the RM was diluted with EtOAc (5 mL) and washed with saturated aqueous NaHCO (10 mL). The aqueous layer was further extracted with EtOAc (2 × 5 mL). The organic layers were combined, washed with saturated aqueous NaCl (10 mL), dried over NaSO, and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0–24% EtOAc in PE to give the title product (12 mg). LCMS (method 1): Rt=1.12, ES + m / z 387.1 / 389.1 [M+H] +

[0310] Preparation of Intermediates 26b to 26f The following intermediates were prepared in a similar manner to intermediate 26a from the starting materials indicated. Where minor modifications to solvents and / or temperatures were made, these are detailed in parentheses.

[0311] [Table 39] [Table 40]

[0312] 26g intermediate [ka]

[0313] 6-chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-N-((1s,3s)-3-(dimethylamino)cyclobutyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Intermediate 26g) To an ice-cooled solution of intermediate 26c (276 mg, 0.509 mmol) in dry DCM (6.9 mL) was added TFA (1.95 mL, 25.4 mmol) dropwise. The RM was stirred at RT for 1 h, then loaded onto an SCX cartridge, washed with methanol, and eluted with methanolic ammonia (7 M). The relevant fractions were concentrated in vacuo. The residue was dissolved in a mixture of formic acid (768 μL, 20.4 mmol) and aqueous formaldehyde (37.0%, 1.52 mL, 20.4 mmol) and stirred at 60 °C overnight. After cooling to RT, the RM was diluted with EtOAc (20 mL), washed with saturated aqueous NaHCO (3 × 15 mL), saturated aqueous NaCl (15 mL), dried over NaSO, and the solvent was removed under reduced pressure to give the title product (144 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.15 min, ES + m / z 470.0 / 472.0 [M+H] +

[0314] Intermediate 27a [ka]

[0315] tert-Butyl (1-((6-chloro-1-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)azetidin-3-yl)carbamate (Intermediate 27a) To a suspension of Intermediate 20 (60.0 mg, 0.14 mmol) and tert-butyl N-(azetidin-3-yl)carbamate hydrochloride (32.6 mg, 0.16 mmol) in tetrahydrofuran (3.5 mL) was added TEA (59.3 μL, 0.43 mmol). The RM was stirred at RT overnight and then partitioned between saturated aqueous NH4Cl and EtOAc. The organic layer was washed with water, saturated aqueous NaCl, dried over Na2SO4, and evaporated to give the title product (62 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.27 min, ES+ m / z 514.1 / 516.0 [M+H] +

[0316] Preparation of intermediates 27b-d The following intermediates were prepared in a similar manner to Intermediate 27a from the starting materials indicated. Where minor modifications to solvents and / or temperatures were made, these are detailed in brackets.

[0317] [Table 41]

[0318] Intermediate 28 [ka]

[0319] 1-(5-Bromo-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 28) Intermediate 5 (2.25 g, 8.25 mmol) and Intermediate 8b (3.92 g, 13.5 mmol) were stirred in NMP (35 mL) at 60 °C for 1 h and then at 120 °C for 2 h. The RM was cooled to RT, and water (250 mL) was added with vigorous stirring. The RM was extracted with EtOAc (3 × 200 mL). The organic layers were combined, washed with saturated aqueous NaHCO (2 × 200 mL), saturated aqueous NaCl (200 mL), and evaporated under reduced pressure. The crude material was triturated with diisopropyl ether and DCM / MeOH (5:1), and dried to give the title product (563 mg). LCMS (method 2): Rt=1.21 min, ES + m / z 471.0 / 473.1 [M+H] +

[0320] Intermediate 29 [ka]

[0321] 2-((4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)acetic acid (Intermediate 29) Methyl thioglycolate (251 mg, 2.37 mmol) in toluene (8 mL) was added dropwise to a mixture of NaH (60.0%, 158 mg, 3.95 mmol) in toluene (10 mL) under a nitrogen atmosphere. The RM was stirred at RT for 90 min, and then Intermediate 28 (930 mg, 1.97 mmol), Xantphos (143 mg, 0.25 mmol), and Pd2(dba)3 (90.4 mg, 0.1 mmol) were added, and the RM was further stirred at 100 °C for 1.5 h. After cooling to RT, the formed precipitate was collected by filtration, triturated in water (5 mL), diisopropyl ether (5 mL), and again in water (5 mL) at pH 5, and dried to give the title product (0.42 g). LCMS (Method 2): Rt=0.57 ES + m / z 483.3 [M+H] +

[0322] Intermediate 30 [ka]

[0323] 1-(2-(Difluoromethoxy)-5-((triisopropylsilyl)thio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Intermediate 30) A solution of tris(propan-2-yl)silanethiol (328 μL, 1.53 mmol) in toluene (2 mL) was added dropwise to a mixture of NaH (60.0%, 102 mg, 2.55 mmol) in toluene (10 mL), and the RM was stirred at RT under nitrogen for 1.5 h. Intermediate 28 (600 mg, 1.27 mmol), Xantphos (92.1 mg, 0.16 mmol), and Pd(dba) (58.3 mg, 0.06 mmol) were added, and the RM was stirred at 100°C for 45 min. The RM was cooled to RT, quenched by the addition of water (20 mL), filtered through a pad of diatomaceous earth, and washed thoroughly with EtOAc (2 × 35 mL). The organic layer was separated, washed with water (20 mL), saturated aqueous NaCl (30 mL), dried over MgSO, and evaporated under reduced pressure. The residue was purified by chromatography on a Si cartridge eluting with 0-100% EtOAc in cyclohexane to give the title product (153 mg). 1 H-NMR (500MHz, DMSO-d6) δ:9.27(d,J=6.7Hz,1H), 9.18(s,1H), 8.90(s,1H), 8.71(d,J=3.6Hz,1H), 8.30(s,1H), 7.64(d,J=1.6Hz,1H), 7.53(dd,J=8.5, 1.7H z,1H), 7.44(d,J=8.6Hz,1H), 7.16(dd,J=6.9, 4.0Hz,1H), 7.13(t,J=73.0Hz,1H), 2.66(s,3H), 0.98(d,J=6.5Hz,18H), 0.92(m,3H)

[0324] Intermediate 31 [ka]

[0325] 4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzenethiol (Intermediate 31) Aqueous 37% w / w HCl (75 μL, 2.45 mmol) was added to a mixture of intermediate 30 (150 mg, 0.258 mmol) in EtOH (3 mL), and the RM was stirred at RT under nitrogen for 2 h. The RM was dried under reduced pressure to give the title product (125 mg), which was used in the next step without further purification. 1 H-NMR (500MHz, DMSO-d6) δ:9.23(dd,J=6.9,1.6Hz,1H), 9.18(s,1H), 8.89(s,1H), 8.71(dd,J=4.0, 1.5Hz,1H), 8.30(s,1H), 7.67(d,J=1.6Hz,1H), 7.5 3(dd,J=8.5, 1.7Hz,1H), 7.44(d,J=8.6Hz,1H), 7.16(dd,J=6.9, 4.0Hz,1H), 7.13(t,J=73.0Hz,1H), 5.94(s,1H), 2.66(s,3H) LCMS (method 2): RT=0.50 min, ES + m / z 425.2 [M+H] +

[0326] Intermediate 32 [ka]

[0327] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-(difluoromethoxy)benzenethiol (Intermediate 32) Tris(propan-2-yl)silanethiol (365 μL, 1.7 mmol) in toluene (2 mL) was added dropwise to a mixture of NaH (60%, 113 mg, 2.8 mmol) in toluene (4 mL), and the RM was stirred at RT for 1.5 h under argon. Intermediate 18k (551 mg, 1.4 mmol) in toluene (4 mL), Xantphos (103 mg, 0.18 mmol), and Pd(dba) (41 mg, 0.071 mmol) were added, and the RM was stirred at 100 °C for 45 min. After cooling to RT, the RM was quenched with saturated aqueous NHCl (20 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (10 mL), saturated aqueous NaCl (10 mL), dried over NaSO, and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-50% EtOAc in cyclohexane to give the title compound (198 mg). LCMS (Method 1): RT=1.16 min, ES + m / z 341.7 / 343.7 [M+H] + 1 H-NMR (300MHz, CDCl3) δ:8.81(s,1H), 7.46(d,J=2.3Hz,1H), 7.36(dd,J=8.5, 2.1Hz,1H), 7.28(d, J=8.1Hz,1H), 7.19(s,1H), 6.31(t,J=73.0Hz,1H), 3.59(s,1H), 2.66(s,3H)

[0328] Purification by flash chromatography afforded the separate pure products. LC-MS analysis confirmed the structure of the dibromo derivative of intermediate 18z, which was identified as intermediate 33. [ka]

[0329] 3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-(difluoromethoxy)benzenethiol, and 6-chloro-1-(2-(difluoromethoxy)-5-((triisopropylsilyl)thio)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine LCMS (method 1): RT=1.80 min, ES + m / z 341.9 / 343.9 [M+H] + 1 H-NMR (300MHz, CDCl3) δ:8.82(s,1H), 7.64(d,J=2.3Hz,1H), 7.58(dd,J=8.5, 2.1Hz,1H), 7.26(d,J =8.1Hz,1H), 6.39(t,J=73.0Hz,1H), 2.68(s,3H), 1.27(m,3H), 1.11(m,18H)

[0330] Intermediate 34a [ka]

[0331] 6-Chloro-1-(2-(difluoromethoxy)-5-((2-methoxyethyl)thio)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 34a) A solution of intermediate 32 (60.0 mg, 0.176 mmol) in acetone (2.6 mL) was added to a mixture of 1-bromo-2-methoxyethane (19.8 μL, 0.21 mmol), NaI (26.3 mg, 0.18 mmol), and KCO (48.5 mg, 0.351 mmol) in acetone (2.6 mL). The RM was stirred at 70 °C for 75 min under an argon atmosphere. After cooling to RT, the RM was partitioned between DCM and saturated aqueous NaHCO. The aqueous phase was extracted with DCM (2x), and the combined organic layers were dried over NaSO and evaporated to dryness to give the title product (65.0 mg), which was used in the next step without further purification. LCMS (Method 1): RT=1.22 min, ES + m / z 400.1 / 402.0 [M+H] +

[0332] Preparation of Intermediates 34b to 34e The following intermediates were prepared in a similar manner to intermediate 34a from the starting materials indicated.

[0333] [Table 42]

[0334] Intermediate 34f [ka]

[0335] 6-Chloro-1-(2-(difluoromethoxy)-5-((3-methoxyphenyl)thio)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 34f) A degassed solution of a mixture of intermediate 33 (200 mg, 0.40 mmol) in i-PrOH (2 mL), CsF (140 mg, 0.92 mmol), CsCO (301 mg, 0.92 mmol), Pd(dba) (12 mg, 0.020 mmol), and 1-bromo-3-methoxy-benzene (118 μL, 0.92 mmol) in i-PrOH (2 mL) was stirred at 100 °C overnight. After cooling to RT, the RM was evaporated under reduced pressure, and the residue was purified by flash chromatography on a Si cartridge eluting with 0–50% EtOAc in cyclohexane to give the title product (83 mg). LCMS (Method 1): Rt=1.43 min, ES + m / z 448.0 / 455.0 [M+H] +

[0336] Intermediate 35a [ka]

[0337] 6-Chloro-1-(2-(difluoromethoxy)-5-((2-methoxyethyl)sulfonyl)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridine (Intermediate 35a) To an ice-bath cooled mixture of intermediate 34a (64.0 mg, 0.16 mmol) in dry DCM (3.3 mL) was added mCPBA (55.2 mg, 0.32 mmol) and the RM was stirred at 0 °C for 70 min. Another equivalent of mCPBA (20 mg, 0.12 mmol) was added and the RM was stirred for an additional 40 min. The RM was diluted with DCM and washed with saturated aqueous NaHCO. The organic layer was dried over NaSO and evaporated in vacuo. The crude material was purified by flash chromatography on a Si cartridge eluting with EtOAc in DCM to give the title product (51.0 mg). LCMS (Method 1): Rt=1.02 min, ES + m / z 432.1 / 434.0 [M+H] +

[0338] Intermediate 35b [ka]

[0339] 3-((3-(6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-(difluoromethoxy)phenyl)sulfonyl)-N,N-dimethylpropan-1-amine (Intermediate 35b) A solution of Oxone® (263 mg, 0.428 mmol) in water (0.86 mL) was added to a mixture of Intermediate 34b (87.0 mg, 0.204 mmol) in MeOH (6.4 mL), and the RM was stirred at RT for 1 h. The RM was diluted with water and extracted twice with DCM, and then extracted again after adjusting the pH of the aqueous phase to approximately pH 7-8. The organic layers were combined, dried over Na2SO4, and the solvent was removed in vacuo. The residue was purified by flash chromatography on a Si cartridge, eluting with 10% MeOH in DCM, to give the title product (16.0 mg). LCMS (method 2): Rt=1.02 min, ES +m / z 459.1 / 461.1 [M+H] +

[0340] Preparation of Intermediates 35c to 35e The following intermediates were prepared in a similar manner to intermediate 35b from the starting materials indicated.

[0341] [Table 43] [Table 44]

[0342] Intermediate 36a [ka]

[0343] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-N,N-dimethyl-1H-pyrazolo[4,3-c]pyridin-4-amine (Intermediate 36a) To a mixture of intermediate 18ac (100 mg, 0.30 mmol), DIPEA (118 mg, 0.91 mmol) in NMP (3 mL) was added dimethylamine (2.0 M in THF, 457 μL, 0.91 mmol), and the RM was heated at 120 °C for 30 min under MW irradiation. After cooling to RT, the RM was partitioned between EtOAc (15 mL) and saturated aqueous NaHCO (15 mL). The organic layer was washed with saturated aqueous NaCl (10 mL) and concentrated in vacuo. The residue was triturated twice with hexane (3 mL), filtered, and dried to give the title product (78 mg). LCMS (method 2): Rt=1.34 min, ES + m / z 337.1 / 339.1 / 341.1 [M+H] +

[0344] Preparation of Intermediates 36b to 36c The following intermediates were prepared in a similar manner to intermediate 36a from the starting materials indicated.

[0345] [Table 45]

[0346] intermediate 36d Process 1 [ka]

[0347] tert-Butyl (6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-yl)glycinate (Intermediate 36d-1) To a mixture of intermediate 18ac (200 mg, 0.61 mmol), DIPEA (318 μL, 1.83 mmol) in NMP (2 mL) was added tert-butyl 2-aminoacetate (250 μL, 1.83 mmol), and the RM was heated at 150° C. under MW irradiation for 45 min. After cooling to RT, the RM was diluted with EtOAc (20 mL) and washed with saturated aqueous NaHCO (5×10 mL) and saturated aqueous NaCl (10 mL). The organic layer was dried over NaSO and concentrated in vacuo. The crude material was purified by flash chromatography on a Si cartridge eluting with 0–10% EtOAc in cyclohexane to give the title product (172.6 mg). LCMS (method 2): Rt=1.41 min, ES + m / z 423.1 / 425.1 / 427.1 [M+H] +

[0348] Process 2 [ka]

[0349] (6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-yl)glycine trifluoroacetate (Intermediate 36d-2) To an ice-cooled solution of intermediate 36d-1 (120 mg, 0.28 mmol) in dry DCM (2 mL) was added TFA (2 mL, 26.1 mmol) dropwise, and the RM was stirred at RT for 48 h. The RM was evaporated under reduced pressure, the residue was suspended in diethyl ether, and the solvent was removed (twice) to give the title product (120 mg), which was used in the next step without further purification. LCMS (method 2): Rt=0.63 min, ES + m / z 367.0 / 369.0 / 371.0 [M+H] +

[0350] Process 3 [ka]

[0351] 2-((6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-yl)amino)-N-methylacetamide (Intermediate 36d) To a mixture of intermediate 36d-2 (40.0 mg, 0.08 mmol) in dry DMF (0-5 mL) was added methylamine hydrochloride (16.8 mg, 0.25 mmol) and DIPEA (72.4 μL, 0.42 mmol), followed by HATU (34.8 mg, 0.09 mmol). The RM was stirred at RT overnight, then diluted with EtOAc (15 mL) and washed with saturated aqueous NaHCO (3 × 10 mL). The organic layer was washed with saturated aqueous NaCl (10 mL), dried over NaSO, and concentrated in vacuo. The crude material was purified by flash chromatography on a Si cartridge eluting with 0-5% MeOH in DCM to give the desired product (24 mg). LCMS (method 2): Rt=1.03 min, ES + m / z 380.0 / 381.9 / 383.9 [M+H] +

[0352] Intermediate 36e [ka]

[0353] N-(6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-yl)acetamide (Intermediate 36e) A mixture of intermediate 18ac (45.0 mg, 0.14 mmol), acetamide (10.5 mg, 0.18 mmol), Pd(dba) (4.5 mg, 7.8 µmol), Xantphos (3.96 mg, 6.9 µmol), and CsCO (66.9 mg, 0.21 mmol) in pre-degassed 1,4-dioxane (1 mL) was heated at 100 °C under a nitrogen atmosphere for 24 h. After cooling to RT, the RM was diluted with water and the precipitate that formed was collected by filtration and purified by flash chromatography on a Si cartridge eluting with 0–15% DCM / MeOH (99:1) in DCM to give the title product (28 mg). LCMS (method 2): Rt=1.11 min, ES + m / z 351.1, 353.1, 355.1 [M+H] +

[0354] Intermediate 36f [ka]

[0355] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (Intermediate 36f) A mixture of CsCO (223 mg, 0.69 mmol) (dried under vacuum at 150 °C for 1 h), intermediate 18ac (150 mg, 0.46 mmol), tert-butyl carbamate (64.2 mg, 0.55 mmol), Pd(dba) (15.0 mg, 26.1 μmol), and Xantphos (13.2 mg, 22.8 μmol) in pre-degassed 1,4-dioxane (4 mL) was stirred at 90 °C under a nitrogen atmosphere for 24 h. After cooling to RT, the RM was partitioned between EtOAc (15 mL) and water (10 mL). The organic layer was washed with water (5 mL), saturated aqueous NaCl (10 mL), and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM (5% MeOH in DCM) to give the title product. LCMS (method 2): Rt=1.06 min, ES + m / z 309.0 / 331.0 / 313.0 [M+H] +

[0356] Intermediate 36g Process 1 [ka]

[0357] 6-Chloro-1-(5-chloro-2-methoxyphenyl)-4-methoxy-1H-pyrazolo[4,3-c]pyridine (Intermediate 36g-1) To a suspension of intermediate 18ac (80 mg, 0.24 mmol) in dry MeOH (2.4 mL) was added sodium methoxide / MeOH (25%, 443 μL, 1.9 mmol) and the RM was stirred at 60° C. for 18 h. The RM was cooled to RT and quenched in water (10 mL). The precipitate that formed was collected by filtration and dried to give the title product (70 mg). LCMS (method 2): Rt=1.40 min, ES + m / z 324.1 / 326.1 / 328.1 [M+H] +

[0358] Process 2 [ka]

[0359] 6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-4-ol (Intermediate 36g) To a suspension of intermediate 36g-1 (38.0 mg, 0.12 mmol) in MeCN (1.5 mL) was added TMS-Cl (44.4 μL, 0.35 mmol) and NaI (52.7 mg, 0.352 mmol), and the RM was stirred at 85 °C for 15 min. After cooling to RT, the RM was partitioned between water (2 mL) and EtOAc (4 mL). The organic layer was washed with 5% (w / w) aqueous NaSO (10 mL), saturated aqueous NaCl (5 mL), and evaporated under reduced pressure to give the title product (14 mg). LCMS (method 2): Rt=0.57 min, ES + m / z 310.1 / 312.1 / 314.0 [M+H] +

[0360] Intermediate 37 Process 1 [ka]

[0361] A mixture of 3-(bromomethyl)-6-chloro-1-trityl-1H-pyrazolo[4,3-c]pyridine (Intermediate 37-1a) and 6-chloro-3-(dibromomethyl)-1-trityl-1H-pyrazolo[4,3-c]pyridine (Intermediate 37-1b) To a mixture of Intermediate 16 (3.72 g, 9.08 mmol) and benzotrifluoride (120 mL), NBS (1.94 g, 10.9 mmol) and AIBN (298 mg, 1.82 mmol) were added, and the RM was stirred at 80 °C under an argon atmosphere for 3.5 h. The precipitate that formed was collected by filtration and washed with EtOAc. The filtrate was partitioned between EtOAc and saturated aqueous NaCl, and the organic layer was dried over NaSO and evaporated to dryness to give a 4:1 mixture of monobrominated (Intermediate 37-1a) and dibrominated products (Intermediate 37-1b) (total 2.57 g), which was used in the next step without further purification. LCMS (Method 2): Rt = 1.55 and 1.63 ES+ ion cluster peak m / z 490.0, 568.0 [M+H] + superiority

[0362] Process 2 [ka]

[0363] A mixture of (6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)methanol (Intermediate 37) and 6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carbaldehyde (Intermediate 37-2) A mixture of intermediate 37-1a from the previous step and intermediate 37-1b (2.00 g) in DMSO (12 mL) / water (1.2 mL) was vigorously stirred at 100° C. for 10 h. After cooling to RT, the RM was diluted with saturated aqueous NaHCO (12 mL). The precipitate formed was filtered, washed with water (5 mL) and EtOAc (2×10 mL), and discarded. The mother liquor was extracted with EtOAc (3×20 mL). The aqueous layer (after adjusting the pH to 6.8) was extracted with EtOAc (3×20 mL), and further extracted with EtOAc (7×10 mL) upon adjusting the pH to 4.8. The organic layers were combined, dried over MgSO, filtered, and evaporated to dryness. The crude product (650 mg) was obtained as a 1:1 mixture of intermediate 37 and intermediate 37-2, which was used in the next synthetic step without further purification. LCMS (Method 2): Rt = 0.34 min and 0.44 min, ES + m / z 182.1 and 184.1 [M+H] +

[0364] Process 3 [ka]

[0365] (6-Chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)methanol (Intermediate 37) A mixture of intermediate 37 (from step 2) from the previous step and intermediate 37-2 (estimated 630 mg, 3.5 mmol) in EtOH (50 mL) was cooled to 0 °C, and NaBH (66 mg, 1.7 mmol) was added. After stirring at 0 °C for 15 min, the RM was quenched with water (20 mL). The precipitate that formed was filtered, washed with water (2 × 5 mL), and discarded. The filtrates were combined and extracted with EtOAc (2 × 20 mL). The aqueous layer (pH adjusted to 6.8) was further extracted with EtOAc (5 × 20 mL). The organic layers were combined, dried over Na SO , filtered, and evaporated to dryness. The residue was purified on a Si cartridge eluting with 0-90% DCM / MeOH (20:1) in DCM to give the title product (450 mg). LCMS (method 2): Rt=0.44, ES + m / z 184.1 [M+H] +

[0366] Preparation of Examples Example 1 [ka]

[0367] 1-(5-Fluoro-2-methoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 1) A degassed mixture of intermediate 18a (70.0 mg, 0.240 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (82.3 mg, 0.336 mmol), aqueous KPO (0.500 M, 0.960 mL, 0.480 mmol), and XPhos Pd G3 (10.2 mg, 0.012 mmol) in THF / water (4.8 mL) was heated at 100 °C under argon for 2 h. The RM was cooled to RT and quenched with water (5 mL). The precipitate was collected by filtration and purified by flash chromatography on a Si cartridge eluting with 0-100% EtOAc in cyclohexane to give the title product (72.6 mg). LCMS (Method 5): Rt=3.37 min, ES + m / z 375.2 [M+H] + 1 H-NMR (300MHz, DMSO-d6) δ:9.22(dd,J=7.1, 1.7Hz,1H), 9.14(d,J=1.0Hz,1H), 8.88(s,1H), 8.70(dd,J=4.1, 1.7Hz,1H), 8.27(d,J=1.0Hz,1H), 7.34-7.47(m,3H), 7.15(dd,J=7.1, 4.1Hz,1H), 3.83(s,3H), 2.64(s,3H)

[0368] Examples 2 to 57 The following examples were prepared in a similar manner to Example 1 from the starting materials indicated. When minor modifications were made to the base, solvent, temperature, ligand and / or palladium source, they are noted in parentheses.

[0369] [Table 46] [Table 47] [Table 48] [Table 49] Table 50 Table 51 Table 52 Table 53 Table 54 Table 55 Table 56 Table 57 Table 58 Table 59 Table 60 Table 61 Table 62 Table 63 Table 64 Table 65 Table 66 [Table 67] [Table 68] [Table 69] [Table 70] [Table 71] [Table 72] [Table 73]

[0370] Example 58 Process 1 [ka]

[0371] 1-(5-Fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 58 - Step 1) To a mixture of intermediate 18u (75.0 mg, 0.18 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (77.3 mg, 0.32 mmol), and KPO (0.5 M, 701 μL, 0.35 mmol) in degassed THF / water (2.7 mL) was added XPhos Pd G3 (7.42 mg, 8.8 μmol), and the RM was stirred at 50 °C under argon for 1 h. After cooling to RT, the RM was diluted with water (5 mL). The precipitate that formed was collected by filtration and purified by flash chromatography on a Si cartridge eluting with 0-100% EtOAc in DCM to give the title product (63 mg). LCMS (method 2), Rt=1.22 min, ES + m / z 511.2 [M+H] +

[0372] Process 2 [ka]

[0373] 2-Fluoro-5-methoxy-4-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol (Example 58) An ice-cold solution of the intermediate from Example 58, Step 1 (57.0 mg, 0.112 mmol) in dry DCM (1 mL) was treated with TFA (1 mL, 13.4 mmol), allowed to warm to RT, and stirred for 1 h. The RM was neutralized with saturated aqueous NaHCO, forming a precipitate that was collected by filtration and subsequently washed with a small amount of water / DCM. The crude material was purified by chromatography on a Si cartridge, eluting with 0-100% DCM / MeCN / NHOH (10:10:1) in DCM to give the title compound (18 mg). LCMS (Method 5), Rt=2.61 min, ES + m / z 390.9 [M+H] + 1H-NMR (300MHz, DMSO-d6) δ:10.44(br. s, 1H), 9.21(dd,J=7.1, 1.7Hz,1H), 9.11(d,J=1.2Hz,1H), 8.87(s,1H), 8.71(dd,J=4.2, 1.7Hz,1H), 8.17(d,J= 1.2Hz,1H), 7.36(d,J=11.1Hz,1H), 7.14(dd,J=7.1, 4.1Hz,1H), 6.87(d,J=8.0Hz,1H), 3.71(s,3H), 2.61(s,3H)

[0374] Examples 59-60 The following examples were prepared in a similar manner to Example 58 by replacing intermediate 18u with the starting material shown in the table below. Where minor modifications were made to the base, solvent, temperature, ligand and / or palladium source, they are noted in parentheses.

[0375] [Table 74]

[0376] Example 61 [ka]

[0377] 1-(2-chloro-5-methoxypyridin-4-yl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 61) The title compound was prepared in a similar manner to intermediate 18a starting from intermediate 6 and 4-bromo-2-chloro-5-methoxy-pyridine. LCMS (Method 5), Rt=3.31 min, ES + m / z 392.4 [M+H] + 1H-NMR (500MHz, CDCl3) δ:9.08(d,J=0.9Hz,1H), 8.98(s,1H), 8.78(dd,J=7.0,1.8Hz,1H), 8.62(dd,J=4.0, 1.8Hz,1H), 8 .46-8.48(m,1H), 8.31(s,1H), 7.65(s,1H), 6.94(dd,J=7.0, 4.0Hz,1H), 4.07(s,3H), 2.73(s,3H)

[0378] Example 62 [ka]

[0379] (4-chloro-2-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)methanol (Example 62) Intermediate 5 (60.0 mg, 0.220 mmol) and Intermediate 8c (20.0%, 377 mg, 0.36 mmol) were stirred in NMP (0.8 mL) at 60 °C for 1 h and at 100 °C for 2 h. After cooling to RT, the RM was diluted with water (10 mL) and then extracted with EtOAc (2 × 10 mL) and DCM (2 × 10 mL). The organic layers were combined, washed with water (4 × 10 mL), saturated aqueous NaCl (10 mL), and evaporated under reduced pressure. The crude material was triturated in DCM to give the title product (6.3 mg). LCMS (Method 6), Rt=3.93 min, ES + m / z 391.44 [M+H] + 1 H-NMR (500MHz, CDCl3) δ:9.22-9.25(m,1H), 9.20(d,J=1.2Hz,1H), 8.90(s,1H), 8.67-8.70(m,1H), 8.27(d,J=1.2Hz,1H), 7.80(d,J=8.2Hz,1H) , 7.68(dd,J=8.5, 2.1Hz,1H), 7.64(d,J=2.1Hz,1H), 7.13-7.18(m,1H), 5.27-5.32(m,1H), 4.33-4.40(m,2H), 2.66(s,3H)

[0380] Example 63 [ka]

[0381] 1-(5-Bromo-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 63) Intermediate 5 (30.0 mg, 0.110 mmol) and intermediate 8b (35.0 mg, 0.121 mmol) were suspended in NMP (0.7 mL) and stirred under MW irradiation at 60 °C for 1 h and then at 120 °C for 2 h. After cooling to RT, the RM was diluted with water (6 mL) and extracted with EtOAc (2 × 8 mL). The organic layers were combined, washed with water (3 × 8 mL), saturated aqueous NaCl (8 mL), dried over NaSO, and evaporated under reduced pressure. The residue was purified by chromatography on a Si cartridge eluting with 0-1% MeOH in DCM to give the title product (15 mg). LCMS (Method 6): Rt=4.88 min, ES + m / z 471.0 / 473.0 [M+H] + 1 H-NMR (400MHz, DMSO-d6) δ / 9.20-9.26(m,1H), 9.19(d,J=1.0Hz,1H), 8.90(s,1H), 8.70(dd,J=4.1, 1.8Hz,1H), 8.32(d,J=1.1Hz,1H), 7.93(d,J =2.4Hz,1H), 7.85(dd,J=8.9, 2.5Hz,1H), 7.51(s,1H), 7.24(t,J=73.0Hz,1H), 7.16(dd,J=7.1, 4.2Hz,1H), 2.66(s,3H)

[0382] Example 64 [ka]

[0383] 4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzonitrile (Example 64) tBuXPhos (9.04 mg, 0.02 mmol) was added to a solution of intermediate 28 (60.0 mg, 0.13 mmol) and zinc cyanide (17.9 mg, 0.15 mmol) in NMP (0.5 mL). The RM was stirred at 120 °C under MW irradiation for 15 min, then allylpalladium chloride dimer (9.32 mg, 0.03 mmol) was added, and stirring was continued under the same conditions for 1 h. After cooling to RT, the RM was diluted with water (5 mL), and the formed precipitate was collected by filtration. The crude material was purified by flash chromatography on a Si cartridge eluting with 0-45% DCM / MeOH / NH4OH (90:9:0.5) in DCM to give the title product (21 mg). LCMS (Method 5): Rt=3.19 min, ES + m / z 418.4 [M+H] + 1 H-NMR (500MHz, DMSO-d6) δ / 9.22-9.27(m,1H), 9.20(s,1H), 8.91(s,1H), 8.68-8.73(m,1H), 8.34(s,1H), 8.26-8.30(m,1H), 8.15 -8.19(m,1H), 7.74(brd,J=8.9Hz,1H), 7.48(t,J=73.0Hz,1H), 7.17(dd,J=6.9, 4.1Hz,1H), 2.67(s,3H)

[0384] Example 65 [ka]

[0385] 1-(2-(Difluoromethoxy)-5-methylphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 65) To a degassed mixture of intermediate 28 (50.0 mg, 0.11 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (74.2 μL, 0.53 mmol), and CsCO (70 mg, 0.21 mmol) in 1,4-dioxane / HO (2:1, 7.2 mL) was added Pd(PPh) (12.3 mg, 0.01 mmol), and the RM was stirred overnight at 80 °C under argon. After cooling to RT, the RM was diluted with water (5 mL), and the precipitate that formed was collected by filtration and purified by flash chromatography on a Si cartridge eluting with 0-100% EtOAc in DCM to give the title product (10 mg). LCMS (Method 5): Rt=3.41 min, ES + m / z 407.0 [M+H] + 1 H-NMR (300MHz, DMSO-d6) δ:9.22(dd,J=6.97, 1.74Hz,1H), 9.16(d,J=1.05Hz,1H), 8.89(s,1H), 8.68(dd,J=4.01, 1.74Hz,1H), 8.28(d,J=1.05Hz,1 H), 7.47-7.52(m,1H), 7.38-7.48(m,2H), 7.14(dd,J=7.14, 4.18Hz,1H), 7.11(t,J=73.36Hz,1H), 2.65(s,3H), 2.40(s,3H)

[0386] Example 66 Process 1 [ka]

[0387] 4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzoic acid (Example 66 - Step 1) To a mixture of Intermediate 28 (500.0 mg, 1.06 mmol), Pd(OAc) (7.15 mg, 32 μmol), Xantphos (18.4 mg, 32 μmol), and formic acid (280 μL, 7.43 mmol) in DMF (5 mL) was added DCC (438 mg, 2.12 mmol) and TEA (296 μL, 2.12 mmol), and the RM was stirred at 80 °C for 6 h. The RM was cooled to RT and diluted with EtOAc (15 mL) to form a precipitate, which was collected by filtration, washed with a small amount of MeOH, and dried. The residue was dissolved in aqueous 1 M NaOH (20 mL), filtered, and the filtrate was acidified with aqueous 2 M HCl to form a precipitate, which was collected by filtration to give the title product (200 mg). LCMS (method 2): Rt=0.51 min, ES + m / z 437.1 [M+H] +

[0388] Process 2 [ka]

[0389] 4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(thiazol-2-yl)benzamide (Example 66) To a mixture of the intermediate from Example 66, Step 1 (30.0 mg, 0.07 mmol), thiazol-2-amine (8.26 mg, 0.08 mmol), and DIPEA (24 μL, 0.14 mmol) in dry DMF (1 mL) was added HATU (28.8 mg, 0.08 mmol), and the RM was stirred at 50° C. for 1 h. The RM was cooled to RT and diluted with water (5 mL), resulting in the formation of a precipitate that was collected by filtration. The crude material was triturated with MeOH to give the title product (19.5 mg). LCMS (Method 5): Rt=3.24 min, ES + m / z 519.1 [M+H] + 1H-NMR (500MHz, DMSO-d6) δ:12.86(brs,1H), 9.17-9.28(m,2H), 8.91(s,1H), 8.64-8.69(m,1H), 8.47(d,J=1.8Hz,1H), 8.37(dd,J=8.8, 2.14Hz,1H), 8.35(s,1 H), 7.72(d,J=8.5Hz,1H), 7.56(d,J=3.4Hz,1H), 7.45(t,J=72.4Hz,1H), 7.27-7.32(m,1H), 7.15(dd,J=7.0, 4.0Hz,1H), 2.70(s,3H)

[0390] Example 67 [ka]

[0391] 2-((4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)-N-methylacetamide (Example 67) To a mixture of intermediate 29 (55.0 mg, 0.11 mmol) in DMF (1 mL) was added HATU (52.0 mg, 0.14 mmol) and DIPEA (80 μL, 0.46 mmol), and the RM was stirred at RT for 45 min. Methylamine (2 M in THF, 171 μL, 0.342 mmol) was added, and stirring was continued at RT for 1 h. The RM was partitioned between EtOAc (8 mL) and water (10 mL). The aqueous layer was further extracted with EtOAc (8 mL). The organic layers were combined, washed with saturated aqueous NaHCO3 (2 × 10 mL), saturated aqueous NaCl (10 mL), and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0–100% DCM / MeOH (19:1) in DCM to give the title product (3.57 mg). LCMS (Method 5): Rt=3.57 min, ES + m / z 496.5 [M+H] + 1H-NMR (600MHz, DMSO-d6) δ / 9.22-9.26(m,1H), 9.17-9.21(m,1H), 8.88(brd,J=1.7Hz,1H), 8.68-8.73(m,1H), 8.29-8.33(m,1H), 8.06-8.12(m,1H), 7.66-7.70( m,1H), 7.59-7.62(m,1H), 7.47-7.52(m,1H), 7.18(t,J=73.0Hz,1H), 7.13-7.17(m,1H), 3.73(s,2H), 2.67(s,3H), 2.56(d,J=4.6Hz,3H)

[0392] Example 68 [ka]

[0393] 2-((4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)acetamide (Example 68) The title compound was prepared in a similar manner to Example 67 starting from intermediate 29 and ammonia (0.5M in 1,4-dioxane). LCMS (Method 6): Rt=3.44 min, ES + m / z 482.6 [M+H] + 1 H-NMR (600MHz, DMSO-d6) δ:9.22(dd,J=7.0, 1.3Hz,1H), 9.18(d,J=1.0Hz,1H), 8.90(s,1H), 8.71(dd,J=4.0, 1.5Hz,1H), 8.32(d,J=0.9Hz,1H), 7.68 (d,J=2.3Hz,1H), 7.61(dd,J=8.7, 2.3Hz,1H), 7.60(bs,1H), 7.50(d,J=8.6Hz,1H), 7.18(t,J=73Hz,1H), 7.18(bs,1H), 7.16 dd,J=7.1, 4.0Hz,1H), 3.73(s,2H), 2.67(s,3H)

[0394] Example 69 [ka]

[0395] 2-((4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)-N-(2-hydroxyethyl)acetamide (Example 69) The title compound was prepared in a similar manner to Example 67 starting from Intermediate 29 and ethanolamine. LCMS (Method 6): Rt=3.35 min, ES + m / z 526.5 [M+H] + 1 H-NMR (600MHz, DMSO-d6, 373K) δ:9.14(d,J=0.8Hz,1H), 9.11(dd,J=7.2, 1.3Hz,1H), 8.85(s,1H), 8.66(dd,J=3.9, 1. 5Hz,1H), 8.29(d,J=0.8Hz,1H), 7.82(bs,1H), 7.68(d,J=2.3Hz,1H), 7.60(dd,J=7.6, 2.3Hz,1H), 7.46(d,J=7.6Hz,1H), 7.09(dd,J=7.1, 4.0Hz,1H), 7.04(t,J=73.0Hz,1H) , 4.31(bs,1H), 3.71(s,2H), 3.37(q,J=5.2Hz,2H), 3.12(q,J=5.4Hz,2H), 2.66(s,3H)

[0396] Example 70 [ka]

[0397] 2-((4-(Difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)acetamide (Example 70) To a mixture of Example 68 (33.0 mg, 0.07 mmol) in EtOH (1.2 mL) was added a suspension of Oxone® (169 mg, 0.27 mol) in water (0.85 mL), and the RM was stirred at 60° C. for 1 h. The RM was diluted with water (2 mL) and DCM (2 mL), and the organic layer was concentrated under reduced pressure at RT. The residue was purified by flash chromatography on a Si cartridge eluting with 0-80% DCM / MeOH / NH4OH (90:9:0.5) in DCM to give the title product (3.6 mg). LCMS (Method 6): Rt=3.32 min, ES + m / z 514.2 [M+H] + 1 H-NMR (DMSO-d6, 600 MHz) δ:9.24(dd,J=7.0, 1.7Hz,1H), 9.22(d,J=1.1Hz,1H), 8.91(s,1H), 8.70(d d,J=4.1, 1.7Hz,1H), 8.40(d,J=1.1Hz,1H), 8.16(d,J=2.4Hz,1H), 8.11(dd ,J=8.8, 2.4Hz,1H), 7.81(d,J=8.8Hz,1H), 7.65(s,1H), 7.52(t,J=72.0Hz ,1H), 7.40(brs,1H), 7.17(dd,J=7.0, 4.0Hz,1H), 4.39(s,2H), 2.70(s,3H)

[0398] Example 71 [ka]

[0399] 1-(5-(cyclopropylthio)-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 71) Intermediate 31 (20.0 mg, 0.05 mmol), cyclopropylboronic acid (5.77 mg, 0.07 mmol), copper(II) acetate (8.13 mg, 0.05 mmol), 2,2'-dipyridyl (6.99 mg, 0.05 mmol), and CsCO (14.6 mg, 0.05 mmol) were stirred in DCE (0.5 mL) at 70 °C overnight. After cooling to RT, the RM was diluted with DCM (5 mL), aqueous ammonia (24%, 5 mL) was added, and the mixture was stirred at RT for 10 min. The organic layer was separated, washed with aqueous ammonia (24%, 5 mL), water (5 mL), saturated aqueous NaCl (5 mL), and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-75% EtOAc in cyclohexane to give the title product (4.1 mg). LCMS (Method 5): Rt=4.12 min, ES + m / z 465.5 [M+H] + 1 H-NMR (400 MHz, DMSO-d6) δ:9.22-9.25(m,1H), 9.17(s,1H), 8.90(s,1H), 8.68(dd,J=4.1, 1.8Hz, 1H), 8.35(d,J=1.2Hz,1H), 7.66(d,J=2.4Hz,1H), 7.56-7.59(m,1H), 7. 48-7.52(m,1H), 7.14-7.18(m,1H), 7.14(t,J=73.0Hz,1H), 2.65(s,3H) , 2.37(ddd,J=7.3, 4.3, 3.1Hz,1H), 1.04-1.11(m,2H), 0.62-0.67(m,2H)

[0400] Example 72 [ka]

[0401] 1-(2-(Difluoromethoxy)-5-((tetrahydro-2H-pyran-4-yl)thio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 72) To a mixture of intermediate 31 (35.0 mg, 0.08 mmol) in DMF (1.5 mL) was added NaI (12.4 mg, 0.08 mmol), K2CO3 (22.8 mg, 0.17 mmol), and 4-bromotetrahydropyran (10.2 μL, 0.09 mmol), and the RM was stirred at RT for 60 h. The RM was partitioned between EtOAc (8 mL) and water (8 mL). The organic layer was washed with water (8 mL), saturated aqueous NaHCO3 (8 mL), saturated aqueous NaCl (8 mL), and evaporated under reduced pressure. The residue was purified by MDAP preparative HPLC (Preparative Method 1) to give the title product (2.5 mg). LCMS (Method 5): Rt=3.74 min, ES + m / z 509.1 [M+H] + 1 H-NMR (500MHz, DMSO-d6) δ:9.22-9.27(m,1H), 9.18(d,J=1.2Hz,1H), 8.90(s,1H), 8.65-8.71(m,1H), 8.30 -8.33(m,1H), 7.69-7.73(m,1H), 7.66(dd,J=8.7, 2.3Hz,1H), 7.49-7.53(m,1H), 7 .22(t,J=73.0Hz,1H), 7.17(dd,J=7.0, 4.3Hz,1H), 3.75-3.82(m,2H), 3.56-3.65( m,1H), 3.34-3.40(m,2H), 2.66-2.68(m,3H), 1.86-1.94(m,2H), 1.48-1.58(m,2H)

[0402] Example 73 [ka]

[0403] 1-(2-(Difluoromethoxy)-5-(oxetan-3-ylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 73) To a mixture of intermediate 31 (33.0 mg, 0.08 mmol) in acetone (3 mL) was added oxetan-3-yl 4-methylbenzenesulfonate (19.5 mg, 0.09 mmol), NaI (11.7 mg, 0.08 mmol), and K2CO3 (21.5 mg, 0.16 mmol). The RM was stirred at reflux for 3 h and at RT overnight. The RM was partitioned between EtOAc (15 mL) and water (10 mL). The organic layer was washed with saturated aqueous NaCl (10 mL) and evaporated under reduced pressure. The residue was purified by MDAP preparative HPLC (Preparative Method 2) to give the title product (8 mg). LCMS (Method 7): Rt=5.25 min, ES + m / z 481.1 [M+H] + 1 H-NMR (400MHz, DMSO-d6) δ:9.22(dd,J=7.0, 1.7Hz,1H), 9.17(s,1H), 8.90(s,1H), 8.66-8.70(m,1H), 8.31(s,1H), 7.53-7.56(m,1H), 7.50(s,2H) , 7.18(t,J=73.0Hz,1H), 7.13-7.17(m,1H), 5.00(t,J=7.0Hz,2H), 4.67-4.78(m,1H), 4.50(t,J=6.4Hz,2H), 2.65(s,3H)

[0404] Example 74 Process 1 [ka]

[0405] tert-Butyl 4-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)piperidine-1-carboxylate (Example 74 - Step 1) To a mixture of intermediate 31 (85.0%, 60.0 mg, 0.12 mmol) in acetone (4 mL), N-Boc-4-bromopiperidine (38.1 mg, 0.14 mmol), NaI (18.0 mg, 0.12 mmol), and KCO (33.2 mg, 0.240 mmol) were added, and the RM was refluxed for 2.5 h. After cooling to RT, the RM was diluted with water (10 mL), and a precipitate formed, which was collected by filtration. The title product (66 mg) was obtained. LCMS (method 2): Rt=1.38 min, ES + m / z 608.4 [M+H] +

[0406] Process 2 [ka]

[0407] 1-(2-(Difluoromethoxy)-5-(piperidin-4-ylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine (Example 74) To a mixture of the intermediate from Example 74, Step 1 (70.0%, 66.0 mg, 0.08 mmol) in DCM (2 mL) was added TFA (113 μL, 1.52 mmol), and the RM was stirred at RT overnight. The RM was evaporated under reduced pressure, and the residue was partitioned between EtOAc (10 mL) and water (10 mL). The aqueous layer was neutralized with saturated aqueous NaHCO (10 mL) and extracted with DCM (2×10 mL). The organic layers were combined, washed with saturated aqueous NaCl (10 mL), dried over NaSO, and evaporated under reduced pressure to give the crude product, which was purified by flash chromatography on a Si cartridge eluting with 0-30% DCM / MeOH / NHOH in DCM (90:9:1.5) to give the title compound (22 mg). LCMS (Method 6): Rt=4.51 min, ES + m / z 508.5 [M+H] + 1H-NMR (500 MHz, DMSO-d6) δ:9.22-9.27(m,1H), 9.18(s,1H), 8.90(s,1H), 8.67-8.71(m,1H), 8.33( s,1H), 7.67(d,J=2.1Hz,1H), 7.60-7.65(m,1H), 7.47-7.52(m,1H), 7.21 (t,J=73.0Hz,1H), 7.13-7.18(m,1H), 3.38-3.47(m,1H), 2.83-2.91(m,2 H), 2.66(s,3H), 2.41-2.49(m,2H), 1.83-1.92(m,2H), 1.34-1.45(m,2H)

[0408] Example 75 [ka]

[0409] 1-(4-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)piperidin-1-yl)ethan-1-one (Example 75) To a mixture of Example 74 (14.0 mg, 0.03 mmol) in DCM (0.4 mL) was added TEA (11.5 μL, 0.08 mmol). The RM was cooled in an ice bath, followed by the addition of acetic anhydride (3.1 μL, 0.03 mmol), and the RM was stirred for 2 h. The RM was dried under reduced pressure, and the residue was partitioned between EtOAc (6 mL) and aqueous 0.1 M HCl. The aqueous layer was neutralized to pH 8 and extracted with EtOAc (2 × 8 mL). The organic layers were combined, washed with saturated aqueous NaHCO3 (2 × 5 mL), saturated aqueous NaCl (5 mL), and evaporated under reduced pressure. The crude material was triturated with EtOAc / hexane to give the desired product (10 mg). LCMS (Method 6): Rt=4.21 min, ES + m / z 550.4 [M+H] + 1H-NMR (500MHz, DMSO-d6) δ:9.22-9.26(m,1H), 9.19(d,J=1.2Hz,1H), 8.91(s,1H), 8.67-8.72(m,1H), 8.33(s,1H), 7.72(d ,J=2.1Hz,1H), 7.67(dd,J=8.7,2.3Hz,1H),7.50-7.54(m,1H),7.23(t,J=73.0Hz,1H),7.13-7.1 9(m,1H), 4.10-4.16(m,1H), 3.68-3.74(m,1H), 3.61-3.67(m,1H), 3.09-3.17(m,1H), 2.77-2.84 (m,1H), 2.67(s,3H), 1.93-2.02(m,4H), 1.45-1.54(m,1H), 1.31-1.40(m,1H), 1.22-1.29(m,1H)

[0410] Example 76 Process 1 [ka]

[0411] tert-Butyl (1-((1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)azetidin-3-yl)carbamate (Example 76 - Step 1) To a degassed mixture of Intermediate 27a (60.0 mg, 0.12 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (45.7 mg, 0.19 mmol), and CsCO (76 mg, 0.23 mmol) in 1,4-dioxane / water (2:1, 1.95 mL) was added Pd(PPh) (13.5 mg, 0.01 mmol), and the RM was stirred at 80 °C under an argon atmosphere for 1.5 h. After cooling to RT, the RM was diluted with EtOAc (15 mL) and washed with saturated aqueous NaHCO (3 × 10 mL) and saturated aqueous NaCl (10 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-30% DCM / MeCN / NH4OH (10:10:1) in DCM. The resulting material was triturated with acetonitrile to give the title compound (36 mg). LCMS (method 2): Rt=1.19 min, ES + m / z 597.2 / 599.2 [M+H] +

[0412] Process 2 [ka]

[0413] 1-((1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)azetidin-3-amine (Example 76) An ice-cold solution of the intermediate from Example 76, Step 1 (26.0 mg, 0.0435 mmol) in dry DCM (2 mL) was treated with TFA (100 μl, 1.31 mmol), and the RM was then allowed to warm to RT and stirred for 3 h. The RM was loaded onto an SCX cartridge, washed with methanol, and eluted with methanolic ammonia (7 N). The crude material was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM / MeOH / NH4OH (90:9:1.5) in DCM. The resulting material was triturated with n-hexane / DCM to give the desired compound (6 mg). LCMS (Method 4): Rt=1.57 min, ES + m / z 497.1 / 499.1 [M+H] + 1 H-NMR (600MHz, DMSO-d6) δ:9.16-9.35(m,2H), 8.83-8.97(m,1H), 8.71(brs,1H), 8.28-8.40(m,1H), 7.82-7.93(m,1H), 7.71-7.81(m,1H), 7.54-7.6 6(m,1H), 7.06-7.40(m,1H), 7.14-7.21(m,1H), 3.93-4.03(m,2H), 3.49-3.63(m,2H), 3.42-3.47(m,1H), 2.72-2.90(m,2H)

[0414] Example 77 Process 1 [ka]

[0415] (1s,3s)-3-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamido)cyclobutyl methanesulfonate (Example 77 - Step 1) To a mixture of Example 34 (240 mg, 0.49 mmol) in DCM (8 mL) cooled to 0 °C, methanesulfonyl chloride (49.3 μL, 0.64 mmol) and TEA (205 μL, 0.09 mmol) were added and the RM was stirred at 0 °C to RT for 1.5 h. The RM was evaporated under reduced pressure and the crude was triturated with water to give the title product (285 mg). LCMS (method 2): Rt=1.06 min, ES + m / z 568.1 / 570.1 [M+H] +

[0416] Process 2 [ka]

[0417] N-((1r,3r)-3-Azidocyclobutyl)-1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 77 - Step 2) To a mixture of the intermediate from Example 76, Step 1 (60.0 mg, 0.11 mmol) in dry DMF (1.5 mL) was added NaN (13.7 mg, 0.21 mmol), and the RM was stirred at 85 °C overnight. After cooling to RT, the RM was diluted with EtOAc (25 mL) and then washed with saturated aqueous NaHCO (3 × 15 mL) and saturated aqueous NaCl (15 mL). The organic layer was dried over NaSO and concentrated in vacuo to give the title product (55 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.23 min, ES + m / z 515.2 / 517.1 [M+H] +

[0418] Process 3 [ka]

[0419] N-((1r,3r)-3-aminocyclobutyl)-1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 77) Triphenylphosphine (84.0 mg, 0.32 mmol) was added to a solution of the intermediate from Example 77, Step 2 (55.0 mg, 0.11 mmol) in 15:1 THF / water (1.6 mL). The RM was stirred at RT for 4 h. The RM was loaded onto an SCX cartridge, washed with MeOH, and eluted with methanolic ammonia (7 M). Fractions containing the product were pooled, evaporated, and subjected to flash chromatography purification on a Si cartridge eluting with 0-65% DCM / MeOH / NH4OH in DCM (90:15:1.5) to give the title product (16 mg). LCMS (Method 5): Rt=2.82 min, ES + m / z 489.1 / 491.3 [M+H] + 1 H-NMR (300 MHz, DMSO-d6) δ:9.46(s,1H), 9.23(d,J=7.0Hz,1H), 8.91(s,1H), 8.87(d,J=7.5Hz,1H), 8.67-8.75(m,1H), 8.31(s,1H), 7.80(d,J=1.9Hz,1H), 7.69(dd,J=8.7, 2. 1Hz,1H), 7.45(d,J=8.9Hz,1H), 7.17(dd,J=6.9, 4.1Hz,1H), 4.53-4.69(m ,1H), 3.85(s,3H), 3.46-3.56(m,1H), 2.28-2.41(m,2H), 1.91-2.09(m,2H)

[0420] Example 78 [ka]

[0421] 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-(methyl(2-(methylamino)-2-oxoethyl)amino)cyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 78) The intermediate from Example 77, step 1 (30.0 mg, 0.05 mmol), N-methyl-2-(methylamino)acetamide (0.5 mL, 4.57 mmol), and DMAP (1.29 mg, 0.01 mmol) were reacted in DMSO (100 μL) at 120° C. under MW irradiation for 3 h. After cooling to RT, the RM was diluted with EtOAc (10 mL) and washed with saturated aqueous NaHCO (3×5 mL) and saturated aqueous NaCl (5 mL). The organic layer was dried over NaSO and concentrated in vacuo to give the crude product, which was purified by chromatography on a Si cartridge eluting with 0-100% DCM / MeCN / MeOH (10:10:2) in DCM to give the title product (2 mg). LCMS (Method 5): Rt=2.89 min, ES + m / z 574.2 / 576.1 [M+H] + 1 H-NMR (300MHz, DMSO-d6, 353K) δ:9.49(s,1H), 9.13-9.22(m,1H), 8.89(s,1H), 8.59-8.80(m,2H), 8.32(s,1 H), 7.73-7.80(m,1H), 7.65-7.71(m,1H), 7.49-7.64(m,1H), 7.46(brd,J=8.9 Hz,1H), 7.10-7.18(m,1H), 4.47-4.58(m,1H), 3.88(s,3H), 3.18-3.23(m,1H ), 2.82-2.90(m,2H), 2.64-2.70(m,3H), 2.23-2.34(m,4H), 2.13-2.21(m,3H)

[0422] Example 79 [ka]

[0423] 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-morpholinocyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 79) The title product was prepared in a similar manner to Example 78 starting from the intermediate of Example 77, Step 1 and morpholine. LCMS (Method 5): Rt=2.93 min, ES + m / z 559.2 / 561.1 [M+H] + 1 H-NMR (300MHz, DMSO-d6) δ:9.46(d,J=1.2Hz,1H), 9.24(dd,J=6.9, 1.7Hz,1H), 8.97(d,J=7.3Hz,1H), 8.91(s,1 H), 8.72(dd,J=4.0, 1.5Hz,1H), 8.31(d,J=0.9Hz,1H), 7.81(d,J=2.7Hz,1H), 7.70(dd ,J=9.0, 2.6Hz,1H), 7.46(d,J=9.2Hz,1H), 7.17(dd,J=6.9, 4.1Hz,1H), 4.50(sxt,J=7 .2Hz,1H), 3.86(s,3H), 3.60(brt,J=4.3Hz,4H), 2.77-2.87(m,1H), 2.18-2.34(m,8H)

[0424] Example 80 [ka]

[0425] 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-(dimethylamino)cyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 80) Example 77 (12.0 mg, 0.0245 mmol) was dissolved in a mixture of formic acid (254 μL, 6.72 mmol) and aqueous formaldehyde (37.0%, 500 μL, 6.72 mmol) and stirred at 60° C. for 4 h. The RM was diluted with EtOAc (15 mL), washed with saturated aqueous NaHCO (3×15 mL), saturated aqueous NaCl (15 mL), dried over NaSO, and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-65% DCM / MeOH / NHOH in DCM (90:9:1.5) to give the title product (10 mg). LCMS (Method 5): Rt=2.91 min, ES + m / z 517.2 / 519.0 [M+H] + 1 H-NMR (300 MHz, DMSO-d6) δ:9.46(s,1H), 9.23(dd,J=6.9, 1.3Hz,1H), 8.95(d,J=7.1Hz,1H), 8.91(s, 1H), 8.67-8.78(m,1H), 8.31(s,1H), 7.81(d,J=2.4Hz,1H), 7.70(dd,J=8.8, 2.5Hz,1H), 7.45(d,J=9.1Hz,1H), 7.17(dd,J=6.8, 4.2Hz,1H), 4.38-4.53( m,1H), 3.85(s,3H), 2.67-2.81(m,1H), 2.22(brt,J=6.4Hz,4H), 2.06(s,6H)

[0426] Example 81 Process 1 [ka]

[0427] 1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 81 - Step 1) To a mixture of Intermediate 23c (100 mg, 0.27 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (105 mg, 0.43 mmol), and CsCO (174 mg, 0.54 mmol) in a degassed mixture of dioxane / water (2:1, 4.5 mL) was added Pd(PPh) (30.9 mg, 0.03 mmol), and the RM was stirred overnight at 80 °C under argon. After cooling to RT, the RM was diluted with EtOAc and extracted with water. The aqueous layer was acidified with aqueous 2 M HCl, and the precipitate that formed was collected by filtration. The crude material was purified by flash chromatography on a Si cartridge eluting with DCM / MeOH / formic acid (90:5:0.3) in DCM to give the title product (15 mg). LCMS (method 2): Rt=0.57 min, ES + m / z 456.9 / 458.9 [M+H] +

[0428] Process 2 [ka]

[0429] N-((1s,3s)-3-aminocyclobutyl)-1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 81) To a mixture of the intermediate from Example 81, Step 1 (15.0 mg, 32.8 μmol), tert-butyl N-(3-aminocyclobutyl)carbamate (7.34 mg, 39.4 μmol), and DIPEA (12 μL, 65 μmol) in dry DMF (1 mL) was added HATU (14 mg, 36.1 μmol), and the RM was stirred at 50° C. for 1 h. After cooling to RT, the RM was diluted with EtOAc (15 mL) and washed with saturated aqueous NaHCO (3×10 mL) and saturated aqueous NaCl (10 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-40% DCM / MeCN / MeOH (10:10:1) in DCM. The resulting material was dissolved in DCM (2 mL) and cooled in an ice bath before the dropwise addition of TFA (122 μl, 50 equiv.). The RM was allowed to warm to RT over 2 h, then loaded onto an SCX cartridge, washed with MeOH, and eluted with methanolic ammonia (1.5 N) to give the title product (10 mg). LCMS (Method 5): Rt=2.88 min, ES + m / z 525.1 / 527.1 [M+H] + 1 H-NMR (500MHz, DMSO-d6) δ:9.50(s,1H), 9.25(brd,J=6.7Hz,1H), 8.93(s,1H), 8.76(brd,J=7.9Hz,1H), 8. 72(brd,J=3.1Hz,1H), 8.38(s,1H), 8.04(d,J=2.1Hz,1H), 7.84(dd,J=9.0, 2.3Hz ,1H), 7.65(d,J=9.1Hz,1H), 7.28(t,J=72.5Hz,1H), 7.18(dd,J=6.9,4.1Hz,1H), 4.04-4.16(m,1H), 3.05(quin,J=7.8Hz,1H), 2.53-2.62(m,2H), 1.82-1.94(m,2H)

[0430] Example 82 [ka]

[0431] N-(2-(Dimethylamino)ethyl)-1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 82) Intermediate 25 (40.0 mg, 0.08 mmol), DABAL-Me3 (32.1 mg, 0.13 mmol), THF (2 mL), and N',N'-dimethylethane-1,2-diamine (13.7 μL, 0.13 mmol) were heated under nitrogen atmosphere at 130 °C under MW irradiation for 10 min. Another equivalent of DABAL-Me3 (32.1 mg, 0.125 mmol) was added, and the RM was further heated under the same conditions for 10 min. The RM was carefully quenched with aqueous 1 M HCl (2 mL) and washed with DCM (10 mL). The aqueous layer was adjusted to pH 9.4 with aqueous 2 M NaOH and extracted with DCM (5 × 5 mL). The organic layers were combined, passed through a phase separator, and evaporated to dryness. The crude material was purified by flash chromatography on a Si cartridge eluting with 0-75% DCM / MeOH / NH4OH (90:9:0.5) in DCM to give the title compound (25 mg). LCMS (Method 5): Rt=2.26 min, ES + m / z 535.3 [M+H] + 1 H-NMR (600 MHz, DMSO-d6) δ:9.52(d,J=1.9Hz,1H);9.25(dd,J=6.9,1.7Hz,1H);8.93(s,1H);8.72(dd,J=4. 1, 1.8Hz,1H);8.59(t,J=5.7Hz,1H);8.34(d,J=0.9Hz,1H);8.22(d,J=2.3Hz,1H) ;8.18(dd,J=8.8, 2.3Hz,1H);7.69(d,J=8.8Hz,1H);7.18(dd,J=6.9, 4.1Hz,1H); 3.98(s,3H);3.45(q,6.5Hz,2H);3.31(s,3H);2.45(t,J=6.8Hz,2H);2.20(s,6H)

[0432] Examples 83-84 The following compounds were prepared in a similar manner to Example 82 from the starting materials indicated.

[0433] [Table 75]

[0434] Example 85 Process 1 [ka]

[0435] 6-Chloro-1-(2-methoxy-5-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 85 - Step 1) To a mixture of intermediate 24c (543 mg, 1.37 mmol) in THF (11.3 mL) was added a solution of LiOH (165 mg, 6.86 mmol) in water (3.75 mL), and the RM was stirred at RT overnight. The RM was concentrated in vacuo. The residue was dissolved in water, and the pH was adjusted to 2.5 with aqueous 1 M HCl. A precipitate formed, which was collected by filtration, washed with water, and dried to give the title product (485 mg). LCMS (method 2): Rt=0.44, ES + m / z 382.0 / 383.9 [M+H] +

[0436] Process 2 [ka]

[0437] tert-Butyl (6-chloro-1-(2-methoxy-5-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate (Example 85 - Step 2) The intermediate from Example 85, Step 1 (330 mg, 0.86 mmol) was dissolved in t-BuOH (15 mL) and TEA (361 μL, 2.6 mmol) and refluxed for 30 min. The RM was cooled to room temperature, and DPPA (279 μL, 1.3 mmol) was added and refluxed for 10 h. The RM was concentrated under reduced pressure, and the residue was purified by flash chromatography on a Si cartridge, eluting with 0-100% EtOAc in cyclohexane. The material was isolated and triturated with ethyl ether to give the title product (224 mg). LCMS (method 2): Rt=1.04, ES + m / z 453.1 / 455.1 [M+H] +

[0438] Process 3 [ka]

[0439] tert-Butyl (1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate (Example 85 - Step 3) To a degassed mixture of the intermediate from Example 85, Step 2 (224 mg, 0.50 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (182 mg, 0.742 mmol), and KPO (262 mg, 1.24 mmol) in a mixture of water (4.4 mL) and THF (8.8 mL) was added XPhos PdG (25 mg, 0.06 mmol), and the RM was stirred at 75 °C under argon for 2 h. After cooling to RT, the RM was diluted with water (15 mL) and saturated aqueous NaHCO (15 mL) and extracted with DCM (4 × 15 mL). The organic layers were combined, washed with saturated aqueous NaCl, dried over NaSO, and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM / MeOH / NH4OH (90:40:1) in DCM to give the title product (45 mg). LCMS (method 2): Rt=1.01, ES + m / z 536.1 [M+H] +

[0440] Process 4 [ka]

[0441] tert-Butyl (1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)(methyl)carbamate (Example 85 - Step 4) To a mixture of Intermediate 85-Step 3 (45.0 mg, 0.08 mmol) in dry DMF (1.5 mL) was added NaH (60% dispersion in mineral oil, 3.4 mg, 0.08 mmol) at 0 °C. The RM was stirred at 0 °C for 1 h, then iodomethane (5.75 μl, 0.09 mmol) was added. The RM was allowed to warm to RT. After stirring for 2 h, the RM was quenched with water and extracted with EtOAc (3x). The organic layers were combined, washed with saturated aqueous NaCl, dried, and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-100% EtOAc in cyclohexane to give the title product (30 mg). LCMS (method 2): Rt=1.07, ES + m / z 550.9 [M+H] +

[0442] Process 5 [ka]

[0443] 1-(2-Methoxy-5-(methylsulfonyl)phenyl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine (Example 85) To a mixture of the intermediate from Example 85, Step 4 (30.0 mg, 0.05 mmol) in DCM (3 mL) was added TFA (243 μL, 3.28 mmol), and the RM was stirred at RT overnight. The RM was dried under reduced pressure, and the residue was dissolved in MeOH, loaded onto an SCX cartridge, washed with MeOH, and eluted with 2 M methanolic ammonia. The resulting material was subjected to flash chromatography on a Si cartridge eluting with 0-100% DCM / MeOH / NH4OH (90:9:1.5) in DCM to give the title product (15 mg). LCMS (Method 7): Rt=3.74 min, ES + m / z 450.0 [M+H] + 1HNMR (500MHz, DMSO-d6) δ:9.21-9.23(m,1H);9.06(d,J=0.6Hz,1H);8.86(s,1H);8.71(dd,J=4.1H z,J=1.7Hz,1H);8.18(d,J=0.9Hz,1H);8.01(d,J=2.4Hz,1H);7.97(dd,J= 8.9Hz,J=2.4Hz,1H);7.58(d,J=8.9Hz,1H);7.16(dd,J=7.0Hz,J=4.1Hz,1 H);6.91(q,J=4.8Hz,1H);4.02(s,3H);3.26(s,3H);2.95(d,J=5.2Hz,3H)

[0444] Example 86 Process 1 [ka]

[0445] N1-(1-(5-amino-2-methoxyphenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine (Example 86 - Step 1) Intermediate 18o (77 mg, 0.12 mmol) in EtOH (1.8 mL), ammonium formate (46 mg, 0.73 mmol), and Pt / C (3% on activated carbon, sulfided, 50%, 9.5 mg, 0.02 mmol) were refluxed for 2 h. The RM was diluted with DCM, filtered through a pad of diatomaceous earth, and washed with DCM. The filtrate was evaporated, and the residue was partitioned between water and DCM. The aqueous layer was further extracted with DCM (2 × 15 mL). The organic layers were combined, washed with saturated aqueous NaCl, dried over NaSO, and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0–100% DCM / MeOH / NHOH (90:9:0.5) in DCM to give the title compound (18 mg). LCMS (method 2): Rt=0.83, ES + m / z 361.1 / 363.1 [M+H] +

[0446] Process 2 [ka]

[0447] N1-(1-(5-amino-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine (Example 86 - Step 2) The title product was prepared in a similar manner to Example 85, Step 3, starting from the intermediate of Example 86, Step 1. LCMS (method 1): Rt=0.76, ES + m / z 443.9 [M+H] +

[0448] Process 3 [ka]

[0449] N-(3-(3-((2-(dimethylamino)ethyl)amino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxyphenyl)methanesulfonamide (Example 86) To a cooled (0 °C) mixture of the intermediate from Example 86, Step 2 (14 mg, 0.03 mmol), pyridine (2.8 mg, 0.03 mmol) was added, followed by methanesulfonyl chloride (2.2 μL, 0.03 mmol). The RM was stirred at 0 °C for 15 min and at RT overnight. The RM was diluted with saturated aqueous NaHCO and extracted with DCM (4 × 15 mL). The organic layers were combined, washed with saturated aqueous NaCl, dried over NaSO, and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM / MeOH / NHOH (90:9:1.5) in DCM to give the title product (5 mg). LCMS (Method 7): Rt=3.14 min, ES + m / z 522.2 [M+H] + 1 H-NMR (600MHz, DMSO-d6) δ:9.61(bs,1H), 9.21(dd,J=7.1, 1.7Hz,1H), 9.09(d,J=1.0Hz,1H), 8.86(s,1H), 8. 70(dd,J=4.0, 1.7Hz,1H), 8.15(d,J=1.0Hz,1H), 7.37(d,J=2.6Hz,1H), 7.31(d,J=8. 9Hz,1H), 7.28(dd,J=8.9, 2.6Hz,1H), 7.15(dd,J=7.1, 4.1Hz,1H), 6.74(t,J=5.6Hz, 1H), 3.87(s,3H), 3.42(q,J=6.1Hz,2H), 2.98(s,3H), 2.60-2.56(m,2H), 2.24(s,6H)

[0450] Example 87 Process 1 [ka]

[0451] tert-Butyl (2-((6-chloro-1-(5-chloro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2-oxoethyl)(methyl) (Example 87 - Step 1) A suspension of BOC-sarcosine (42.8 mg, 0.23 mmol) and EEDQ (56.0 mg, 0.23 mmol) in DCE (1 mL) was stirred at room temperature for 10 min. Intermediate 18l (35.0 mg, 0.11 mmol) in DCE (2 mL) was added, and the RM was stirred at 80 °C overnight. The RM was diluted with DCM and washed with saturated aqueous NaHCO (2 × 5 mL). The organic layer was dried over NaSO and concentrated to give a residue that was purified by flash chromatography on a Si cartridge eluting with 0–100% DCM / MeOH (20:1) in DCM. The resulting material was triturated with diethyl ether and cyclohexane to give the title product (29 mg). LCMS (method 2): Rt=1.20 min, ES + m / z 479.1 / 481.0

[0452] Process 2 [ka]

[0453] tert-Butyl (2-((1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2-oxoethyl)(methyl)carbamate (Example 87 - Step 2) A mixture of 1,4-dioxane / water (2:1, 0.9 mL) and Pd(PPh) (6.98 mg, 6.0 μmol) was added to a vial charged with the intermediate from Example 87, Step 1 (29.0 mg, 0.06 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (22.2 mg, 0.09 mmol), and CsCO (39.3 mg, 0.12 mmol). The RM was stirred at 80 °C under argon for 2 h. After cooling to RT, the RM was diluted with EtOAc (15 mL) and then washed with saturated aqueous NaHCO (3 × 5 mL) and saturated aqueous NaCl (5 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by flash chromatography on a Si cartridge eluting with 0-10% MeOH in EtOAc to give the title product (15 mg). LCMS (method 2): Rt=1.12 min, ES + m / z 563.3 / 565.2

[0454] Process 3 [ka]

[0455] N-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(methylamino)acetamide (Example 87) A solution of Intermediate 87-Step 2 (15.0 mg, 26.6 μmol) in DCE (0.5 mL) was treated with TFA (69.3 μL, 0.93 mmol) and the RM was stirred at RT for 1 h. The RM was evaporated under reduced pressure and the residue was purified by flash chromatography on a Si cartridge eluting with 0-100% DCM / MeOH / NHOH (90:1:0.1) to give the title product (11.5 mg). LCMS (method 3): Rt=0.97 min, ES + m / z 462.9 [M+H] + 1H-NMR (300MHz, DMSO-d6) δ:9.41(d,J=1.0Hz,1H), 9.23(dd,J=7.1, 1.7Hz,1H), 8.88(s,1H), 8.71(dd,J=4.1, 1.7Hz,1H), 8.22(d,J=1.0Hz,1H), 7.67 - 7.56(m,2H), 7.45 - 7.39(m,1H), 7.16(dd,J=7.0, 4.0Hz,1H), 6.73(brs,1H), 3.86(s,3H), 3.43(s,2H), 2.38(s,3H)

[0456] Example 88 Process 1 [ka]

[0457] (6-chloro-1-(5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methanol (Example 88 - Step 1) Intermediate 37 (193 mg, 1.05 mmol), Intermediate 13a (538 mg, 1.58 mmol), K2CO3 (291 mg, 2.10 mmol), copper(I) iodide (100 mg, 0.526 mmol), and DMCHA (166 μL, 1.05 mmol) in DMF (2.9 mL) were stirred at 100 °C under an argon atmosphere for 10 h. After cooling to RT, the RM was diluted with EtOAc and washed several times with aqueous ammonia (1 M). The organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by silica gel column chromatography eluting with 0-50% EtOAc in DCM to give the title product (108 mg). LCMS (method 2): Rt=1.02 min, ES + m / z 444.1 / 446.1 [M+H] +

[0458] Process 2 [ka]

[0459] 6-chloro-1-(5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carbaldehyde (Example 88 - Step 2) DMP (115 mg, 0.272 mmol) was added to a suspension of the intermediate from Example 88, Step 1 (107 mg, 0.23 mmol) in DCM (10 mL). The RM was stirred at RT for 1 h and then quenched with a mixture of saturated aqueous NaSO / NaHCO (1:1, 10 mL) and stirred for an additional 30 min. The organic layer was dried over NaSO and the solvent was removed under reduced pressure to give the title product (102 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.33, ES + m / z 442.1 / 444.1 [M+H] +

[0460] Process 3 [ka]

[0461] 6-chloro-1-(5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (Example 88 - Step 3) A solution of NaClO (207 mg, 2.3 mmol), NaHPO (274 mg, 32.3 mmol) in water (0.61 mL) was added to a solution of the intermediate from Example 88, Step 2 (101 mg, 0.23 mmol) in THF (3.7 mL), followed by 2-methyl-2-butene (1.1 mL, 10 mmol), and the RM was stirred at 40 °C overnight. After cooling to RT, the RM was concentrated under reduced pressure and diluted with water. The pH of the aqueous mixture was adjusted to 3 with aqueous 1 N HCl, forming a precipitate which was collected by filtration, washed with water, and dried to give the desired product (104 mg), which was used in the next step without further purification. LCMS (method 2): Rt=0.72, ES + m / z 458.1 / 460.0 [M+H]+

[0462] Process 4 [ka]

[0463] 6-chloro-N-(3-(dimethylamino)propyl)-1-(5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 88 - Step 4) To a solution of the intermediate from Example 88, Step 3 (72.0 mg, 0.14 mmol), N',N'-dimethylpropane-1,3-diamine (34.0 μL, 0.27 mmol), and DIPEA (70.7 μL, 0.41 mmol) in dry DMF (0.7 mL) was added HATU (56.6 mg, 0.15 mmol). The RM was stirred at 60 °C for 1 h. Another equivalent of HATU (56.6 mg, 0.15 mmol) was added, and the RM was stirred for an additional 50 min. The RM was diluted with EtOAc and washed with saturated aqueous NH4Cl, saturated aqueous NaHCO3, water, and saturated aqueous NaCl. The organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by flash chromatography on a Si cartridge eluting with 5-10% MeOH in DCM to give the title product (42 mg). LCMS (method 2): Rt=1.28, ES + m / z 542.3 / 544.2 [M+H] +

[0464] Process 5 [ka]

[0465] N-(3-(dimethylamino)propyl)-1-(5-fluoro-2-methoxy-4-((4-methoxybenzyl)oxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 88 - Step 5) THF (1.58 mL) and water (0.55 mL) were added to a vial containing the intermediate from Example 88, Step 4 (40.7 mg, 0.07 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (26.2 mg, 0.11 mmol), and KPO (30.3 mg, 0.14 mmol). XPhos Pd G (6.04 mg, 7.1 μmol) was added, and the RM was stirred at 60 °C under an argon atmosphere for 75 min. After cooling to RT, the RM was partitioned between DCM and water. The organic layer was washed with water and saturated aqueous NaCl, dried over NaSO, and evaporated to dryness. The residue was purified by chromatography on a silica gel column eluting with DCM / MeOH / NH4OH (90:9:1.5) in DCM to give the title product (24.5 mg). LCMS (method 2): Rt=1.20, ES + m / z 625.4 [M+H] +

[0466] Process 6 [ka]

[0467] N-(3-(dimethylamino)propyl)-1-(5-fluoro-4-hydroxy-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide (Example 88) A suspension of the intermediate from Example 87, Step 5 (22.3 mg, 0.04 mmol) in dichloromethane (0.5 mL) was cooled in an ice bath and treated with TFA (318 μL, 4.28 mmol). The RM was stirred at RT for 20 min. The RM was evaporated to dryness and partitioned between DCM and water (pH adjusted to approximately 8 with saturated aqueous NaHCO3). The precipitate that formed was collected by filtration, washed with water, and dried to give the title product (6.20 mg). LCMS (method 3): Rt=0.94 min, ES + m / z 505.3 1H-NMR (500MHz, DMSO-d6) δ:9.48(s,1H), 9.23(brd,J=7.0Hz,1H), 8.91(s,1H), 8.76(brd,J=5.5Hz,1H), 8.72(brd,J=3.1Hz,1H), 8.26(s,1H), 7.53(brd,J=11.0Hz,1H), 7.1 5(dd,J=6.7, 4.0Hz,1H), 6.90(brd,J=7.6Hz,1H), 3.72(s,3H), 3.35(m,2H, overlaps with HDO), 2.28(brt,J=6.9Hz,2H), 2.14(s,6H), 1.70(quin,J=6.9Hz,2H)

[0468] Example 89 Process 1 [ka]

[0469] 1-(6-chloro-1-trityl-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylmethanamine (Example 89 - Step 1) A solution of intermediate 37-1a / intermediate 37-1b (a mixture obtained after step 1 of intermediate 37) (563 mg, 1.15 mmol) in THF (11.7 mL) was added dropwise to a solution of methylamine (2.0 M in THF, 5.76 mL, 11.5 mmol) and stirred at RT for 45 min. The RM was dried under reduced pressure, and the residue was partitioned between EtOAc and saturated aqueous NaHCO. The organic layer was dried over NaSO and evaporated to dryness. The residue was chromatographed on a silica gel column eluted with DCM / MeOH (20:1) in DCM to give the title product. LCMS (method 2): Rt=1.37, ES + m / z 439.2 / 441.1 [M+H] +

[0470] Process 2 [ka]

[0471] 1-(6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylmethanamine (Example 89 - Step 2) TFA (5.91 mL, 79.6 mmol) was added to a solution of Intermediate 89 - Step 1 (520 mg, 1.18 mmol) and triethylsilane (568 μL, 3.55 mmol) in dichloromethane (5.91 mL). The RM was stirred at RT for 2 h. The RM was evaporated under reduced pressure and the residue was chromatographed on silica gel eluting with DCM / MeOH / NH4OH (90:9:1.5) to give the title product. LCMS (method 2): Rt=0.50, ES + m / z 197.0 / 199.0 [M+H] +

[0472] Process 3 [ka]

[0473] tert-Butyl ((6-chloro-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)(methyl)carbamate (Example 89 - Step 3) Triethylamine (417 μL, 2.99 mmol) and BocO (256 mg, 1.17 mmol) were added to a solution of the intermediate from Example 89, Step 2 (210 mg, 1.07 mmol) in DCM (5 mL). The RM was stirred at RT for 100 min and then partitioned between DCM and saturated aqueous NaHCO. The organic layer was washed with water and saturated aqueous NaCl, dried over NaSO, and evaporated under reduced pressure. The residue was chromatographed on a silica gel column eluting with DCM / MeOH (20:1) to give the title product (199 mg). LCMS (method 2): Rt=0.91, ES + m / z 297.1 / 299.1 [M+H] +

[0474] Process 4 [ka]

[0475] tert-Butyl ((6-chloro-1-(2-methoxy-5-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)(methyl)carbamate (Example 89 - Step 4) The intermediate from Example 89, Step 3 (70.0 mg, 0.24 mmol), Intermediate 11c (93.8 mg, 0.35 mmol), KCO (65.2 mg, 0.472 mmol), copper(I) iodide (33.7 mg, 0.18 mmol), and DMCHA (50.3 mg, 0.35 mmol) were stirred in DMF (0.8 mL) at 100 °C under an argon atmosphere overnight. After cooling to RT, the RM was partitioned between EtOAc and water. The organic layer was washed with water, saturated aqueous NaCl, dried over NaSO, and the solvent was removed under reduced pressure. The residue was purified on a silica gel column eluted with DCM / MeOH (30:1) in DCM, followed by a separate purification on a silica gel column eluted with EtOAc / n-hexane (2:1) to give the title product (29.0 mg). LCMS (method 2): Rt=1.11, ES + m / z 481.0 / 482.9 [M+H] +

[0476] Process 5 [ka]

[0477] tert-Butyl ((1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)(methyl)carbamate (Example 89 - Step 5) The intermediate from Example 89, Step 4 (27.0 mg, 0.06 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (24.8 mg, 0.10 mmol), and KPO (23.8 mg, 0.11 mmol) were degassed with argon in THF (1.18 mL) and water (0.41 mL), and then XPhos Pd G (4.75 mg, 5.6 μmol) was added. The RM was stirred under argon at 60° C. for 1 h. After cooling to RT, the RM was partitioned between DCM and water. The organic layer was washed with water, saturated aqueous NaCl, dried over NaSO, and the solvent was removed under reduced pressure. The residue was chromatographed on a silica gel column eluting with 0-1:30 MeOH / DCM, followed by further purification on a silica gel column eluting with DCM / EtOAc (1:1) to give the title product (26.0 mg). LCMS (Method 5): Rt=4.28, ES + m / z 564.3 [M+H] +

[0478] Process 6 [ka]

[0479] 1-(1-(2-Methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylmethanamine (Example 89) A suspension of the intermediate from Step 5 of Example 88 (23.0 mg, 0.04 mmol) in DCM (0.5 mL) was treated with TFA (106 μL, 1.43 mmol) at RT for 1 h. The RM was evaporated under reduced pressure and the residue was chromatographed on a silica gel column eluting with DCM / MeOH / NHOH (90:9:1.5) to give the title product (17.5 mg). LCMS (method 3): Rt=0.78 min, ES + m / z 464.2 [M+H] + 1H-NMR (500MHz, DMSO-d6) δ:9.32(d,J=0.9Hz,1H), 9.23(dd,J=7.0, 1.8Hz,1H), 8.89(s,1H), 8.71(dd,J=4.0, 1.8Hz,1H), 8.33(d,J=0.9Hz,1H), 8.09(dd,J=8.9,2 .1Hz,1H), 8.05(d,J=2.1Hz,1H), 7.65(d,J=8.9Hz,1H), 7.17(dd,J=7.0, 4.3Hz,1H), 4.13(s,2H), 4.00(s,3H), 3.28(s,3H), 2.38(s,3H)

[0480] Example 90 Process 1 [ka]

[0481] 1-(5-Fluoro-2-methoxyphenyl)-N-(3-methoxypyrazin-2-yl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-amine (Example 90 - Step 1) To a degassed mixture of intermediate 18a (70 mg, 0.24 mmol), 2-amino-3-methoxypyrazine (39 mg, 0.31 mmol), and sodium t-butoxide (35 mg, 0.36 mmol) in 1,4-dioxane (2.1 mL) was added RuPhos-Pd-G3 (30 mg, 0.04 mmol), and the RM was stirred at 100 °C under an argon atmosphere for 3 h. After cooling to RT, the RM was diluted with water (5 mL), and a precipitate formed which was collected by filtration to give the title product (110 mg), which was used in the next step without further purification. LCMS (method 2): Rt=1.21, ES + m / z 381.1 [M+H] +

[0482] Process 2 [ka]

[0483] 3-((1-(5-Fluoro-2-methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one (Example 90) TMS-Cl (110 μL, 0.84 mmol) and NaI (126 mg, 0.84 mmol) were added to a mixture of the intermediate from Example 90, Step 1 (107 mg, 0.28 mmol) in acetonitrile (8 mL). The RM was stirred at 85° C. for 2 h, then cooled to RT and evaporated under reduced pressure. The residue was purified by flash chromatography on a Si cartridge eluting with 0-40% DCM / MeOH / NH4OH (90:9:0.5) in DCM to give the title compound (51 mg). LCMS (Method 5): Rt=3.26 min, ES + m / z 367.1[M+H] + 1 H-NMR (300MHz, DMSO-d6) δ=12.19(brs,1H), 8.87(d,J=0.9Hz,1H), 8.75(s,1H), 8.19(d,J=1.0Hz,1H), 7.30-7.44(m,3H), 6.83-6.97(m,2H), 3.82(s,3H), 2.58(s,3H)

[0484] Examples 91 to 99 The following examples were prepared from the indicated starting materials in a similar manner to Example 90. Where minor modifications to the ligand and / or palladium source were made, these are detailed in parentheses.

[0485] [Table 76] [Table 77] [Table 78] [Table 79] [Table 80]

[0486] Pharmacological activity of the compound (1-99) of the present invention Biochemical potency against JAK1, JAK2, JAK3 and Tyk2 Assay principle The purpose of this study was to evaluate the ability of compounds of the present invention to inhibit the activity of all four JAK isoforms in a cell-free environment. Assays for JAK1, JAK2, JAK3, and TYK2 were performed using time-resolved fluorescence resonance energy transfer (TR-FRET) technology, which involves the interaction of two labeled binding partners, detected by energy transfer from an excited donor to an acceptor dye and measurement of the emission emitted by the acceptor dye. The LANCE Ultra kinase assay was used. In the presence of JAK1, JAK2, JAK3, and TYK2 kinases and ATP (corresponding to the Km), the ULight peptide substrate (LANCE Ulight-JAK-1(Tyr1023) Peptide, Perkin Elmer, TRF0121) is phosphorylated. It is then captured by a Eu-antiphosphosubstrate antibody (LANCE Eu-W1024 anti-phosphotyrosine (PT66), Perkin-Elmer, AD0069), thereby bringing the Eu-chelate donor and ULight acceptor dye into close proximity. Upon excitation at 320 nm, the Eu-chelate transfers its energy to the ULight dye, resulting in fluorescence emission at 665 nm.

[0487] Compound testing Serial dilutions of compounds in pure DMSO were prepared from a 10 mM DMSO stock solution. Compounds were tested in 384-well plates using 11 serial 5-fold dilutions (20 μM–2 pM), starting with a top concentration of 20 μM. 200 nL of compound was transferred from the mother plate to the test plate using a Mosquito (TTP Labtech). Assays were performed in 384-well Perkin-Elmer test plates with a 20 μL assay volume (kinase reaction) and a 40 μL total volume (stop reagent and antibody detection reagent). 10 μL of substrate solution (peptide + ATP) was added to JAK1, JAK2, JAK3, and TYK2 at 30 / 50 / 20 / 10 nM peptide and 20 / 0.7 / 0.2 / 12 μM ATP, respectively. Ten microliters of enzyme solution was added to the kinase reactions at these concentrations of 0.15, 0.083, 0.025, and 0.144 ng / μL for JAK1, JAK2, JAK3, and TYK2, respectively. After shaking and incubation at room temperature for 1.5 hours, 20 μL of Stop (10 μL EDTA) and Detection mix (10 μL of eutopium-anti-phospho antibody, final: 0.5 nM) were added. After incubation for 1 hour, readings were taken on an EnVision 2104 reader (Perkin Elmer).

[0488] Calculation of IC50 data, curves, and QC analysis was performed using Excel tools and GraphPadPrism software, v9. Briefly, individual concentration-effect curves were generated by plotting the logarithm of the test concentration of the test compound (X) against the corresponding percent inhibition value (Y) using ordinary least squares (OLS) fit. The optimal IC50 value was calculated using the equation Log(inhibitor) vs. normalized response-variable slope, where Y = 100 / (1 + 10^((LogIC50-X) * HillSlope)). QC criteria parameters (Z', S:Z, R2, HillSlope)) were checked for all IC curves. Calculation of IC50 data, curves, and QC analysis was performed using Excel tools and GraphPadPrism software. QC criteria parameters: Z' > 0.5, hill gradient range 0.5~5, S:B>2

[0489] The compounds of the present invention (including Examples 1a-10a and 1-99) exhibit pIC50 values ​​of greater than 6 for their inhibitory activity against all JAK isoforms, corresponding to an inhibitory concentration of <1 μM. Most compounds preferably exhibit pIC50 values ​​of greater than 7.3, more preferably greater than 8.3, for their inhibitory activity against JAK1, corresponding to an inhibitory concentration of <1 μM. < Corresponding to 50nM.

[0490] Data for compounds 1-99 are reported in the table below. [Table 81] [Table 82] [Table 83] [Table 84]

[0491] The compounds are classified in the above table in terms of potency with respect to their inhibitory activity against JAK1, JAK2, JAK3 and Tyk2 isoforms according to the following classification criteria: +++:pIC50 > 8.3 ++ :8.3>pIC50 > 7.3 + :pIC50<7.3

[0492] Where a numerical limit or range is given in the specification, the endpoints are included, and all values ​​and subranges within that numerical limit or range are also included, unless specifically and expressly stated otherwise. As used herein, terms such as "a" and "an" mean "one or more." Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Claims

1. Formula Io: 【Chemistry 1】 [In the formula, W is heteroaryl selected from pyrazolo[1,5-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl, and (3-oxo-3,4-dihydropyrazin-2-yl)amino; R １ is selected from the group pyridinyl, piperidinyl, phenyl or benzyl, which is halogen, -OH, -CN, -NO ２ 、 -(CH ２ ) ｍ NR ４ R ５ 、 (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkylthio-, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) haloalkoxy, (C １ -C ６ ) haloalkylthio-; and Formula K: 【Chemistry 2】 (In the formula: L is absent or O, S, S(O) ２ , (CO), C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ )C(O),NHCONH,N(R ６ ) S (O) ２ , S(O) ２ N (R ６ is a divalent group selected from Z is H, —OH, —CN, or —NO ２ , (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl, (C １ -C ６ ) alkoxycarbonyl, —(CH ２ ) ｍ NR ４ R ５ , -C(O)NH(R ６ ), (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl and (C ３ -C ６ ) heterocycloalkyl; wherein said (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl and (C ３ -C ６ ) Heterocycloalkyl can further include (C １ -C １０ ) alkyl, (C １ -C ６ ) alkoxy, alkanoyl, (C １ -C ６ ) alkoxycarbonyl, oxo, —C(O)NH(R ６ ), (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl) When R 1 is phenyl, at least one of the groups is present in the meta position relative to the point of attachment of R 1 to the remainder of the molecule. optionally substituted with 1, 2, or 3 more independently selected groups; R ２ and R ３ If present, H, (C １ -C ６ ) alkyl, and a group of formula J: 【Transformation 3】 (In the formula, V is absent or O, S, S(O) ２ , C(O), C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ )C(O);N(R ６ )-(CH ２ ) ｍ -N(R ６ ), -N(R ６ )- is a divalent group selected from; Q is H, —CN, —OH, (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxycarbonyl, hydroxycarbonyl, -(CH ２ ) ｍ NR ４ R ５ , —C(O)NR ４ R ５ , -N(R ６ ) C(O)R ６ , -CH(CN)NR ４ R ５ , (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl and (C ３ -C ６ ) heterocycloalkyl; wherein said (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl and (C ３ -C ６ ) Heterocycloalkyl is —OH, oxo, (C １ -C １０ ) alkyl, (C １ -C １０ ) alkyl-S(O) ２ —O—, alkanoyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl, (C １ -C ６ ) alkoxycarbonyl, (C １ -C ６ ) alkoxycarbonyl-NH-, -N(R ６ ) (CH ２ ) ｍ C(O)NR ４ R ５ , -NR ４ R ５ , (C ３ -C ６ ) heterocycloalkyl; n and m, in each occurrence, are independently 0 or an integer selected from 1, 2, 3, and 4; R ４ and R ５ are the same or different, -H, (C １ -C ６ ) alkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) hydroxyalkyl, Alkanoyl, (C １ -C ６ ) alkoxycarbonyl, and (C ３ -C ６ ) heterocycloalkyl selected from the group consisting of: R ６ At each occurrence, H,(C １ -C ６ ) alkyl, (C １ -C ６ ) independently selected from the group consisting of hydroxyalkyl, and alkanoyl; R ７ At each occurrence, H,(C １ -C ６ ) alkyl, —NR ４ R ５ (independently selected from the group consisting of and independently selected from the group consisting of groups represented by the formula: The compound represented by the formula: embedded image and its single enantiomers, diastereomers, and mixtures in any proportion, or pharmaceutically acceptable salts and solvates thereof.

2. R １ but, halogens, preferably Cl and F; -OH, (C １ -C ６ ) alkoxy, preferably methoxy, (C １ -C ６ ) alkylthio-, preferably methylthio, (C １ -C ６ ) haloalkoxy, preferably difluoromethoxy phenyl substituted by two or three more independently selected groups; The compound of claim 1.

3. Formula (Ib): 【Chemistry 4】 [In the formula, R ８ teeth (C １ -C ６ ) alkoxy, (C １ -C ６ ) Haloalkoxy selected from the group consisting of: L is O, S, S(O) ２ , C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ )C(O); Z is H, (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxycarbonyl, —(CH ２ ) ｍ NR ４ R ５ , -C(O)NH(R ６ ), (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) heterocycloalkyl, wherein said (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) heterocycloalkyl is (C １ -C １０ ) alkyl, alkanoyl, (C １ -C ６ ) alkoxycarbonyl, —C(O)NH(R ６ ), (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl; R ３ is -H or (C １ -C ６ ) alkyl; V is absent or O, S, S(O) ２ , C(O), C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ ) C(O), N(R ６ )-(CH ２ ) ｍ -N(R ６ ), -N(R ６ )-; Q is H, —CN, —OH, (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxycarbonyl, —(CH ２ ) ｍ NR ４ R ５ , —C(O)NR ４ R ５ , -N(R ６ ) C(O)R ６ , -CH(CN)NR ４ R ５ , (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) heterocycloalkyl, wherein said (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) Heterocycloalkyl is —OH, oxo, (C １ -C １０ ) alkyl, (C １ -C １０ ) alkyl-S(O) ２ —O—, alkanoyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl, (C １ -C ６ ) alkoxycarbonyl, (C １ -C ６ ) alkoxycarbonyl-NH-, -N(R ６ ) (CH ２ ) ｍ C(O)NR ４ R ５ , -NR ４ R ５ , (C ３ -C ６ ) heterocycloalkyl; n and m, in each occurrence, are independently 0 or an integer from 1 to 4; R ４ and R ５ are the same or different, -H, (C １ -C ６ ) alkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) hydroxyalkyl, Alkanoyl, (C １ -C ６ ) alkoxycarbonyl, and (C ３ -C ６ ) heterocycloalkyl selected from the group consisting of: R ６ In each occurrence, H,(C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl; R ７ In each occurrence, H,(C １ -C ６ ) alkyl, independently selected from the group consisting of 2. The compound of claim 1, wherein: [0022] the single enantiomers, diastereomers, and mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof.

4. Formula (Ib1): 【Transformation 5】 [In the formula, R ８ teeth, (C １ -C ６ ) alkoxy, (C １ -C ６ ) Haloalkoxy selected from the group consisting of: L is O, S, S(O) ２ , C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ )C(O); Z is H, (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxycarbonyl, —(CH ２ ) ｍ NR ４ R ５ , -C(O)NH(R ６ ), (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) heterocycloalkyl (optionally, (C １ -C １０ ) alkyl, alkanoyl, (C １ -C ６ ) alkoxycarbonyl, —C(O)NH(R ６ ), (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl; R ３ is -H or (C １ -C ６ ) alkyl; V is absent or O, S, S(O) ２ , C(O), C(O)O, O(O)C, C(O)N(R ６ ), N(R ６ )C(O);N(R ６ )-(CH ２ ) ｍ -N(R ６ ), -N(R ６ )-; Q is H, —CN, —OH, (C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) alkoxy, (C １ -C ６ ) alkoxycarbonyl, —(CH ２ ) ｍ NR ４ R ５ , —C(O)NR ４ R ５ , -N(R ６ ) C(O)R ６ , -CH(CN)NR ４ R ５ , (C ３ -C ８ ) cycloalkyl, aryl, heteroaryl, and (C ３ -C ６ ) heterocycloalkyl (optionally —OH, oxo, (C １ -C １０ ) alkyl, (C １ -C １０ ) alkyl-S(O) ２ —O—, alkanoyl, (C １ -C ６ ) hydroxyalkyl, (C １ -C ６ ) alkoxy(C １ -C ６ ) alkyl, (C １ -C ６ ) alkoxycarbonyl, (C １ -C ６ ) alkoxycarbonyl-NH-, -N(R ６ ) (CH2) ｍ C(O)NR ４ R ５ , -NR ４ R ５ , (C ３ -C ６ ) heterocycloalkyl; n and m, in each occurrence, are independently 0 or an integer from 1 to 4; R ４ and R ５ are the same or different, -H, (C １ -C ６ ) alkyl, (C １ -C ６ ) haloalkyl, (C １ -C ６ ) hydroxyalkyl, Alkanoyl, (C １ -C ６ ) alkoxycarbonyl, and (C ３ -C ６ ) heterocycloalkyl selected from the group consisting of: R ６ In each occurrence, H,(C １ -C ６ ) alkyl, (C １ -C ６ ) hydroxyalkyl; R ７ In each occurrence, H,(C １ -C ６ ) alkyl, independently selected from the group consisting of 2. The compound of claim 1, wherein:

5. 1-(5-fluoro-2-methoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-methoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-(difluoromethyl)-2-methoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2-methoxy-5-(trifluoromethyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-(methylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-((difluoromethyl)thio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-cyclopropoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2,5-dimethoxyphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 3-((4-methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)propan-1-ol; 1-(2-methoxy-5-(propylsulfonyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 4-chloro-2-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol; 1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 4-Methoxy-N-methyl-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzenesulfonamide; N-(2-hydroxyethyl)-4-methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzenesulfonamide; 4-methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)benzenesulfonamide; 4-methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-((1-methylazetidin-3-yl)methyl)benzenesulfonamide; 4-methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzenesulfonamide; 4-Methoxy-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(2-morpholinoethyl)benzenesulfonamide; 1-(2-(difluoromethoxy)-5-((2-methoxyethyl)sulfonyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 3-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)-N,N-dimethylpropan-1-amine; 2-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)ethan-1-ol; 1-(2-(difluoromethoxy)-5-((2-(piperidin-1-yl)ethyl)sulfonyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(3-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)pyrrolidin-1-yl)ethan-1-one; 1-(2-(difluoromethoxy)-5-((3-methoxyphenyl)sulfonyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2-(difluoromethoxy)-5-(methylsulfonyl)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 3-Methoxy-4-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol; 2-(1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)acetonitrile; (1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methanol; 1-(1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N,N-dimethylmethanamine; 1-(1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylmethanamine; (1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methanamine; 1-(5-chloro-2-(difluoromethoxy)phenyl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(5-chloro-2-methoxyphenyl)-N-((1s,3s)-3-hydroxycyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; (1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)(1,1-dioxidethiomorpholino)methanone; 1-(5-chloro-2-(difluoromethoxy)phenyl)-N-((1s,3s)-3-(dimethylamino)cyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-N-(3-(dimethylamino)propyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; N-(3-(dimethylamino)propyl)-1-(5-fluoro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine; N-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)acetamide; 1-(5-chloro-2-methoxyphenyl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine; 1-(5-chloro-2-methoxyphenyl)-N,N-dimethyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine; 1-(2-methoxy-5-(methylsulfonyl)phenyl)-N-(2-morpholinoethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine; N1-(1-(5-(difluoromethyl)-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine; N1-(1-(2-methoxy-5-methylphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine; N1-(1-(2-(difluoromethoxy)-5-(methylthio)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N3,N3-dimethylpropane-1,3-diamine; 1-(4-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)piperazin-1-yl)ethan-1-one; 1-(5-chloro-2-methoxyphenyl)-3-(piperazin-1-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; (1-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)methanol; 1-(5-chloro-2-methoxyphenyl)-3-methoxy-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(5-chloro-2-methoxyphenyl)-N,N-dimethyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine; 1-(5-chloro-2-methoxyphenyl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine; N-(2-((1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-yl)amino)ethyl)acetamide; 2-((1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-yl)amino)-N-methylacetamide; N-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-yl)acetamide; 1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine; 1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-ol; 2-fluoro-5-methoxy-4-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol; 2-chloro-5-methoxy-4-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol; 5-methoxy-2-methyl-4-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenol; 1-(2-chloro-5-methoxypyridin-4-yl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; (4-chloro-2-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)methanol; 1-(5-bromo-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzonitrile; 1-(2-(difluoromethoxy)-5-methylphenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-(thiazol-2-yl)benzamide; 2-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)-N-methylacetamide; 2-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)acetamide; 2-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)-N-(2-hydroxyethyl)acetamide; 2-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)sulfonyl)acetamide; 1-(5-(cyclopropylthio)-2-(difluoromethoxy)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2-(difluoromethoxy)-5-((tetrahydro-2H-pyran-4-yl)thio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2-(difluoromethoxy)-5-(oxetan-3-ylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(2-(difluoromethoxy)-5-(piperidin-4-ylthio)phenyl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine; 1-(4-((4-(difluoromethoxy)-3-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl)thio)piperidin-1-yl)ethan-1-one; 1-((1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)methyl)azetidin-3-amine; N-((1r,3r)-3-aminocyclobutyl)-1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-(methyl(2-(methylamino)-2-oxoethyl)amino)cyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-morpholinocyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(5-chloro-2-methoxyphenyl)-N-((1r,3r)-3-(dimethylamino)cyclobutyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; N-((1s,3s)-3-aminocyclobutyl)-1-(5-chloro-2-(difluoromethoxy)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; N-(2-(dimethylamino)ethyl)-1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; N-(3-(dimethylamino)propyl)-1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(2-methoxy-5-(methylsulfonyl)phenyl)-N-(3-morpholinopropyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(2-methoxy-5-(methylsulfonyl)phenyl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine; N-(3-(3-((2-(dimethylamino)ethyl)amino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-4-methoxyphenyl)methanesulfonamide; N-(1-(5-chloro-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(methylamino)acetamide; N-(3-(dimethylamino)propyl)-1-(5-fluoro-4-hydroxy-2-methoxyphenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1-(1-(2-methoxy-5-(methylsulfonyl)phenyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylmethanamine; 3-((1-(5-fluoro-2-methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 3-((1-(5-(difluoromethyl)-2-methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; N-(2-hydroxyethyl)-4-methoxy-3-(3-methyl-6-((3-oxo-3,4-dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzenesulfonamide; 3-((1-(2-(difluoromethoxy)-5-((2-methoxyethyl)thio)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 3-((1-(2-(difluoromethoxy)-5-(methylsulfonyl)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 3-((1-(2-(difluoromethoxy)-5-((2-methoxyethyl)sulfonyl)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; N-(3-(dimethylamino)propyl)-1-(5-fluoro-2-methoxyphenyl)-6-((3-oxo-3,4-dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 3-((3-((3-(dimethylamino)propyl)amino)-1-(5-fluoro-2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 3-((1-(5-(difluoromethyl)-2-methoxyphenyl)-3-((2-(dimethylamino)ethyl)amino)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 3-((1-(5-chloro-2-(difluoromethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2(1H)-one; 10. The compound of claim 1, single enantiomers, diastereomers, and mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, selected from:

6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, in admixture with one or more pharmaceutically acceptable carriers or excipients.

7. 7. A pharmaceutical composition according to claim 6, suitable for administration by inhalation, selected from an inhalable powder, a propellant-containing metered aerosol, or a propellant-free inhalable formulation.

8. 10. A device for delivering the pharmaceutical composition of claim 7, wherein the device is a single or multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.

9. A pharmaceutical composition according to any one of claims 1 to 7 for use as a medicament.

10. 10. The pharmaceutical composition according to claim 9, for use in the prevention and / or treatment of a pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS).

11. 6. A combination of a compound according to any one of claims 1 to 5 with one or more active ingredients selected from the group consisting of beta2-agonists, antimuscarinics, corticosteroids, mitogen-activated kinase (P39MAP kinase) inhibitors, inhibitors of nuclear factor kappa-B kinase subunit beta (IKK2), human neutrophil elastase (HNE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modifiers, nonsteroidal anti-inflammatory drugs (NSAIDs) and mucus modifiers.

Images